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Abstract 
Conservation  efforts  to  prevent  the  extinction  of  the  endangered  western  barred 
bandicoot  Perameles  bougainville  (WBB)  are  currently  hindered  by  a  debilitating 
progressive  papillomatosis  and  carcinomatosis  syndrome.  Now  extinct  on  mainland 
Australia, wild populations of the WBB are known only to exist on Bernier and Dorre 
Islands  in  Shark  Bay,  Western  Australia.  This  thesis  describes  and  analyses  the 
pathological (gross, histological, ultrastructural) and immunohistochemical features of a 
papillomatosis  and  carcinomatosis  syndrome  in  the  WBB.  The  detection  and 
characterisation of a novel virus, the bandicoot papillomatosis carcinomatosis virus type 
1 (BPCV1), found in association with cutaneous and muco-cutaneous papillomas and 
carcinomas,  is  described.  BPCV1  was  found  to  exhibit  genomic  and  morphological 
features of both the Papillomaviridae and the Polyomaviridae, and may represent the 
first member of a new family of viruses. The findings of this study provide evidence 
that BPCV1 is the causative agent of the papillomatosis and carcinomatosis syndrome. 
Clinical, pathological and molecular evidence of the syndrome and BPCV1 were found 
in  the  Bernier  Island  WBB  population  at  Red  Cliff  and  in  captive  populations 
comprising all or a proportion of founder WBBs from this site, but not at all in the 
WBB  population  on  Dorre  Island  or  Heirisson  Prong.  The  papillomatosis  and 
carcinomatosis syndrome in the western barred bandicoot is a pertinent example of a 
disease process hampering efforts to prevent the extinction of an endangered species.   V
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Chapter 1: Background and general introduction 
 
 
 
 
 
Adult western barred bandicoot. 
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The  western  barred  bandicoot  (WBB)  is  a  small,  delicate  Australian  marsupial  that 
inhabits Bernier and Dorre Islands, in the World Heritage Area of Shark Bay Western 
Australia (UNESCO 1991; Short et al. 1997; Richards and Short 2003). Insectivorous, 
solitary  and  largely  nocturnal,  the  WBB  is  the  smallest  of  the  bandicoot  species, 
weighing between 190 and 250 gm and between 200 and 300 mm in length (Seebeck et 
al. 1990; Short et al. 1998). Once widespread across southern and western Australia, 
wild populations of the WBB are now extinct on the mainland (Figure 1.1) and the 
species  is  listed  as  nationally  endangered  under  the  Environment  Protection  and 
Biodiversity Conservation Act 1999 (EPBC Act 1999) and by the International Union 
for Conservation of Nature and Natural Resources (IUCN) (Australasian Marsupial & 
Monotreme Specialist Group 1996). It is also listed under Schedule 1 ‘Fauna that is 
likely  to  become  extinct  or  is  rare’  under  Section  14(2)  of  the  Western  Australian 
Wildlife Conservation Act 1950. Initiatives to prevent the extinction of the WBB include 
captive breeding and reintroduction of individuals into predator proof enclosures, or fox 
and cat baited habitat, located in the species historic distribution range on mainland 
Western Australia and South Australia.   3
 
 
 
 
 
 
 
 
  
 
Figure 1.1 Distribution of past and present wild populations of the western barred bandicoot. 
Locations  of  last  collection  of  specimens  occurred  at  1)  Rawlinna,  2)  Ooldea,  and  3)  Mt 
Crombie. Arrows indicate Bernier and Dorre Islands (adapted from Richards 2005). 
 
Conservation efforts are presently hampered by a progressively debilitating cutaneous 
and muco-cutaneous papillomatosis and carcinomatosis syndrome observed in captive 
and wild WBBs. This syndrome was first detected in 1999 in a captive adult female 
WBB at a captive breeding colony in Perth. Additional WBBs housed at the facility 
were noticed to develop skin lesions by 2000, with lesions progressing to substantial 
sizes,  declines  in  breeding  observed  in  affected  animals  and  death  often  ensuing 
(Thomas and Friend 2003). Similar skin lesions were also observed in captive WBBs in 
another  breeding  colony  over  1000  km  north  of  Perth.  Introduction  of  seemingly 
healthy, wild WBBs into captive colonies of WBBs affected with the skin lesions was 
associated with development of skin lesions in the introduced bandicoots, prompting 
ideas that an infectious agent may be involved in the pathogenesis of this disease. A 
detailed  investigation  into  this  novel  disease  was  subsequently  instigated,  involving 
members from the Western Australian Department of Environment and Conservation 
Former Distribution
Present Distribution
1 
3
2   4
(DEC)  and  the  Murdoch  University  School  of  Veterinary  and  Biomedical  Sciences. 
Preliminary  pathological  investigations  supported  of  the  involvement  of  a  viral 
aetiological agent in the pathogenesis of this disease (O'Hara et al. 2004).  
 
This novel syndrome is the subject of this thesis. Chapter 2 describes and documents the 
pathologic (gross, histological, ultrastructural) and immunohistochemical features of the 
papillomatosis and carcinomatosis syndrome. Chapter 3 provides an overview of the 
general  features  of,  diseases  associated  with  and  pathogenic  mechanisms  of  the 
differential aetiological agents presented in Chapter 2. Chapter 4 describes the detection 
and  characterisation  of  a  novel  viral  aetiological  agent  in  association  with  the 
papillomatosis  and  carcinomatosis  syndrome.  Chapter  5  explores  the  frequency  and 
geographical distribution of this disease in both wild and captive WBB populations, and 
explores  potential  risk  factors  that  may  be  associated  with  the  presence  of  disease. 
Finally,  a  summary  of  the  main  findings  of  the  study,  recommendations  for  the 
management of this syndrome and future research directions are presented in Chapter 6.  
 
Investigations of this nature are important in the preservation of endangered species. 
Captive breeding and reintroduction programmes form the basis of many animal species 
conservation  efforts,  and  vigilance  must  be  maintained  for  the  emergence  of  new 
diseases, which form a major threat to biodiversity and have been shown to undermine 
the success of breeding programmes  (Viggers  et al. 1993; Daszak  and Cunningham 
1999; Daszak et al. 2000; Young and Deane 2003). It is hoped that the findings of this 
research will provide guidance for the future management and conservation of the WBB 
population. 
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Chapter 2: Pathological features of a 
papillomatosis and carcinomatosis syndrome in 
the western barred bandicoot 
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Summary: 
Conservation efforts to prevent the extinction of the western barred bandicoot (WBB) 
are currently hindered by a debilitating papillomatosis and carcinomatosis syndrome. 
This  chapter  describes  the  gross,  histopathological,  ultrastructural  and 
immunohistochemical  findings  of  this  syndrome  in  48  WBBs.  The  disease  was 
characterised  by  multicentric  proliferative  lesions  involving  cutaneous  and  muco-
cutaneous surfaces which were seen clinically to increase in size with time. Grossly and 
histologically the smaller epithelial lesions resembled papillomas, whereas the larger 
lesions  were  most  commonly  observed  to  be  squamous  cell  carcinomas.  Large 
amphophilic intranuclear inclusion bodies were observed in hyperplastic conjunctival 
lesions of eight WBB under light microscopy. Conjunctival lesions from three WBBs 
displaying the large amphophilic intranuclear inclusions examined using transmission 
electron microscopy contained a crystalline array of spherical electron dense particles 
~45 nm diameter within the nucleus of conjunctival epithelial cells consistent with a 
papillomavirus or polyomavirus. These same conjunctival samples also demonstrated a 
positive  immunohistochemical  reaction  after  indirect  immunohistochemistry  for 
papillomavirus  structural  antigens.  Ultrastructural  and/  or  immunohistochemical 
evidence  of  an  aetiological  agent  was  not  identified  in  the  non-conjunctival  lesions 
examined. The discernable stages of lesion development and the progression in lesion 
size and malignancy seen with increasing age were consistent with a multistage model 
of  carcinogenesis.  The  involvement  of  a  papillomavirus  or  polyomavirus  in  the 
pathogenesis of this disease is also considered.   7
2.1 Introduction  
Conservation efforts to prevent the extinction of the western barred bandicoot (WBB) 
are currently hampered by a progressively debilitating cutaneous and muco-cutaneous 
papillomatosis and carcinomatosis syndrome observed in both captive and wild WBBs. 
Affected animals develop multicentric papillomatous lesions which appear clinically to 
progress to larger sizes. These lesions are extremely debilitating. Involvement of the 
feet, eyes and the mouth, leads to problems with ambulation, vision and eating. Affected 
animals often die due to secondary infections or are euthanased on welfare grounds. 
Awareness of this syndrome first arose in 1999, when lesions were noticed developing 
on a captive adult female housed at Kanyana Wildlife Rehabilitation Centre in Perth 
(Thomas and Friend 2003). Within a year, additional WBBs housed at the facility were 
noticed  to  have  developed  lesions.  Similar  cutaneous  lesions  were  also  noticed  on 
captive WBBs at another breeding colony in Shark Bay, and identified on wild WBBs 
on  Bernier  Island  by  the  Western  Australian  Department  of  Environment  and 
Conservation (DEC) in 2001. A historical trace back performed by one of the authors 
(SH) on 93 museum specimens from five museums in Australia found similar lesions to 
be present on Western Australian Museum WBB specimens dating back to 1982 (Hill 
2003; Hill 2005).  
 
Skin  diseases  of  Australian  marsupials  characterised  by  hyperplastic  dermatitis  or 
papillomatous thickening of epithelia have been associated with putative papillomaviral 
infection in a brush-tail possum (Trichosurus vulpecula) (Perrott et al. 2000) and with 
poxvirus infection in macropod species (Papadimitriou and Ashman 1972; Speare 1988; 
Speare et al. 1989). Herpes viruses have been associated with proliferative skin disease 
in non-marsupial species (Yamamoto et al. 1983; Jacobsen et al. 1986; Quackenbush et 
al. 1998; Styles et al. 2004), however in marsupials, macropod herpes virus (MHV) is   8
associated  with  disease  characterised  by  conjunctivitis,  mucocutaneous  blisters  and 
ulcerations, lethargy and in some cases death (Johnson et al. 1985; Speare et al. 1989; 
Guliani et al. 1999). Parasitic infections have also been associated with hyperplastic 
and/  or  hyperkeratotic  dermatitis  in  Australian  marsupials.  These  include  sarcoptic 
mange (Sarcoptes scabiei) (Martin et al. 1998; Skerratt 1998; Skerratt 2003), dermatitis 
caused by chigger mite larvae (Odontacarus (Leogonius) adelaideae) (O'Callaghan et 
al. 1994) and cutaneous leishmaniasis (Rose et al. 2004).  
 
Various  neoplastic  disease  affecting  the  skin  and  mucosae  have  been  described  in 
Australian marsupials, including the recently characterised devil facial-tumour disease 
(DFTD). These large solid tumours of Tasmanian devils (Sarcophilus harrisii) which 
are often multicentric, first appear in the oral, face, or neck regions and are a malignant 
undifferentiated soft tissue neoplasia of neuroectodermal origin (Loh et al. 2006a; Loh 
et al. 2006b). These tumours appear to be transmitted between devils as an allograft 
during fighting, mating and feeding (Pearse and Swift 2006). Cutaneous squamous cell 
carcinoma and adenocarcinoma of the perianal and mammary glands have also been 
recorded  in  Tasmanian  devils  (Griner  1979).  Other  epithelia-associated  neoplasia 
reported in Australian marsupials include a trichoepithelioma in a wild eastern grey 
kangaroo  (Macropus  giganteus)  (Speare  and  Banks  1987)  and  cutaneous 
lymphosarcoma in a sugar glider (Petaurus breviceps) (Hough et al. 1992). 
 
The papillomatosis and carcinomatosis syndrome observed in the WBB is a novel and 
emerging disease and, to the authors’ knowledge, is unlike skin diseases of Australian 
marsupials  previously  documented.  This  chapter  details  the  gross,  histological, 
ultrastructural  and  immunohistochemical  features  of  a  papillomatosis  and 
carcinomatosis syndrome recently identified in captive and wild WBBs.   9
2.2 Materials and methods 
2.2.1 Study population and sample collection 
Between 2000 and 2007, submissions from 48 adult WBBs (19 male and 29 female) 
displaying focal or multifocal cutaneous and/ or muco-cutaneous thickenings or masses 
were received by the pathology section at the Murdoch University School of Veterinary 
and Biomedical Sciences (Table 2.1). Essential criteria for inclusion in this study were 
epithelial  lesions  with  gross  and  histological  characteristics  consistent  with  either 
papilloma formation and/ or squamous cell carcinomas, as classified by Goldschmidt 
(Goldschmidt  et  al.  1998).  All  animals  in  the  study  were  sourced  from  captive 
populations  of  WBBs  held  at  either  Kanyana  Wildlife  Rehabilitation  Centre, 
Gooseberry Hill, WA; Dryandra Field Breeding Centre, near Narrogin, WA; the Peron 
Captive  Breeding  Centre  (PCBC),  Shark  Bay,  WA;  or  the  Adelaide  and  Monarto 
Zoological  Gardens,  SA.  Of  these  animals,  15  were  originally  captured  in  the  wild 
(eight  as  adults,  seven  as  juveniles)  and  subsequently  placed  in  captive  breeding 
facilities and 33 were born and raised within the captive breeding colonies (Table 2.1). 
   10
Table 2.1 Identification and origin of WBBs included in the study cohort.  
WBB ID  SEX  WC or 
CB 
Origin  Where skin 
disease noted 
Murdoch Pathology No.  Murdoch Histology No. 
125F83F  F  WC  Bernier  PCBC  DAFWA AS-00-3562  DAFWA AS-00-3562 
602F2D4  F  WC  Bernier  ARP  IDEXX V003700  IDEXX V003700 
B02M01  F  WC  Bernier  Monarto  02-0851  H02-0889 
B02P02a  F  WC  Bernier  Bernier  02-0218  H02-0258BC 
B02P02b  F  WC  Bernier  Bernier  02-0218  H02-0258BC 
B03P01  F  WC  Bernier  PCBC  03-0775  H03-0858 A 
B03P03  F  WC  Bernier  PCBC  03-0775  H03-0858 E 
B03P04  F  WC  Bernier  PCBC  03-0775  H03-0858 G 
B06K02  F  WC  Bernier  Kanyana  06-0250  H06-0249 
B06K08  F  WC  Dorre  Kanyana  06-0597  H06-1142 
6031E6D  M  WC  Bernier  Bernier  DAFWA AS-00-3562  DAFWA AS-00-3562 
B03P02  M  WC  Bernier  PCBC  03-0775  H03-0858 C 
B07K01  M  WC  Bernier  PCBC  07-0190  H07-0159 
B02K03  M  WC  Dorre  Kanyana  02-0309  H02-0345 
B04K01  M  WC  Dorre  Kanyana  04-0418  H04-0267 
13AF156  F  CB  Kanyana  Kanyana  DAFWA P-00-2825  DAFWA P-00-2825 
6FFE45  F  CB  Kanyana  Kanyana  VetPath 63295  
& DAFWA P-00-2308 
VetPath 63295  
& DAFWA P-00-2308 
B00K01  F  CB  Kanyana  Kanyana  00-0860  H00-0822  
& DAFWA P-00-2308 
B02K04  F  CB  Kanyana  Kanyana  02-0310  H02-0347 
B02K05  F  CB  Kanyana  Kanyana  02-0311  H02-0348 
B02K07  F  CB  Kanyana  Kanyana  02-0662  H02-0708 
B02K08  F  CB  Kanyana  Kanyana  02-0758  H02-0800 
B06K03  F  CB  Kanyana  Kanyana  06-0251  H06-0250 
B02K06  M  CB  Kanyana  Kanyana  02-0644  H02-0680 
B05K09  M  CB  Kanyana  Kanyana  05-0415  H05-0314 
B06K07  M  CB  Kanyana  Kanyana  06-0596  H06-0529 
B06K09  M  CB  Kanyana  Kanyana  06-0598  H06-0530 
B06K01  F  CB  Kanyana  Dryandra  06-0249  H06-0248 
B03P05  F  CB  PCBC  PCBC  03-0775  H03-0858I 
B03P08  F  CB  PCBC  PCBC  03-0775  H03-0858 N 
B03P09  F  CB  PCBC  PCBC  03-0775; 04-0756  H03-0858P; H04-0537H 
B04P03  F  CB  PCBC  PCBC  04-0756  H04-0537EF 
B04P04  F  CB  PCBC  PCBC  04-0756  H04-0537G   11
Table 2.1 Cont’d. 
WBB ID  SEX  WC or 
CB 
Origin  Where skin 
disease noted 
Murdoch Pathology No.  Murdoch Histology No. 
B05K03  F  CB  PCBC  PCBC  05-1222  H05-0949 
B02K01  F  CB  PCBC  Kanyana  02-0307  H02-0343 
B04K02  F  CB  PCBC  Kanyana  04-1053  H04-0752 
B03P06  M  CB  PCBC  PCBC  03-0775  H03-0858 K 
B03P07  M  CB  PCBC  PCBC  03-0775  H03-0858 M 
B03P10  M  CB  PCBC  PCBC  03-0775  H03-0858 R 
B04P01  M  CB  PCBC  PCBC  04-0756  H04-0537ABC 
B04P02  M  CB  PCBC  PCBC  04-0756  H04-0537D 
B05K04  M  CB  PCBC  PCBC  05-0888  H05-0697 
B02K02  M  CB  PCBC  Kanyana  02-0308  H02-0344 
B02P01  M  CB  PCBC  Kanyana  02-0201  H02-0246 
B05DrN3  F  CB  Dryandra  Dryandra  06-0946  H06-0913 
B05DrS05  M  CB  Dryandra  Dryandra  05-0403  H05-0285 
B05K07  M  CB  Dryandra  Dryandra  05-0095  H05-0044 
B05K10  F  CB  Dryandra  Dryandra  05-0424  H05-0315 
DAFWA = Western Australian Department of Agriculture and Food; WC = wild caught; CB = captive bred. 
2.2.2 Submissions 
Submissions consisted of either surgical biopsies collected into 10% neutral buffered 
formalin  or  entire  deceased  WBBs  for  post  mortem  examination.  Entire  animals 
submitted for post mortem were subjected to a complete post mortem examination and 
tissue samples were collected from cutaneous and muco-cutaneous lesions and all the 
major organ systems into 10% neutral buffered formalin. Samples of cutaneous and 
muco-cutaneous  lesions  were  trimmed  to  <3  mm  in  thickness  and  immersed  in  5% 
glutaraldehyde for the purpose of transmission electron microscopy.  Surgical biopsies 
and post mortem samples were fixed in formalin for at least 24 hours before processing 
for routine light microscopy.    12
2.2.3 Clinical records 
Clinical records relating to the detection of skin disease and progression of lesions in 
cohort individuals were sourced from the aforementioned captive facilities as well as 
VetPath Diagnostic Laboratory Western Australia, the Western Australian Department 
of  Agriculture  and  Food  (DAFWA)  and  the  Western  Australian  Department  of 
Environment and Conservation (DEC). 
2.2.4 Histopathology 
Tissues  fixed  in  10%  neutral  buffered  formalin,  collected  as  described  above,  were 
routinely processed for examination by light microscopy (Bancroft and Stevens 1982). 
Following fixation for a minimum of 24 hours, tissues were trimmed to 5 mm thick 
sections and placed into labelled cassettes. Sections were dehydrated through graded 
ethanol concentrations, cleared with xylene and embedded with paraffin wax in a Leica 
EG  1150C  automated  processor  (Leica  Microsystems,  Nussloch,  Germany).  Tissue 
blocks were sectioned at 5 µm using a Leica 2135 microtome (Leica Microsystems, 
Nussloch, Germany). Slides were stained with Harris’s Haematoxylin and 1% Eosin, 
dehydrated, cleared and mounted with a cover-slip using DPX.   
2.2.5 Immunohistochemistry 
Indirect  immunohistochemistry  using  a  polyclonal  antibody  recognising  conserved 
papillomavirus  capsid  antigens  (Rabbit  Anti-Bovine  Papillomavirus  [BPV1],  Dako 
corporation, B0580) (Kurman et al. 1984) was performed on 5  m paraffin sections 
according to a modified manufacturer’s protocol. Sections from a canine oral papilloma 
confirmed  to  be  associated  with  a  papillomavirus  infection  (by  a  combination  of 
characteristic  histological  features,  viral  particles  demonstrable  via  transmission 
electron  microscopy  and  positive  immunohistochemistry)  were  used  as  a  positive 
control. Briefly, 5  m paraffin sections were deparaffinised in xylene. Sections were   13
then subjected to antigen retrieval. The sections were placed in a pH 9 Tris-EDTA-
Sucrose (TES) Buffer Solution and microwaved twice on the reheat setting and twice on 
the low setting: each cycle was for four minutes. The sections were then cooled by a 
gradual addition of de-ionized water.  Following this, the sections were treated with 3% 
hydrogen peroxide for five minutes then washed with distilled water followed by pH 7.8 
Tris/ HCl buffered washing solution. Sections were ringed with a wax pencil and treated 
with serum-free protein block (Dako corporation, X0909) for 10 minutes. Protein block 
was poured from the test slides without washing and the primary antibody diluted 1:600 
with Dako or Chemicon antibody diluent was applied for 10 minutes. The negative 
control slides remained in the protein block for this 10 minute period. The slides were 
then washed in pH 7.8 Tris/ HCl buffered washing solution, and then treated with anti-
rabbit antibody (ENVISION+, Dako corporation, K4003) for 30 minutes. Following this 
they were treated with DAB+ Substrate-Chromogen system (Dako corporation, K3468) 
solution for 3.5 minutes, changing the solution twice. Slides were counter stained with 
Harris’s haematoxylin, dehydrated, cleared and mounted with a cover-slip using DPX.   
2.2.6 Ultrastructural examination  
For ultrastructural examination using transmission electron microscopy, tissue sections 
were  immersed  in  glutaraldehyde  solution  (5%  [v/v])  for  at  least  24  hours  prior  to 
processing.  For  tissues  fixed  in  10%  neutral  buffered  formalin,  the  formalin  was 
removed and the tissue resuspended in Sorenson’s Buffer for a maximum of 30 minutes, 
following which the buffer was removed and discarded. This process was repeated three 
to four times. Tissues were then placed in glutaraldehyde solution (5% [v/v]). Tissues 
were post-fixed in Dalton’s Chrome Osmic Acid (aqueous osmium tetroxide, potassium 
dichromate, aqueous sodium chloride), dehydrated in sequential ethanol concentrations, 
propylene oxide and embedded in TAAB 812 epoxy resin. Sections were cut to 1  m in 
thickness using a Reichart OM U3 ultramicrotome (Reichart, Austria) and stained with   14
1%  toluidine  blue  for  examination  by  light  microscopy  to  select  appropriate  resin 
embedded tissue blocks for transmission electron microscopy. Ninety nanometre ultra 
thin sections from selected blocks were cut onto grids, stained with lead citrate (0.1-
0.4% [w/v]) and uranyl acetate (2% [saturated aqueous w/v] pH 4.5), and examined 
using  a  transmission  electron  microscope  (Philips  CM100  BioTwin  Transmission 
Electron Microscope, Eindhoven, Netherlands). Tissue sections were then photographed 
(Kodak Electron Microscope Film 4489, 6.5 x 9 cm).    15
2.3 Results 
2.3.1 Disease onset, duration and age affected  
The  maximum  life  expectancy  of  WBB  in  captivity  is  estimated  at  6  years  of  age 
whereas in wild populations it is estimated at only 4 years of age (J. Butcher and N. 
Thomas pers. comm., 2005). The age of death of cohort WBB was known for 39/48 
affected individuals but unknown for nine individuals as eight of these animals were 
captured in the wild as adults and records were unavailable for one individual kept in 
captivity. The average age of death was 4.6 years (median 5 years, range 2 – 6.5 years). 
The average age at which lesions were first detectable was 3.17 years (median 3 years, 
range  1  –  5.75  years).  The  time  course  of  lesion  progression  was  known  for  40 
individuals  and  occurred  over  a  period  of  months  to  years.  The  average  duration 
between detection of skin lesions and euthanasia or death was 1.5 years (median 1.33 
years, range 2 weeks – 4.5 years).  
 
2.3.2 Gross morphological appearance and lesion distribution 
The cutaneous and/ or muco-cutaneous lesions in affected animals were variable in size 
and either solitary or multicentric. They ranged from regions of alopecia and small (1-2 
mm diameter and height) nodular papillomatous thickenings to large exophytic masses 
(>5x5x5 mm) often with an exudative crust or ulceration. Sites at which lesions were 
observed included skin of the digits (32/48, 66.7% of study cohort); haired skin of the 
neck, thorax and abdomen (26/48, 54.2%); the periaural region (23/48, 47.9%); and 
muco-cutaneous junctions of the lips (30/ 48, 62.5%), conjunctiva (24/48, 50.0 %) and 
pouch/ inguinal region (13/48, 27.1%) (Figures 2.1 to 2.5). Within the cohort, seven 
(14.6%) animals displayed a lesion at a single anatomical location only. The remaining 
41 (85.4%) affected WBBs displayed lesions with a multicentric distribution.    16
 
 
Figure 2.1 Western barred bandicoot; skin of the eyelids, lips, forelimbs and digits demonstrates 
nodular and irregular papillomatous thickening.   17
 
 
 
 
Figure 2.2 Western barred bandicoot ventral abdomen; irregular papillomatous thickening of the 
dorsal skin of the hind digits and muco-cutaneous junctions of the pouch and cloacal opening. A 
large exophytic papillomatous mass is seen arising from the muco-cutaneous junction of the 
pouch.    18
 
 
A.    B.   
C.    D.   
Figure 2.3 Western barred bandicoot; skin of the digits demonstrates focally extensive nodular 
and irregular papillomatous thickening. Severe hyperonychia is observed in images A and C.   19
 
 
Figure  2.4  Western  barred  bandicoot;  palpebrae  demonstrate  nodular  and  irregular 
papillomatous thickening. 
 
 
Figure 2.5 Western barred bandicoot; skin of the dorsal cranium demonstrates nodular, irregular 
and exophytic papillomas.   20
2.3.3 Histological features of lesions 
One hundred and twenty six cutaneous and/ or muco-cutaneous lesions were examined 
by light microscopy (Table 2.2). Of these, 63 were classified as epithelial hyperplasia 
(50.0%), 32 as carcinoma in situ (25.4%) and 30 as squamous cell carcinoma (SCC) 
(23.8%). Adenocarcinoma of the pouch was recorded in one individual. 
 
There were 41 WBBs in the study cohort with multicentric lesions.  Purely multicentric 
hyperplastic  epithelial  lesions  were  seen  in  16  WBBs  (39.0%),  entirely  malignant 
lesions were seen in six WBBs (14.6%) and both malignant and benign lesions were 
seen concurrently in 19 WBBs (46.3%). Solitary lesions were seen in the remaining 
seven animals, and consisted of either epidermal hyperplasia of the digit (3/7) or SCC of 
the oral muco-cutaneous junction (4/7). 
 
Thirty five WBBs displayed one or more lesions classified as epithelial hyperplasia (n = 
63).  These  lesions  were  characterised  by  mild,  moderate  or  marked,  irregular 
hyperplasia of the stratifying epithelium. The hyperplasia was attributable to an increase 
in the number of suprabasilar epithelial cells at mucosal sites and an increase in the 
number of keratinocytes within both the stratum spinosum and stratum granulosum of 
the epidermis. Hyperplasia of the outer root sheath of hair follicles and the glandular 
elements of sebaceous and sweat glands were also seen. Koilocytes and epithelial cells 
with  marginated  nuclear  chromatin  and  large  amphophilic  intranuclear  inclusions 
(Figure 2.5) were evident in nine cases with hyperplastic conjunctival lesions.  
   21
 
 
 
 
Figure  2.6  WBB  conjunctival  epithelium;  Irregular  hyperplasia  of  the  mucosal  epithelium. 
Multiple  keratinocytes  demonstrate  margination  of  nuclear  chromatin  and  central  glassy 
amphophilic inclusions. Koilocytes are also evident. HE. Bar = 200  m.   22
Lesions categorized as carcinoma in situ (n = 32) were seen in 19 individuals. These 
lesions showed an expansion of the stratum spinosum and stratum granulosum and mild 
to moderate dysplastic changes in keratinocyte morphology and epidermal architecture, 
such  as  disturbed  polarity  of  keratinocyte  differentiation  and  suprabasilar  mitoses. 
Individual  cellular  characteristics  included  hyperchromasia  of  nuclei,  prominent 
nucleoli, clear or vacuolated cytoplasm and mild anisocytosis and anisokaryosis. In one 
conjunctival lesion classified as carcinoma in situ, the nuclei of some keratinocytes in 
the stratum granulosum displayed margination of nuclear chromatin and amphophilic 
inclusions. 
 
Lesions categorized as SCC (n = 30) were located at cutaneous and muco-cutaneous 
sites in 21 individuals (Figures 2.8 and 2.9). Histologically, the carcinomas consisted of 
invasive  cords,  islands  and  trabeculae  of  neoplastic  epithelial  cells  showing  varying 
degrees of differentiation. In well differentiated tumours there was formation of keratin 
“pearls” circumscribed by neoplastic keratinocytes. The neoplastic epithelium extended 
into  the  dermis,  with  or  without  association  with  the  overlying  epidermis.  The 
neoplastic cells themselves showed abundant eosinophilic cytoplasm with distinct cell 
borders,  intercellular  desmosomes  and  varying  degrees  of  anisocytosis  and 
anisokaryosis. Nuclei were often large, ovoid and vesicular with prominent nucleoli. 
The squamous cell carcinomas were locally aggressive, invading into the surrounding 
dermis,  subcutis  and  even  bone  (n  =  1).  Inflammatory  infiltrates  were  frequently 
observed  within  SCCs  or  in  the  surrounding  subcutis,  comprising  neutrophilic, 
histiocytic, lymphoplasmacytic or mixed cellular populations.  In three animals in this 
study with cutaneous and muco-cutaneous SCC, metastases were observed in a lymph 
node (n = 1) and the lungs (n = 2).    23
 
Figure  2.7  WBB  cutaneous  squamous  cell  carcinoma;  Islands  of  neoplastic  epithelial  cells 
containing  central  cores  of  keratin  extend  from  the  epidermis  and  invade  the  dermis.  A 
serocellular crust overlies the neoplastic epithelium. 
   
Figure  2.8  WBB  cutaneous  squamous  cell  carcinoma,  greater  magnification  of  Figure  2.7; 
Neoplastic  epithelial  cell  are  closely  apposed  with  intercellular  desmosomes  visible,  have 
abundant  eosinophilic  cytoplasm  and  basophilic  staining  nuclei  with  prominent  and  often 
multiple  nucleoli.  There  is  moderate  to  marked  anisokaryosis  and  anisocytosis  and  mitotic 
figures  are  observed  frequently.  A  mild  neutrophilic  infiltrate  is  seen  in  the  subcutis  and 
neoplastic epithelium. HE. Bar = 200  m.   24
The distribution and histological classification of lesions according to their anatomical 
site is detailed in Table 2.3. SCCs were seen most commonly over the haired skin of the 
thorax  and  abdomen,  and  in  the  periaural  region.  Adenocarcinoma  of  the  pouch 
mammary  glands  was  observed  in  one  female  affected  by  papillomatous  and 
carcinomatous  lesions  at  other  anatomical  sites.  Conjunctival  lesions  were  least 
frequently  observed  to  undergo  malignant  transformation,  with  only  4/24  lesions 
designated  carcinoma  in  situ  and  no  cases  of  SCC  observed  at  this  site.  However, 
lesions at this site exclusively displayed hyperplastic epithelium (n = 8) or carcinoma in 
situ (n = 1) in which keratinocytes demonstrated nuclear chromatin margination and 
amphophilic intranuclear inclusions. 
   25
Table 2.2 Histological classification of cutaneous and muco-cutaneous lesions in WBBs. 
Lesion site  No. lesions examined 
at site 
Hyperplasia  Hyperplasia + 
intranuclear inclusions 
Carcinoma in situ  Squamous Cell 
Carcinoma 
Adenocarcinoma 
Conjunctival muco-cutaneous junction  24 (WBB = 21)  12 (50.0%)  8 (33.3%)  4 (16.7%)  0 (0.0%)  0 (0.0%) 
Oral muco-cutaneous junction  23 (WBB = 22)  12 (52.2%)  0 (0.0%)  5 (21.7%)  6 (26.1%)  0 (0.0%) 
Periaural skin  19 (WBB = 18)  6 (31.6%)  0 (0.0%)  4 (21.1%)  9 (47.4%)  0 (0.0%) 
Digital skin  22 (WBB = 21)  11 (50.5%)  0 (0.0%)  6 (27.3%)  5 (22.7%)  0 (0.0%) 
Haired skin (thorax/ abdomen)  27 (WBB = 20)  8 (29.6%)  0 (0.0%)  10 (37.0%)  9 (33.3%)  0 (0.0%) 
Pouch/ inguinal region  11 (WBB = 11)  6 (54.5%)  0 (0.0%)  3 (27.3%)  1 (9.1%)  1 (9.1%) 
Total  126 (WBB = 48)  55 (36.0%)  8 (6.8%)  32 (25.6%)  30 (23.9%)  1 (0.9%)   26
2.3.4 Ultrastructural examination of lesions 
Ultra thin sections from a range of hyperplastic and malignant lesions from 13 WBBs 
were examined by transmission electron microscopy. Three hyperplastic conjunctival 
lesions from three individuals that displayed keratinocyte intranuclear inclusions visible 
on the toluidine blue stained slides displayed a crystalline array of spherical electron 
dense  particles,  ~  45  nm  in  diameter  (Figure  2.11),  within  keratinocyte  nuclei.  The 
morphology and size of these particles were consistent with that of a papillomavirus or 
polyomavirus.  
 
Figure 2.9 Electron micrograph of western barred bandicoot conjunctival keratinocyte nuclei; 
Crystalline array of spherical electron dense virus-like particles ~ 45 nm in diameter seen within 
hyperplastic  keratinocyte  nuclei.  Bar  =  500  nm.  Image  courtesy  A.J.  O’Hara,  Murdoch   27
University. 
2.3.5 Immunohistochemistry 
Indirect  immunohistochemistry  using  a  polyclonal  antibody  against  BPV1  (Dako 
Corporation) was performed on skin lesions from 16 individuals. Positive intranuclear 
staining (Figures 2.12) was observed in conjunctival epithelial samples from the three 
WBBs whose conjunctival lesions demonstrated ultrastructural evidence of PV or PyV 
virions.  
 
 
 
Figure  2.10  Serial  section  of  2.6.  Immunohistochemical  demonstration  of  papillomavirus 
structural antigens by use of rabbit polyclonal antibody developed from bovine papillomavirus 
type 1 (BPV1). Haematoxylin counterstain. Bar = 200  m.   28
2.4 Discussion  
This chapter describes the pathological features of a recently recognised papillomatosis 
and  carcinomatosis  syndrome  in  48  WBBs.  The  spectrum  of  cutaneous  and  muco-
cutaneous lesions recorded resembles the stepwise progression of epithelia from pre-
malignant  stages  into  invasive  squamous  cell  carcinomas.  A  single  case  of 
adenocarcinoma of the pouch mucosa was observed; however, the significance of this 
tumour in relation to the otherwise exclusively squamous carcinomatosis syndrome is 
yet unclear. This disease occurs in adult individuals (on average > three years of age), 
lesions increase in size and number with age (See also Chapter 5 Section 5.3.2) and 
malignant  transformation  was  observed  in  those  lesions  >  5x5x5  mm  in  size.  The 
discernable  stages  of  lesion  development  and  the  progression  in  lesion  size  and 
malignancy  seen  with  increasing  age  is  consistent  with  a  multistage  model  of 
carcinogenesis, reflecting the acquisition of genetic alterations by tumour cells driving 
progressive  transformation  into  highly  malignant  derivatives  (Weinstein  et  al.  1995; 
Hanahan and Weinberg 2000). 
 
Malignantly transformed lesions were observed in 31 individuals in the study cohort.  
Individuals in whom cutaneous and muco-cutaneous malignancies were not observed (n 
= 17) may have died or been euthanased before lesions had transformed. Alternatively, 
for reasons not yet elucidated, transformation of lesions may never have occurred in 
these individuals. The development of malignancy involves often complex interactions 
between exogenous (environmental) and endogenous (genetic, hormonal, immunologic) 
factors  (Weinstein  et  al.  1995).  Certain  viruses  are  known  to  play  key  roles  in 
carcinogenesis  in  humans  and  animals  (Howely  1995).  Gross  and  histopathological 
features of cutaneous and muco-cutaneous lesions combined with the ultrastructural and 
immunohistochemical features of conjunctival lesions in affected WBBs in this study   29
are  supportive  of  the  involvement  of  either  a  PV,  or  less  probably  a  polyomavirus 
(PyV), in the pathogenesis of this disease. In addition, the observation of skin lesion 
development  in  seemingly  healthy,  wild  WBBs  introduced  into  captive  colonies  of 
WBBs affected with the skin lesions provides further support that the syndrome may be 
caused by an infectious agent.  WBBs are largely solitary, territorial and both males and 
females display aggression. Fight wounds and incidental trauma including loss of tails, 
ears and eyes have been observed by the authors in both captive and wild WBBs. These 
incidents may facilitate the entry of an epitheliotropic agent, such as a PV or PyV, or 
activate  a  latent  infection,  and  thus  it  must  be  considered  that  a  multicentric  lesion 
distribution  may  be  related  to  sites  of  epithelial  trauma  (Siegsmund  et  al.  1991; 
Longworth  and  Laimins  2004).  Alternatively  the  multicentric  distribution  of  lesions 
may have arisen secondary to autoinoculation or perhaps viraemia as has been alluded 
to in other species infected with PVs or PyVs (Scinicariello et al. 1992; Armbruster-
Moraes et al. 1993; Azzi et al. 1996; Dubois et al. 1997; Bossart et al. 2002).  
 
In  general,  PVs  are  species-specific  and  induce  excessive  irregular  proliferation  of 
cutaneous and mucosal epithelia in both humans and a range of animal species (zur 
Hausen 1996; Sundberg et al. 1997). Papillomatosis is not always associated with PV 
infection  however,  with  a  range  of  infectious  as  well  as  non-infectious  agents  also 
recognised  to  induce  proliferative  and  papillomatous  lesions  in  animal  species 
(Sundberg et al. 1997). 
 
Despite  often  appearing  early  in  the  course  of  disease  (author  observation)  and  an 
increase  in  lesion  size  seen  clinically,  conjunctival  lesions  were  rarely  observed  to 
undergo  malignant  transformation.  In  addition,  all  lesions  that  demonstrated  both 
ultrastructural and immunohistochemical evidence (n = 3) of PV virions were derived   30
from the conjunctiva only. Non-conjunctival lesions examined in this study may have 
lacked  ultrastructural  and  immunohistochemical  evidence  for  PV  infection  if 
intermittently infected,  a condition described in PV-induced lesions in  other species 
(Sundberg  et  al.  1985).  Alternatively,  non-conjunctival  lesions  may  have  lacked 
evidence of virions if sampled early in the course of development; experimental PV 
infections in other species have shown that lesions do not express the capsid antigen 
(L1) until seven weeks or more after infection. Consequently, early proliferative lesions 
often  prove  negative  by  immunohistochemistry  for  L1  capsid  antigens,  and  do  not 
contain  viral  particles  on  ultrastructural  examination  (Nicholls  et  al.  2001). 
Furthermore, epithelia undergoing malignant transformation in association with PV (or 
PyV) infection may be negative for structural antigens by immunohistochemistry and be 
unremarkable on ultrastructural examination if viral DNA has become integrated into 
the host genome, leading to a non-productive infection.  Integration of viral DNA into 
host genomic DNA has been well documented in malignant lesions associated with high 
risk human PV infections (Cullen et al. 1991; Jeon et al. 1995; Jeon and Lambert 1995; 
Pirami et al. 1997; Hudelist et al. 2003) and PyV infections (Cole and Conzen 2001). 
  
The  development  of  malignancy  involves  a  complex  interaction  between  both 
exogenous and endogenous factors. Indeed the outcome of a PV or PyV infection and 
the  role  of  the  virus  in  carcinogenesis  may  be  influenced  by  factors  such  as  the 
virulence of the particular PV type (Sundberg et al. 1985; Brandsma 1994; zur Hausen 
1996; Stanley et al. 1997) compromise of the host immune system (Boules Bavinck and 
Berkhout 1997; Palefsky 1998; Nicholls et al. 1999; Major 2001; Berger 2003), host 
genetics (Wank and Thomssen 1991; Han et al. 1992; Apple et al. 1994; Breitburd et al. 
1997; Majewski et al. 1997) and the presence of various chemical cofactors (Rous et al. 
1953;  Jarrett  et  al.  1978;  Clarke  et  al.  1982).  Immunodeficiency  and/  or   31
immunocompromise in the WBB may be potential risk factors for development of this 
disease.    An  increased  incidence  of  PV  related  disease  is  being  reported  in  other 
endangered animal populations (Joslin et al. 2000; Bossart et al. 2002) with decreases in 
genetic diversity a proposed cause of increased susceptibility to disease agents in some 
endangered species (Tachezy et al. 2002b). In attempts to elucidate the pathogenesis of 
this disease in the WBB, it must be considered that a complex interaction between viral 
and other factors may be driving the development of malignant epithelial tumours.  
 
Immunohistochemical  staining  of  WBB  conjunctival  lesions  in  this  study  led  to 
consideration of the involvement of a PV in the pathogenesis of this disease. However, 
the  involvement  of  a  PyV  alternatively  could  not  be  ruled  out  on  the  basis  of 
immunohistochemical  results  alone.  Significant  antigen  retrieval  techniques  were 
required to demonstrate PV structural antigens, which in the authors’ experience have 
not  been  required  for  PV-associated  epithelial  lesions  from  other  species  using  an 
otherwise identical technique. In addition gross, histological and ultrastructural features 
of lesions did not discount a PyV as an alternative etiological agent. The mammalian 
PyVs display a narrow host range and do not productively infect other species, typically 
causing apathogenic subclinical natural infections in immunocompetent hosts. These 
viruses may cause severe disease in the immunocompromised host or can cause tumour 
formation when they are introduced into an unnatural host (Cole and Conzen 2001; 
Major 2001).
 The hyperplastic changes seen affecting  root sheath epithelia in WBB 
lesions from areas of haired skin were reminiscent of the appearance of Hamster PyV 
associated  trichoepitheliomas  (Graffi  et  al.  1968).  These  tumours  of  hamsters  form 
spontaneously  and  occur  primarily  on  the  skin  of  the  head,  chin,  neck,  back  and 
frequently  around  the  eyes  and  external  ears;  histologically  they  demonstrate   32
proliferation of the hair root epithelium, forming cyst-like masses filled with cornified 
material (Scherneck et al. 2001).  
 
Papillomatous  lesions  have  also  been  described  in  a  common  brush-tail  possum 
(Trichosurus vulpecula) in association with a putative PV infection, this being the only 
potentially PV associated skin disease documented in an Australian marsupial to the 
authors’ knowledge (Perrott et al. 2000). PV particles were visualised in tissue sections 
and  homogenates  by  transmission  electron  microscopy,  and  novel  sequence  data 
homologous to the L1 region of known PV types was amplified from extracted lesional 
DNA  using  a  broad  spectrum  polymerase  chain  reaction  (PCR)  technique. 
Papillomatous lesions have also been recorded in a North American opossum (Didelphis 
virginiana)  associated  with  a  PV  (Sundberg  et  al.  1997).  The  papillomatosis  and 
carcinomatosis syndrome observed in the WBB is a novel and emerging disease in this 
species and, to the authors’ knowledge is unlike skin diseases of Australian marsupials 
previously documented.
 
 
On the basis of pathological investigations alone, it appears that a PV, or PyV, may be a 
contributing aetiological agent in the papillomatosis and carcinomatosis syndrome in 
the WBB. However, definitive evidence to support or refute the presence of these agents 
is lacking on the basis of pathological investigations alone as not all affected WBB 
displayed lesions with histological, ultrastructural and immunohistochemical evidence 
of viral infection. Subsequent chapters detail the features of and disease caused by PVs 
and PyVs, respectively, molecular techniques for the detection of viral agents and the 
frequency  of  the  papillomatosis  and  carcinomatosis  syndrome  in  wild  and  captive 
populations (Chapter 5), in order to better understand the pathogenesis of this novel and 
debilitating disease.   33
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Papillomaviridae and Polyomaviridae 
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3.1 Introduction 
The  gross,  histological,  ultrastructural  and  immunohistochemical  features  of  the 
papillomatosis  and  carcinomatosis  syndrome  discussed  in  Chapter  2  supported  the 
involvement of a papillomavirus (PV) in the pathogenesis of this disease. However, for 
reasons discussed in Section 2.5, the involvement of a polyomavirus (PyV) rather than a 
PV could not be ruled  out on the basis of pathological investigations  alone. At the 
completion of pathological investigations there was found to be an absence of definitive 
evidence  to  support  or  refute  the  role  of  a  specific  aetiological  agent,  as  non-
conjunctival  epithelial  lesions  did  not  demonstrate  intranuclear  inclusion  bodies  nor 
ultrastructural  or  immunohistochemical  evidence  of  viral  infection.  As  pathological 
investigations alone were inconclusive, it was decided to adopt molecular techniques to 
screen benign and malignant, cutaneous and muco-cutaneous lesions for papillomaviral 
and polyomaviral genomic DNA (presented subsequently in Chapter 4). This Chapter 
presents a review of the literature relevant to the research reported in this thesis. It is 
composed of two broad sections, devoted to diseases associated with, general features 
pertaining to, and oncogenic mechanisms of the Papillomaviridae and Polyomaviridae, 
respectively.  
 
Previously  considered  subfamilies  of  Papovaviridae,  PVs  and  PyVs  are  small  non-
enveloped  DNA  viruses  comprising  a  single  double-stranded  circular  DNA  genome 
within an icosahedral capsid. Furthermore, they share the ability to cause malignant 
neoplasia, and use similar strategies to take control of the host cell DNA replication and 
transcription processes (Howely 1995). It was later recognised that the two virus groups 
had significantly different genome sizes (Papillomaviridae ~ 8kb vs. Polyomaviridae ~ 
5kb) and organisation, and encode a different number and type of structural and non-
structural proteins, thus they are currently classified as two separate families by the   35
International Committee on the Taxonomy of Viruses (ICTV) (Howley and Lowy 2001; 
de Villiers et al. 2004). The two families can also be distinguished by the presence of 
conserved family-specific epitopes in their major capsid proteins (Jenson et al. 1980). 
 
No PyVs have been detected in, and very little is known in regards to PV infections in 
Australian  marsupial  species.  Previous  studies  have  detailed  the  amplification  of 
putative PV sequences from the skin of marsupial species, namely from a cutaneous 
papilloma of a common brush-tail possum (Trichosurus vulpecula) (Perrott et al. 2000), 
and  from  the  healthy  skin  of  koalas  (Phascolarctos  cinereus)  and  an  eastern  grey 
kangaroo (Macropus giganteus) (Antonsson and McMillan 2006). However, complete 
genomic sequences were not deduced in these studies, rather sequencing was restricted 
to that of amplicons obtained from the L1 region of each virus using degenerate primer 
PCR. This chapter provide an overview of PV-associated disease, as well as general 
information  regarding  the  viral  properties  and  biological  characteristics  of  the 
Papillomaviridae. As PyVs were considered an important differential aetiological agent 
in pathogenesis of the papillomatosis and carcinomatosis syndrome, a summary of PyV-
associated disease, viral properties and biological characteristics of the Polyomaviridae 
is also provided in Section 3.3.   36
3.2 Papillomaviruses 
3.2.1 General features of papillomavirus infections 
Papillomaviruses  (PVs)  are  transmissible  epitheliotropic  and  species-specific  viruses 
that typically cause excessive irregular proliferation of cutaneous and mucosal epithelia 
in humans and many animal species (Sundberg et al. 1997; Lowy and Howley 2001). 
These  viruses  exhibit  a  range  of  pathogenicity  and  have  been  associated  with  both 
benign and malignant disease (Sundberg et al. 1988; Brandsma 1994; zur Hausen 1996; 
Stanley et al. 1997).   
 
PVs are epitheliotropic and most types exhibit a site predilection for either cutaneous or 
mucosal  surfaces  (Van  Ranst  et  al.  1992).  A  limited  number  of  PVs  display  dual 
tropism, e.g. bovine PV type 4 (BPV4), which is known to induce papillomas when 
inoculated into the mucous epithelium of the alimentary canal, but not when inoculated 
into  the  cutaneous  epithelium  (Jarrett  1985).  Some  PVs  are  known  to  induce 
fibropapillomas through specific targeting of fibroblasts (Sundberg et al. 1997). This 
distinct group, found primarily in ungulates, includes BPV1, BPV2, European elk PV, 
the deer PV and the reindeer PV (Lowy and Howley 2001). 
 
Hundreds of putative PV types have been detected and at least 120 PVs across a broad 
range of species completely described (Sundberg et al. 1997; Lowy and Howley 2001; 
de Villiers et al. 2004). Classification of PVs, as for other viruses, has previously been 
influenced  by  biological  properties  (species  affected,  site  tropism  etc),  pathological 
properties and genomic organisation. In 1995, criteria for the classification of PV types 
were established by the International Committee on the Taxonomy of Viruses (ICTV). 
With advances in molecular techniques leading to increased availability of sequenced   37
PV genomes and ease of detection of novel PV types, the classification system has 
evolved to become based on comparisons between complete sequences of the L1 ORF, 
the  most  conserved  region  across  PV  types  (de  Villiers  et  al.  2004).  Members  of 
Papillomaviridae are presently grouped into genera, an organisational group previously 
known as higher order clusters, e.g. “genital PVs”, “supergroups” or “major branches”.  
Different genera share less than 60% nucleotide sequence identity in the L1 ORF.  In 
the case of full length PV genomic sequences, complete genomes share more than 23% 
but  less  than  43%  of  nucleotide  sequence  identity  when  comparing  genera  of  the 
Papillomaviridae. Genera are subsequently divided into species, a level of classification 
previously known as lower order cluster “groups”, subgroups” or “minor branches”. 
Species  within  a  genera  share  between  60%  and  70%  nucleotide  identity  (30-40% 
dissimilarity) in the  L1  ORF. Types form the next level of classification, PVs of  a 
certain type sharing between 71% and 89% nucleotide identity in the L1 ORF (i.e. at 
least 10% dissimilarity). Subtypes contain 90-98% similarity (2-10% dissimilarity) in 
the L1 ORF and variants possess a maximum of 2% dissimilarity in L1 ORF. A novel 
isolate is recognised as such if the complete genome has been cloned and the DNA 
sequence of the L1 ORF differs by more than 10% from the closest known PV type 
(International Papillomavirus Workshop, Quebec, 1995).  
 
PVs  are  species-specific,  with  interspecies  transmission  a  very  rare  event.  Reasons 
proposed  for  species-specificity  include  the  virus’  requirement  for  certain  cellular 
receptors for uptake, or for specific cellular factors necessary for replication or gene 
expression (Campo 1997). Circumstantial and experimental data supports the notion 
that PVs are ancient viruses that originated early in vertebrate evolution and have co-
evolved and speciated in synchrony with the host species (Shadan and Villarreal 1993; 
Van Ranst et al. 1995). This notion has been supported by various studies exploring the   38
host co-evolution of human PV types with certain ethnic groups (Ho et al. 1993; Ong et 
al.  1993)  and  phylogenetic  studies  of  human  PVs  (Chan  et  al.  1992),  non-human 
primate PVs (Chan et al. 1997) and more recently with PVs of felid species (Rector et 
al. 2007).  
 
An exception to the rule of species-specificity is the association of bovine PV types 
with  equine  sarcoid  lesions.  A  direct  causal  relationship  has  not  been  established, 
however many studies have demonstrated BPV1 and BPV2 viral DNA in very high 
proportions of equine sarcoid lesions (Martens et al. 2001), with expression of bovine 
papillomaviral genes (including oncogenes) reported (Nasir and Reid 1999). Further 
investigations confirmed the detection of BPV DNA in equine sarcoids, yet found these 
infections to be non-productive (Chambers et al. 2003).  
 
PVs typically cause excessive irregular proliferation of cutaneous or mucosal epithelia. 
Lesions  may  comprise  exophytic,  verrucous  thickenings  or  inverted  proliferation  of 
epithelial  surfaces  (papillomas),  or  less  commonly  take  the  form  of  flat  plaques. 
Histologically, benign lesions are characterised by mild, moderate or marked exophytic 
expansion of the epithelium, notably caused by hyperplasia of the stratum spinosum and 
stratum granulosum. This thickening of the epithelium is due to stimulation by viral 
proteins and the delayed maturation of cells in the upper layers of the epithelium (Frazer 
2004). Sundberg et al. (1997) separated benign PV-associated lesions of animal species 
into  three  categories  of  tumour  type:  papillomas  (epidermal  proliferation  on  thin 
fibrovascular  stalks),  fibropapillomas  (epidermal  proliferation  on  prominent 
fibrovascular structures forming a verrucous pattern), or fibromas (primarily fibroblasts 
and dense irregular collagenous connective tissue). 
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Not all papillomas are caused by PVs and a range of other agents are recognised to 
induce  papillomatous  lesions,  such  as  poxviruses,  herpesviruses,  adenoviruses, 
rhabdoviruses, retroviruses, anaerobic bacteria and chemical carcinogens (Sundberg et 
al. 1997). Goldschmidt and Hendrick (2002) describe points of differentiation between 
virally induced and non-viral associated squamous papillomas (Table 3.1). There are a 
number  of  morphologic  features  of  PV-induced  lesions  that  reflect  the  biologic 
properties of the virus and the actions of specific viral products.  
 
Table 3.1 Points of differentiation between viral and squamous papillomas (Goldschmidt and 
Hendrick 2002). 
Viral Papilloma  Squamous papilloma 
Epidermal differentiation may show orthokeratosis or parakeratosis  Epidermal differentiation is normal 
 
Enlarged keratohyaline granules  Normal size to Keratohyaline granules 
Koilocytes present  Koilocytes absent 
Keratinocytes show viral cytopathic effect  Keratinocytes normal 
Intranuclear inclusions may be present  No intranuclear inclusions 
Elongated rete slant inward  Elongated rete slant outward 
 
Koilocytosis is an atypical change of keratinocytes most commonly seen in the upper 
layers  of  the  epidermis  and  is  often  typical  of  PV  infections.  These  cells  are  often 
enlarged and have eccentric and pyknotic nuclei surrounded by a halo. The mechanisms 
underlying  this  cytopathic  change  are  unknown,  as  most  abnormal  nuclei  are  not 
associated with virus particles or virus protein (Lowy and Howley 2001). Keratohyaline 
granules are often prominent in the stratum granulosum and occasionally intranuclear 
inclusions can be detected in the upper layer of the epidermis. Intranuclear inclusions 
are seen in productively infection lesions, most commonly in the stratum granulosum 
and stratum spinosum, and may comprise partially assembled and/ or mature virions. 
Occasionally intracytoplasmic inclusions may be seen, such as in the mucosal lesions 
induced by feline PVs (Sundberg et al. 2000). In these feline lesions, inclusions were   40
observed as large and irregular keratohyalin-like cytoplasmic granules (thought to be an 
E4 gene product) or condensed cytoplasmic inclusions (putative feature of degenerating 
keratinocytes) and did not stain positive for PV structural antigens. Intracytoplasmic 
inclusions have been described in human “plantar” warts associated with human PV 
type 1 (HPV1), also believed to be associated with an E4 gene product (Croissant et al. 
1985; Rogel-Gaillard et al. 1992). 
 
Papillomaviruses and cancer 
During  the  last  century,  PVs  have  emerged  as  one  of  the  most  important  viral  risk 
factors  for  a  broad  range  of  human  cancers.  As  such,  the  wealth  of  knowledge 
concerning  these  viruses  is  considerable.  Perhaps  one  of  the  most  well  known  and 
clinically  important  PV-related  diseases  in  humans  are  genital  cancers,  specifically 
squamous cell carcinoma, or less commonly adenocarcinoma, of the cervix (zur Hausen 
1996).  Evidence for a link between PV infection and cervical cancer emerged between 
1974  and  1976,  and  the  first  study  to  propose  the  involvement  of  PV  infections  in 
cervical lesions was published in 1976 (Meisels and Fortin 1976). The first cervical 
cancer linked PV, human PV type 16 (HPV16), was isolated and cloned in 1983 (Durst 
et al. 1983). Since then, numerous studies have provided pathological, molecular and 
epidemiological evidence for the involvement of various HPV types in cervical cancer 
(zur Hausen 2002). Infection with HPV16, the highest risk genotype, is believed to be 
responsible for more than 50% of cervical cancers worldwide (Munoz et al. 2003), and 
nearly  100%  of  cervical  cancers  are  associated  with  the  presence  of  PV  DNA. 
Interestingly  however,  cervical  cancer  is  estimated  to  develop  in  less  than  5%  of 
individuals infected with HPV16 over their lifetime (Goldie 2003).  
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One of the earliest studied models of PV-related oncogenesis was epidermodysplasia 
verruciformis (EV) (Jablonska et al. 1972; Orth et al. 1978; Pfister et al. 1983). EV is a 
genetically determined, unusual susceptibility to infection with EV-specific human PV 
types  (EV-HPVs),  PVs  which  are  otherwise  harmless  to  the  general  population 
(Majewski and Jablonska 1995). Disease onset occurs at childhood with the appearance 
of refractory widespread macules and flat wart-like lesions, which commonly undergo 
malignant transformation. The malignant form of disease is associated with infection 
with EV-HPV types 5 and 8. However, the presence of these EV-HPVs alone, although 
necessary, is not sufficient for malignant transformation of lesions. Transformation is in 
large part due to the action of co-carcinogens such as ultraviolet light and  - irradiations 
(Jablonska and Majewski 2003). A defect in the responsiveness of the EV patient’s 
immune  system  to  the  presence  of  the  EV-HPV  is  thought  to  be  responsible  for 
persistence of  cutaneous infection and tumour progression (Majewski and Jablonska 
1995), a theory is supported by the occurrence of EV-like lesions, induced by  EV-
HPVs,  in  heavily  immunosuppressed  patients  (Bunney  et  al.  1987).  A  close  link 
between psoriasis, a T – cell mediated skin disease of people, and EV has also been 
proposed: a 1998 study demonstrating that over 90% of psoriatic lesions in the cohort 
harboured  EV-HPV  DNA  (Favre  et  al.  1998b).  Further  to  this,  co-localisation  of 
susceptibility loci for both psoriasis and EV has been shown on chromosomes 17qtr and 
2,  respectively  (Ramoz  et  al.  1999;  Ramoz  et  al.  2000).  Epidermodysplasia 
verruciformis is a unique and complex malignant skin disease resulting from interaction 
between specific PV types, host genetics and environmental co-carcinogens (Jablonska 
and Majewski 2003) . 
 
In  addition  to  the  much  studied  EV-HPVs  and  high  risk  HPVs  involved  in  the 
pathogenesis of cervical cancer, PV infection in people has also been associated with   42
anogenital carcinoma (zur Hausen 1990), upper respiratory tract cancer (Lindeberg et al. 
1986),  oral  and  neck  squamous  cell  carcinomas  (Gillison  and  Shah  2001),  non-
melanoma skin cancers and solar keratosis (Forslund et al. 2003; Masini et al. 2003), 
alimentary tract cancer (Chang et al. 1990) and bladder cancer (Anwar et al. 1992).  
 
As in humans, PVs are emerging with increasing frequency as risk factors for cancer in 
animal species. The discovery of the malignant progression of PV-associated lesions in 
animal species led to their adoption as models for HPV-related oncogenesis (Brandsma 
1994). The cotton tailed rabbit PV (CRPV) was the first PV identified and characterised 
in an animal species (Shope and Hurst 1933). Cutaneous papillomas induced by CRPV 
were  observed  to  undergo  malignant  transformation,  which  provided  an  important 
model for the study of viral tumorigenesis (Kreider and Bartlett 1985).  
 
The bovine PVs, and their association with benign and malignant epithelial tumours, 
were  also  some  of  the  first  and  most  extensively  studied  PV  types  (Campo  1997). 
Bovine PVs (BPVs) fall into two subgroups: A, comprising the fibropapillomaviruses 
(BPV1, 2 and 5); and B, comprising the epitheliotropic PVs (BPV3, 4 and 6) (Jarrett 
1985).  In  healthy  and  immunocompentent  cattle,  papillomas  induced  by  BPV  types 
normally regress. However, persistent papillomatosis and malignant transformation of 
BPV4-associated upper alimentary tract lesions and BPV2-associated bladder lesions in 
cattle occurs in the presence of environmental co-carcinogens, such as following the 
feeding of bracken fern (Pteridium aquilinum) (Leach et al. 1971; Jarrett et al. 1978; 
Campo et al. 1992; Campo et al. 1994).  
 
PV infection and associated malignancies have been documented in rodent species such 
as the multimammate rat Mastomys natalensis (MnPV) and the wild European harvest   43
mouse, Micromys minutus (MmPV) (Sundberg et al. 1988; Brandsma 1994). MnPV 
DNA has been observed to amplify spontaneously in epidermal cells of endogenously 
infected M. natalensis, with the development of papillomas or keratinising squamous 
cell carcinomas observed to occur simply as the animals aged, following treatment with 
tumour promoters or by mechanical irritation (Brandsma 1994). Hairless mice have an 
endogenous  PV  that  is  activated  when  exposed  to  UV  light  (Tilbrook  et  al.  1989). 
Natural  MmPV  infection  in  wild  M.  minutus  has  been  associated  with  a  variety  of 
lesions such as epidermal hyperplasia, epidermal inclusion cysts, squamous papillomas, 
inverted  papillomas,  trichoepitheliomas  and  sebaceous  carcinomas  (Sundberg  et  al. 
1988). 
 
Although PV-associated disease in cats is thought to be rare (Sundberg et al. 2000), PV-
associated benign and malignant, cutaneous and mucosal tumours have been described 
in both domestic and wild felids (Baer and Helton 1993; Scott et al. 1995; Joslin et al. 
2000; Sundberg et al. 2000; Goldschmidt and Hendrick 2002). A particularly interesting 
and  potentially  devastating  PV  infection  is  that  described  in  the  endangered  snow 
leopard Panthera uncia (Joslin et al. 2000). Captive snow leopards were identified with 
raised, thickened and black cutaneous lesions of the face and forelimbs. Histological 
features of benign lesions were suggestive of PV infection and PV structural antigens 
were  identified  by  immunohistochemistry.  Benign  lesions  were  noted  to  undergo 
malignant transformation to squamous cell carcinomas (SCC) in all affected individuals, 
and PV antigens were identified in carcinomas using immunohistochemistry. The first 
snow leopard diagnosed with the virally-induced papillomas developed SCC on his feet 
nine  years  after  the  initial  diagnosis.  A  retrospective  analysis  of  snow  leopard 
mortalities from 66 institutions found that 21 individuals had SCC lesions present at the 
time of death (Joslin et al. 2000).    44
 
The  first  canine  disease  to  be  associated  with  PV  infection  were  oral  papillomas 
(Chambers  et  al.  1960),  the  causative  canine  oral  PV  (COPV)  subsequently 
characterised in 1994 (Delius et al. 1994). However, the involvement of PVs in canine 
malignancies was first suspected following a study of oral carcinomas (Watrach et al. 
1970), and subsequently reported in 1987 in association with cutaneous squamous cell 
carcinomas (Bregman et al. 1987). A wide range of benign and malignant cutaneous and 
mucosal lesions in dogs have since been associated with PV infection and additional 
canine PV types subsequently proposed (Nicholls and Stanley 1999; Zaugg et al. 2005).  
 
The host immune response to papillomavirus infection 
The fate of cutaneous and mucosal lesions induced by PV infection is influenced by 
factors  such  as  the  virulence  of  the  virus  and  the  involvement  of  exogenous  or 
endogenous co-factors. Importantly, the fate of a PV-induced lesion may be influenced 
by  the  status  of  the  host’s  immune  system.    Most  benign  PV-induced  lesions  will 
regress  spontaneously  (Jenson  et  al.  1991),  although  some  may  induce  recurrent 
infections  or  fail  to  regress  and  persist  on  the  host  (Nicholls  et  al.  1999)  and 
alternatively  some  may  undergo  malignant  progression.  Immune  responses  to  PV 
infection are concomitant, involving a humoral, or “protective”, immune response and a 
cell-mediated response, the latter of which is believed to be most critical in inducing the 
regression  of  established  infections.  In  many  ways  PVs  have  evolved  to  avoid  the 
immune system, eliciting a poor immune response in the host and infections lasting 
months to years. This is thought in large part to be due to infections being non-lytic, 
viral  replication  taking  place  in  the  avascular  epithelium  and  the  fact  that  minimal 
inflammatory response is elicited leading to little local or systemic presentation of PV 
antigens to the immune system (Frazer 1996).     45
 
The  humoral  response  that  develops  in  the  immunocompetent  host  following  PV 
infection allows protection from future infection (Nicholls and Stanley  2000). Early 
experimental studies with COPV demonstrated that dogs could not be reinfected three 
weeks post infection despite continued growth of existing warts, a finding supportive of 
the development of protective immunity (Chambers et al. 1960; Konishi et al. 1972). 
More recent experimental work with COPV demonstrated that passive transfer of serum 
immunoglobulin from immune dogs (immunised with L1 protein) was able to prevent 
PV  infection  in  previously  naive  dogs  (Suzich  et  al.  1995).  Identical  findings  were 
observed in similar experimental work performed with rabbits and CRPV (Breitburd et 
al. 1995). Cross-species immunity has also been observed, human sera demonstrating 
precipitating antibodies against animal PVs and vice-versa (Pyrhonen and Neuvonen 
1978). The reason for this cross-species immunity was later elucidated by the discovery 
that antibodies are often formed against epitopes common to multiple PV types (Dillner 
et al. 1991). However, antibody mediated immunity directed against one or many PV 
types does not infer protection from all PVs, even within groups of PVs infecting the 
same species (Jarrett et al. 1990).  
 
Experimental  studies  have  demonstrated  that  the  neutralising  antibodies  produced 
through  a  humoral  immune  response  can  provide  protection  from  PV  challenge. 
However it is cell-mediated immunity  which is integral  for lesion regression in PV 
infected hosts. Histological observations have provided strong evidence for the role of 
cell  mediated  immunity  in  lesion  regression,  regressing  lesions  associated  with 
infiltration of lymphocytes (T-cells predominantly) (Nicholls and Stanley 2000). The 
predominance of CD4
+ cells seen in both BPV4 and COPV-induced lesions suggest 
they  are  playing  a  key  role  in  the  regression  of  mucosal  papillomas,  possibly  by   46
assisting  in  the  clearance  of  viral  infection  by  activating  macrophages,  through 
cytokine-mediated  inhibition  or  by  killing  of  infected  keratinocytes  (Nicholls  and 
Stanley 2000).  
 
The competence of the infected host’s immune system can determine both susceptibility 
to  and  the  outcome  of  PV  infection.  Otherwise  mildly  pathogenic  PVs  in  the 
immunocompetent host have been shown to cause moderate to marked disease in those 
individuals in which the immune system is unable to mount an appropriate response. 
The involvement of these viruses in both benign and malignant epithelial lesions of 
immunosuppressed people has been well documented, with persistence of PV-induced 
lesions  and  the  malignant  progression  of  lesions  seen  to  be  more  common  in  the 
immunosuppressed host (Majewski and Jablonska 1995; Boules Bavinck and Berkhout 
1997;  Palefsky  1998;  Nicholls  et  al.  1999).  Impairment  of  cell  mediated  immunity, 
rather than humoral, is believed to be the most important factor in PV- related disease in 
immunosuppressed  people.  A  study  by  Morrisson  (1975)  found  cutaneous  warts  to  
occur  more  frequently  in  patients  with  tumours  associated  with  depressed  T-cell 
function,  such  as  leukaemias  and  lymphomas,  but  not  in  patients  in  patients  with 
impaired humoral immunity, for example multiple myeloma (Morrison 1975).  
 
HPV  infections  are  considered  one  of  the  most  frequently  occurring  diseases  in 
iatrogenically immunosuppressed organ transplant recipients, with a wide diversity of 
HPV types detected in skin cancers (basal cell carcinoma and squamous cell carcinoma) 
and premalignant lesions of these patients (Boules Bavinck and Berkhout 1997). The 
source  of  PVs  in  immunosuppressed  people  is  much  speculated,  however  the  hair 
follicles  have  been  proposed  as  a  reservoir  of  infection  (Astori  et  al.  1998).  An 
increased  susceptibility  to,  or  persistence  of  PV  infections,  has  also  been  widely   47
reported in patients infected with human immunodeficiency virus (HIV) and acquired 
immunodeficiency syndrome (AIDS). In HIV positive individuals, the prevalence of 
HPVs, the incidence of multiple HPV type infections and the prevalence of anogenital 
and cervical premalignant HPV-associated lesions increases with decreasing CD4
+ T 
cell count (Palefsky 1998). Another example of decreased host immunity leading to an 
increased  susceptibility  to  PV  infection  in  people  is  that  of  epidermodysplasia 
verruciformis  (EV).  In  this  disease,  EV  patients  demonstrate  a  profound  defect  of 
immunity (deranged cell mediated immunity) specifically towards causative PVs, with 
pronounced inhibition of NK cells and cytotoxic T cells (Cooper et al. 1990; Majewski 
et al. 1990).  
 
Similarly in animal species, compromise of the host immune system can lead to an 
increased incidence or severity of outcome in PV infections. Although PV-associated 
disease is considered rare in the immunocompetent felid, non-regressing PV-associated 
skin  lesions  have  been  described  in  a  cat  seropositive  for  Feline  Immunodeficiency 
Virus  (FIV)  with  clinical  evidence  of  immunosuppression  (Egberink  et  al.  1992). 
Reasons proposed for increased susceptibility to PV infection were similar to those of 
HIV  infected  humans,  including  decreased  T  cell  responses,  low  CD4
+  counts,  and 
inversed ratios of CD4
+:CD8
+.  Iatrogenic immunosuppression has been associated with 
canine cutaneous papillomatosis, with the regression of lesions seen three weeks after 
the  cessation  of  corticosteroid  therapy  (Le  Net  et  al.  1997).  Multiple  PV-associated 
epidermal hamartomas and squamous cell carcinoma in situ have also been recorded in 
a dog following chronic immunosuppressive therapy with prednisone and cyclosporine 
(Callan  et  al.  2005).  Similarly  in  cattle,  immunosuppression  resulting  from  the 
administration  of  azothiaprine  or  feeding  of  bracken  fern  were  seen  to  increase  the 
severity of PV-associated disease (Campo et al. 1992; Campo et al. 1994).    48
Host factors aside from immune competence may also be influential in the outcome of 
PV  infection.  Certain  polymorphisms  for  major  histocompatibility  complex  (MHC) 
genes  (specifically  HLA-DQ)  have  been  associated  with  genetic  susceptibility  to 
cervical cancer development following infection with high risk PV types (Wank and 
Thomssen  1991;  Apple  et  al.  1994)  and  with  susceptibility  to  recurrent  respiratory 
papillomatosis  in  humans  (Gelder  et  al.  2003).  Similarly,  certain  polymorphisms  in 
MHC class I and II genes leading to defective proteins and subsequent derangement of 
antigen  presentation  by  APCs  in  the  epidermis  is  proposed  in  the  pathogenesis  of 
epidermodysplasia  verruciformis  (Majewski  et  al.  1997).  Majewski  et  al.  (1997) 
suggested  that  the  resulting  lack  of  co-stimulatory  signals  in  the  epidermis  due  to 
presentation of viral antigens by non specialist cells (e.g. virally infected keratinocytes) 
without co-stimulation could lead to immunotolerance and subsequent failure to reject 
the viral induced lesions, leading to life long disease. Studies with cotton-tail rabbit 
papillomavirus induced lesion in rabbits also suggest that progression or regression of 
lesions  may  be  linked  to  MHC-II  allotype  (Han  et  al.  1992)  as  well  as  to  the  host 
haplotype (Breitburd et al. 1997). A study by Nicholls et al. (1999) described a case of 
non-regressing COPV infection in an otherwise apparently immunocompetent dog, an 
infection normally found to be self-limiting in other individuals. An active humoral 
immune response in concert with an absence of significant lymphocyte infiltration in 
clinical biopsies were suggestive of defective cellular immunity (Nicholls et al. 1999).     49
3.2.2 Papillomavirus structure, genome and life cycle 
PVs are small non-enveloped DNA viruses with an icosahedral capsid ranging in size 
from 52 to 55 nm in diameter. The protein capsid contains a single molecule of the 
double-stranded circular DNA viral genome which ranges between 7100 base pairs (bp) 
(Muller et al. 1989) and 8607 bp in length (Delius et al. 1994). The position, size and 
function of many of the open  reading frames (ORF)  are well  conserved among the 
various PV types that have been sequenced and studied thus far (Chan et al. 1995). The 
conserved nature of the genomes is due to the relative stability of the PV DNA genome. 
As PVs are dependent on the host cell mechanisms for DNA replication, the genomic 
stability  is  likely  due  to  the  benefit  received  from  the  high  fidelity,  proof  reading 
capacity  and post-replication DNA repair mechanisms of the host DNA polymerase 
(Van Ranst et al. 1995).  All ORFs are located on one strand. The PV genome typically 
comprises up to ten ORFs which encode proteins classified as either “early” (E) or 
“late”  (L)  and  numbered  with  decreasing  size  (Figure  3.1).  The  early  region  is 
approximately  4000  nt  in  length  and  encodes  regulatory  proteins  involved  in  viral 
transcription,  replication  and  host  cell  cycle  control.  The  late  region,  comprising 
approximately  3000  nt,  encodes  the  structural  (capsid)  proteins  of  the  virus.  The 
remaining  1000  nt  non-coding  or  long  control  region  (LCR)  contains  cis  elements 
which regulate viral replication and expression. PVs encode limited mechanisms by 
which to synthesise their own DNA and as such they are reliant on host mechanisms, 
their life cycle tightly linked to the maturation of differentiating epithelia.    50
 
Figure  3.1  Schematic  representation  of  classical  Papillomaviridae  (HPV16)  genomic 
organisation. 
 
The  highly  conserved  early  genes  E1  and  E2  encode  proteins  involved  in  viral 
transcription. E1 encodes DNA-dependent ATPase and DNA helicase (Seo et al. 1993). 
It binds to the origin of replication and is necessary for both initiation and elongation of 
viral synthesis (Liu et al. 1995). E2 encodes DNA binding proteins that function as 
regulators of viral transcription and replication (Ham et al. 1991). In combination with 
cellular  DNA  machinery,  E1  and  E2  replicate  viral  DNA  episomally  in  the  basal 
epithelial cells and their subsequent progeny (transient amplifying cells). The E3 ORF 
was initially assigned to the early region, however no protein was found to be encoded 
by this region (Zheng and Baker 2006).   
 
The E5, E6 and E7 ORFs are involved in manipulation of the host cell cycle, most 
notably through their proliferative and cell stimulatory activity. E5 is only encoded by 
some PVs and its level of involvement in the PV lifecycle varies across PV types. In 
human PVs, E5 appears to be most important in the early stage of infection through its 
involvement in the stimulation of cell growth, providing a good environment for DNA 
replication (Hwang et al. 1995). It is particularly well conserved across the PV types 
that induce fibropapillomas, e.g. BPV1, deer PV and European elk PVs, suggesting that   51
E5 may play an important role in the tropism that these particular viruses exhibit for 
fibroblasts (Howley and Lowy 2001). In studies with human PVs, E5 has been shown 
not  to  be  essential  in  the  events  of  carcinogenesis  (Schwarz  et  al.  1985),  however 
studies with BPV1 have demonstrated that E5 is involved in the events of oncogenesis, 
and  alone  is  sufficient  to  cause  malignant  transformation  of  rodent  cells  in  culture 
(DiMaio et al. 1986; Schiller et al. 1986).   
 
Expression of the E6 and E7 proteins manipulates the host cell cycle in order to create a 
favourable environment for vegetative viral replication. The actions of these proteins in 
the  infected  keratinocyte  result  in  cell  stimulation  and  a  delay  in  differentiation, 
producing the epidermal thickening, or “wart” lesion, seen grossly that is characteristic 
of  many  PV  infections  (Frazer  2004).  The  E6  and  E7  proteins  stimulate  cell 
proliferation by activating cyclins E and A, and manipulate the host cell cycle through 
their interactions with cellular p53 and Retinoblastoma protein (Rb) respectively (zur 
Hausen  1996).  E6  complexes  with  cellular  p53  targeting  it  to  ubiquitination  and 
degradation (Scheffner et al. 1990; Werness et al. 1990). The role of p53 is to maintain 
genomic integrity after DNA damage has occurred through preventing or delaying cell 
division, or diverting the cell to apoptosis. Interference with p53 assists the PV to avoid 
the cell’s normal response to undergo apoptosis in response to foreign or unscheduled 
DNA  replication,  which  prolongs  synthesis  of  viral  DNA  and  delay  terminal 
differentiation  of  keratinocytes.  E6  also  induces  telomerase,  which  maintains 
chromosome integrity and postpones cell death. The E7 protein binds to cellular Rb 
resulting in its inhibition (Dyson et al. 1989). Rb plays an important role in the cell 
cycle check point, capable of inducing cell cycle arrest (G1), as well as in the regulation 
of transcription factors. By inhibiting Rb, E7 overcomes cell cycle arrest, reactivates 
DNA replication, and extends the cell life span, all of which favour the survival and   52
replication of the PV. Studies with human PVs have shown E6 and E7 to be necessary 
for the maintenance of extrachromosomal forms of PV DNA in undifferentiated basal 
cells (Thomas et al. 1999). The E6 and E7 proteins have stimulated much research 
interest  through  their  role  in  the  malignant  transformation  of  cells,  which  shall  be 
delved into further in the discussion of PV mechanisms of oncogenesis.  
 
The E8 ORF, not highly conserved over PV types, it is believed to encode a protein that 
functions as a negative regulator of viral transcription and regulation (Zheng and Baker 
2006). In several rabbit PVs it is believed to function as an oncogene (Han et al. 1998).  
 
E4  is  a  small  multifunctional  protein  expressed  from  a  spliced  E1^E4  mRNA  that 
contributes to both the early and late stages of the virus lifecycle (Nicholls et al. 2001; 
Nakahara  et  al.  2005).  This  protein  is  expressed  most  abundantly  in  the  productive 
stages  of  the  PV  lifecycle,  coinciding  with  the  onset  of  viral  amplification  and 
contributing to efficient genome amplification in the upper epithelial layers (Doorbar et 
al. 1997; Peh et al. 2004).  The E4 protein associates with cellular keratin filaments, and 
is thought to affect the mechanical stability of the keratin network and enhance the 
release of viral particles in mature keratinocytes (Doorbar et al. 1991; Khan et al. 2007).  
 
The NCR region of PVs typically lies between the stop codon of L1 and the start codon 
of E6. PVs usually contain an E1-recognition site flanked by two E2 binding sites, for 
binding of an E1/E2 complex in order to activate the origin of replication.  
 
The late coding region is highly conserved across PV types, and encodes the major 
capsid protein (L1) and the minor capsid protein (L2). These proteins are only expressed 
in productively infected cells (Baker and Howely 1987). The L1 region encodes the   53
major structural protein of the virus capsid. L2 encodes the minor capsid protein, which 
assists in stability of the capsid and the coordination of L1 in capsid assembly. L2 is 
also thought to be involved in packaging viral DNA (Zhou et al. 1991).  
 
Transmission of the virus between individuals occurs through direct contact or contact 
with contaminated surfaces or fomites. An individual’s own productively infected lesion 
can  provide  a  source  of  infectious  virus  for  transmission  to  uninfected  epithelia  by 
autoinoculation, e.g. between apposing areas of skin or mucous membranes (Lowy and 
Howley 2001). PVs are resistant to desiccation and can potentially remain infectious in 
the  environment  for  extended  periods  of  time  (Roden  et  al.  1997).  They  are 
epitheliotropic  and  their  life  cycle  is  tightly  linked  to  the  stages  of  epithelial 
differentiation, as demonstrated for human PV types in Figure 3.2. Some variation may 
be seen in the timing and order of events between PV types. A study by Peh et al. 
(2002) compared ten human and animal, cutaneotropic and mucosotropic, PV lifecycles. 
The study revealed that although key life cycle events, such as the onset of genome 
amplification  and  virus  assembly,  were  likely  to  be  similarly  regulated  in  all  PVs, 
considerable  differences  were  seen  between  the  viruses  examined  in  regards  to  the 
timing of events. The differences were thought to be explained to some extent by the 
variation in virus transmission routes, site tropism and the tendency of the virus type to 
induce persistent infection (Peh et al. 2002).  
 
PVs  infect  the  basal  cells  of  the  epithelium  gaining  access  to  these  cells  through 
microtrauma  or  abrasions  to  the  skin  (Longworth  and  Laimins  2004).  This  is  an 
essential step in the virus lifecycle as these cells are the only actively dividing layer of 
the  epithelia.  These  viruses  encode  limited  enzymes  involved  in  DNA  replication,   54
therefore  viral  replication  and  production  is  entirely  dependent  on  host  cell  DNA 
synthesis material.   
 
Figure  3.2  Stratified  squamous  epithelial  cell  architecture  and  the  expression  of  human 
papillomavirus (HPV) proteins after infection. After introduction of HPV into stem cells in the 
basal  layer  of  the  epithelium,  expression  of  viral  non-structural  proteins  occurs.  Under  the 
regulation of these proteins, the dividing cell population expands vertically and epithelial cell 
differentiation is delayed and is less complete. Viral proteins are expressed sequentially with 
differentiation as shown, and mature virions are produced only in the most superficial layers of 
the epithelium (Frazer 2004). 
 
Cells  in  the  basal  layer  consist  of  stems  cells  and  transit-amplifying  cells  that  are 
continually  dividing  and  provide  a  reservoir  of  cells  for  the  suprabasilar  regions 
(Hummel  et  al.  1992).  In  general,  as  the  host  cell  undergoes  differentiation  and 
movement towards the epithelial surface, there is activation of the early genes (E1 and 
E2) resulting in viral DNA transcription and low level viral DNA synthesis in the host 
cell nuclei. In the suprabasilar keratinocytes there is expression of early proteins E6 and 
E7, resulting in cell cycle arrest and a delay in cell differentiation, which allows further   55
amplification of the viral genome. In the squamous layers of epithelium, late genes (L1 
and  L2)  are  expressed  leading  to  production  of  capsid  proteins  and  assemblage  of 
virions. Virions are released into the environment with the desquamated keratinocytes. 
Low level viral replication can also occur in the infected host leading to persistence of 
infection. Viruses are thought to persist in infected “self renewing” epithelial stem cells, 
the  descendents  of  these  cells  being  the  origin  for  latent  infections  (Frazer  2004). 
Activation of PV infections can occur through immunosuppression of the host (Benton 
et al. 1992; Campo et al. 1994) or through mechanical trauma (Siegsmund et al. 1991). 
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3.2.3 Mechanisms of oncogenesis 
PVs are often classified as either “high risk” or “low risk” depending on the severity of 
disease  with  which  they  are  associated.  High  risk  PVs  have  the  potential  to  cause 
malignant transformation, or “immortalization” of the cells they infect, typically the 
human PVs that are associated with cervical and anogenital cancers (zur Hausen 2002). 
Low risk PVs on the other hand are associated with benign proliferations of epithelia 
and these lesions often regress in immunocompetent hosts. Neoplastic transformation is 
a dead end process for the virus as the transformed cell is no longer permissive for 
virion maturation (Campo 1997). Depending on the PV type involved, the fate of the 
viral genetic material in transformed cells may vary: viral DNA may be incorporated 
into the host DNA (Schwarz et al. 1985), it may be maintained as an extrachromosomal 
element (episome) which replicates in synchrony with the cell cycle (Botchan et al. 
1986), or it may be lost by the transformed cells (Campo et al. 1985).  
 
Malignant transformation is thought to come about through a number of mechanisms. 
However, most consistently it involves the deregulation of, and subsequent uncontrolled 
expression of, the viral oncoproteins E6 and E7. In studies with HPV16, E6 and E7 
expression  was  shown  early  in  PV  research  to  be  both  necessary  and  sufficient  for 
maintenance of the malignant phenotype in infected cells (Munger et al. 1989).   Studies 
with HPV16 have shown that both E6 and E7 can independently immortalize human 
cells, but the  greatest potential for malignant transformation occurs when these two 
proteins act together in a complementary and synergistic manner (zur Hausen 2002) 
(Figure 3.3). 
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Figure 3.3 Functions of the E6 and E7 oncoproteins, and their interaction with each other in 
steps that lead to cell immortalization. E6 functions to activate telomerase and the SRC kinases 
and inhibit p53 and BAK. E7 inhibits Rb, which releases E2F and results in the upregulation of 
INK4A, but also inactivates INK4A. In addition, E7 seems to stimulate cyclins A and E, and 
inactivate the cyclin-dependent kinase inhibitors WAF1 and KIP1. E6 and E7 synergize in cell 
immortalisation and malignant transformation. E6 prevents apoptosis that is induced by high 
E2F levels, and E7 rescues E6 from inhibition by INK4A (zur Hausen 2002).  
 
The  unregulated  production  of  oncogenic  proteins  often  comes  about  through 
interaction between viral and host DNA. Campo (1997) describes the regulation of viral 
gene  transcription  as  a  “finely  tuned  circuit  where  positive  and  negative,  viral  and 
cellular controlling elements all contribute to the spacially and temporally  regulated 
expression of the viral genome”, and states that “if this delicate balance is subverted, the 
outcome is often cell transformation to the neoplastic state”.  Integration of the viral 
DNA is often an important event in the path of malignant transformation. Neoplastic 
transformation  of  cells  infected  with  high  risk  HPVs  has  been  shown  to  be  more 
efficient when there is integration of the viral genome into the host genome (Jeon et al.   58
1995). In some high risk PV infections, such as those involving HPV18, the severity of 
the  lesion  can  often  be  correlated  with  the  level  of  integration  (Cullen  et  al.  1991; 
Pirami et al. 1997; Hudelist et al. 2003). In transformed cells, expression of E6 and E7 
is constantly maintained following integration, whereas other portions of the viral DNA 
are deleted or their expression is disturbed (Baker et al. 1987).  In the case of HPVs, 
integration often occurs near common fragile sites of the human genome (Thorland et 
al. 2003), however no apparent “hotspots” for integration have been found nor is there 
evidence for insertional mutagenesis (Ziegert et al. 2003). Integration of viral genomic 
sequences can cause deletion of and/ or a disruption to the E2 gene, resulting in a loss of 
its function as a regulator of viral gene expression (Figure 3.4) (Cripe et al. 1987). This 
event is often followed by upregulation of E6 and E7 protein expression and is likely a 
critical event in malignant transformation (Jeon and Lambert 1995). This theory has 
been supported by  experimental work which has shown that  re-expression of E2 in 
human cervical cancer cell lines causes growth suppression (Francis et al. 2000).    59
 
Figure 3.4 The organisation of circular HPV DNA and its integration into host-cell DNA. In the 
course of malignant transformation of cells, the viral molecule frequently becomes integrated 
into the host-cell DNA. The ring molecule is most often opened within the E2 reading frame, 
disrupting the continuity of that gene. Part of E2 and open reading frames that are adjacent to E2 
(E4,  E5  and  part  of  L2)  are  regularly  deleted  after  integration  (*  =  partial  genes).    Viral 
transcripts, which uniformly span the E6 and E7 region, and are often linked to flanking cellular 
sequences, are present and transcription might be modulated (enhanced) by flanking host-cell 
promoters (zur Hausen 2002). 
 
Upregulated E6 and E7 expression may also come about through the action of cellular 
transcription promoters acting on the viral DNA (Campo 1997). Genomic instability 
resulting from integration of the viral genome into the host genome also contributes to 
the malignant phenotype, and studies with HPV16 have shown evidence that integration 
leads to increased mRNA E6 and E7 stability (Jeon and Lambert 1995). 
 
As alluded to earlier, integration of viral DNA into the host genome is not always a 
prerequisite for neoplastic transformation of tissues. Studies of HPV-induced cancer 
have demonstrated that neoplastic transformation is more efficient when there is viral 
integration, however HPV16 can still cause neoplastic transformation when maintained   60
episomally (Matsukura et al. 1989; Cullen et al. 1991; Pirami et al. 1997; Hudelist et al. 
2003). The absence of viral integration is also observed in neoplastic lesions of EV. A 
characteristic feature of EV-HPV induced lesions, in contrast to other oncogenic HPVs, 
is  that  viral  DNA  is  not  integrated  into  the  host  DNA,  and  interestingly,  the  E6 
oncoprotein does not degrade p53 and the E7 oncoprotein has very low transforming 
ability (Favre et al. 1997; Majewski et al. 1997).  The mechanism of carcinogenesis of 
the EV-HPVs is not yet fully understood and differs from the much studied genital HPV 
mechanisms of oncogenesis (Androphy 1994; Majewski and Jablonska 2004). In BPV4 
associated alimentary tract lesions, the continued presence of viral genes is not required 
for the malignant transformation of lesions, and as such can viewed as a “hit and run” 
phenomenon (Campo 1997). 
 
There  is  increasing  evidence  that  in  many  malignancies  PV  infection  alone  is  not 
sufficient to cause malignant transformation. The requirement of other factors to be 
involved in the transformation of many naturally occurring and experimentally induced 
PV-associated malignancies is well recognised. Some of the first co-factors recognised 
were those working in concert with bovine PVs. As discussed earlier, bracken fern has 
been  shown  to  be  a  co-carcinogen  in  the  pathogenesis  of  BPV4-associated  bovine 
alimentary tract cancer and BPV2 bladder cancer. UV light along with  -radiation has 
been  shown  to  be  an  important  cofactor  in  human  EV-HPV  type  malignancies 
(Jablonska and Majewski 2003), as well as in certain PV-associated malignancies in 
mice (Tilbrook et al. 1989). Chemical co-factors, such as smoking as a risk factor for 
cervical  cancer  in  humans  (Clarke  et  al.  1982),  may  also  be  involved  in  increased 
susceptibility to malignancy or PV infection. Immunocompetence and host genetics, as 
discussed  earlier,  may  also  be  influencial  in  the  pathogenesis  of  PV-associated 
malignancies.   61
3.3 Polyomaviruses 
3.3.1 General features of polyomavirus infections 
Polyomaviruses (PyVs) are small transmissible host-adapted viruses known to infect 
humans and a variety of mammalian and avian species. Since the discovery of murine 
PyV (Polyoma) in 1953, these viruses have been intensively studied and provided much 
insight  into  the  understanding  of  cell  cycle  regulation,  oncogenes  and  tumour 
suppressor genes (Cole and Conzen 2001).  
 
Within the family Polyomaviridae and its sole genus, Polyomavirus, sixteen PyVs have 
been  genomically  characterised  and  listed  on  NCBI  GenBank  to  date  (Table  3.2). 
Phylogenetic
  analysis  of  the  genome  sequences  of  all  PyVs  have  shown  separate 
branching  of  the  PyVs  of  birds  and  mammals,  indicating
  a  separate  grouping  and 
phylogenetic  development  of  these  viruses  (Perez-Losada  et  al.  2006;  Johne  et  al. 
2006b). Like papillomaviruses (PVs), cophylogenetic studies have indicated that these 
are  ancient  viruses  that  have  co-evolved  with  their  mammalian  and  avian  hosts 
(Crandall et al. 2006; Perez-Losada et al. 2006). Typically, the mammalian PyVs cause 
apathogenic subclinical infections in their natural and immunocompetent hosts, but may 
cause severe disease in the immunocompromised or can cause tumour formation when 
they  are  introduced  to  an  unnatural  host  (Sambrook  1978;  Cole  and  Conzen  2001; 
Major 2001). Mammalian PyVs can also cause unapparent or mild primary infections in 
young animals followed by lifelong, non-pathogenic, persistent maintenance of non-
integrated, non-defective, episomal PyV DNA (Dubensky and Villarreal 1984). Unlike 
mammalian species, fatal disease is often associated with PyV infection in birds (Muller 
and Nitschke 1986; Guerin et al. 2000; Johne et al. 2006b; Johne and Muller 2007).  
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The mammalian PyVs display a narrow host range and do not productively infect other 
species.  Experimentally  however,  a  broader  range  of  hosts  may  be  susceptible  to 
infection. For example, BK and JC viruses have been shown to induce various types of 
malignant  tumours  in  rodents  depending  on  the  route  of  administration  (Barbanti-
Brodano et al. 1998). Similarly injection of SV40 into newborn hamsters will also lead 
to the development of tumours in this species (Eddy et al. 1961; Girardi et al. 1962).  
 
PyVs demonstrate a broader range of tissue tropism than PVs. Most PyVs infect and 
replicate  primarily  in  fibroblastic  and  a  range  of  epithelial  cells  (Cole  and  Conzen 
2001), although some PyVs also display tropism for B lymphocytes (zur Hausen and 
Gissmann 1979; Ritchie 1995; Lacroux et al. 2004) and after infection of budgerigars 
with budgerigar fledgling disease virus (BFDV), the virus can be detected
 in essentially 
all organs (Phalen et al. 1993). PyVs replicate in the nucleus and most virus-induced 
pathology in productive infections is characterised by nuclei that are enlarged and have 
glassy basophilic intranuclear inclusions. Non-productive infections occur when cells 
are non-permissive for infection and viral DNA replication cannot occur, which may 
lead to malignant transformation of the cell (discussed in greater depth in Section 3.3.3).  
 
JC  virus  and  BK  virus  are  two  PyVs  known  to  naturally  infect  humans.  Both  are 
associated with diseases affecting immunocompromised hosts and known to establish 
subclinical  persistent  infection  in  the  kidney  and  peripheral  blood  in  much  of  the 
population worldwide (Major 2001). JC and BK viruses are thought to lie latent in 
tissues until reactivated during times of immunosuppression, proposed sites of latency 
including the kidney and lymphoid tissues (Padgett et al. 1983; Houff et al. 1988). Both 
viruses can be detected in the urine of diseased and normal healthy individuals (Major 
2001).   63
 
The  murine  PyV  (or  Polyoma)  was  the  first  member  of  the  Polyomaviridae  to  be 
discovered.  Its  detection  came  about  following  the  development  of  parotid  gland 
carcinomas in mice administered extracts from infected individuals during studies with 
murine leukaemia virus (Gross 1953).  This virus was named “polyoma” due to its 
ability to cause a variety of tumour types in newborn mice (Eddy et al. 1958). Since 
then,  a  broad  range  of  both  epithelial  and  mesenchymal  tumour  types  have  been 
described in response to murine PyV infection, for example epithelial tumours of the 
hair  follicle,  thymus,  mammary  gland  and  salivary  gland,  fibrosarcomas  and 
mesenchymal tumours of the renal medulla and bone (Dawe et al. 1987). A second PyV 
affecting mice, murine pnuemotropic PyV (MPtV), has been described associated with 
interstitial  pneumonia  and  high  mortality  in  newborn  mice  (Greenlee  1981).  In 
immunocompetent mice, MPtV leads to a persistent and unapparent infection and the 
virus localises in the kidney following primary infection, as seen in other mammalian 
polyomavirus infections.  
 
A hamster PyV (HaPyV) was first isolated in 1968 from keratinizing epithelial cells in 
naturally  occurring  trichoepitheliomas  in  a  colony  of  Syrian  hamsters  (Graffi  et  al. 
1968). In hamsters naturally infected with HaPyV, cutaneous lesions are seen to occur 
on skin of chin, head,  neck, back and frequently around the  eyes  and  external ears 
(Graffi et al. 1968; Scherneck et al. 2001). Histologically, proliferation of the hair root 
epithelium  is  seen,  which  forms  cyst-like  masses  filled  with  cornified  material  and 
sometimes containing melanin. Virus particles are abundant in differentiated stratum 
corneum but absent in cells of stratum basale and stratum spinosum (Graffi et al. 1968). 
The tight linkage between the virus productive lifecycle and terminal differentiation of 
the skin is similar to that seen in PV-associated lesions. However, the tissue tropism for   64
HaPyV differs in that the hair root epithelium is targeted rather than the interfollicular 
epidermal  keratinocytes  (Scherneck  et  al.  2001).  A  second  manifestation  of  HaPyV 
infection is a multicentric lymphoma seen in immunologically naïve young hamsters 
injected with virus extracted from skin epitheliomas (Graffi et al. 1969).  
 
Bovine PyV (BPyV) was initially thought to be a simian serum contaminant formerly 
known as the CK isolate of the stump-tailed macaque virus (Schuurman et al. 1990). 
BPyV infections appear quite common in cattle and do not seem to be pathogenic. The 
importance  of  BPyV  lies  in  its  significance  to  the  biotechnology  industry,  posing  a 
contamination  risk  for  human  therapeutic  products  due  to  it  presence  in  foetal  calf 
serum (Schuurman et al. 1991). The concern over contamination of cell cultures with 
BPyV lies in its zoonotic and oncogenic potential. Schuurman et al. (1992) transformed 
primary  rodent  cells  through  transfection  with  a  plasmid  construct  encoding  the 
complete early region of BPyV under the transcriptional control of the long terminal 
repeat of Rous sarcoma virus. The transformed cells were found to be oncogenic in 
immunocompromised newborn rats, raising concerns that BPyV should be considered 
as a potentially tumorigenic PyV (Schuurman et al. 1992). 
 
JC  virus,  first  isolated  in  1971  (Padgett  et  al.  1971),  has  since  been  shown  as  the 
causative  agent  of  the  demyelinating  disease,  progressive  multifocal 
leukoencephalopathy (PML) in humans The occurrence of PML was very rare until the 
advent of the AIDS pandemic, but now it is much more prevalent and affects ~5% of 
human immunodeficiency virus-infected people (Berger 2003). Microscopic features of 
PML include areas of demyelination and oligodendrocytes may demonstrate enlarged 
glassy nuclei and inclusion bodies at the periphery of active lesions in cells in which 
viral replication is occurring (Khalili et al. 2003). When the nuclear inclusion bodies are   65
viewed by electron microscopy, dense sheets of 45nm icosahedral capsids can be seen. 
Able to transform cells in culture and shown to be oncogenic in laboratory animals, JC 
virus has also been implicated in a range of human cancers (Major 2001; Khalili et al. 
2003). BK virus, first derived from the urine of an immunosuppressed renal transplant 
recipient (Gardner et al. 1971), has been associated with haemorrhagic cystitis in bone 
marrow patients, ureteric stenosis in renal transplant recipients and pulmonary infection 
(Major 2001). Like JC virus, BK virus has also been associated with a range of human 
cancers,  however  the  significance  of  this  virus  in  human  carcinogenesis  is  not  yet 
known and keenly debated (Tognon et al. 2003).  
 
Two recently discovered human polyomaviruses are KI and WU PyVs. WU PyV was 
detected  in  respiratory  secretions  from  human  patients  with  symptoms  of  acute 
respiratory  tract  infection  (Gaynor  et  al.  2007)  and  KI  detected  in  pooled  clinical 
nasopharyngeal  aspirate  samples  from  human  patients  (Allander  et  al.  2007).  The 
prevalence and pathogenicity of these viruses are yet to be elucidated.  
 
Primate PyVs have also been the focus of much research interest. The natural host of 
SV40 is the rhesus macaque (Macaca mulatta)(Shah and Southwick 1965), however 
greatest interest in this virus has revolved around its speculative involvement in the 
development  of  human  cancers.  SV40  was  first  isolated  during  the  screening  of 
secondary  rhesus monkey  kidney cell cultures used for the production of poliovirus 
vaccines (Sweet and Hilleman 1960). It was later discovered that injection of SV40 into 
newborn hamsters resulted in the development of tumours (Eddy et al. 1961; Girardi et 
al. 1962) and that SV40 was capable of transforming human cells in culture (Jenson et 
al. 1963), raising concerns that this virus may be oncogenic in humans. It has been 
estimated that 10% to 30% of inactivated poliovirus vaccines contained live SV40 and   66
that  similar  percentages  of  the  approximately  98  million  Americans  who  had  been 
vaccinated between 1955 and 1961 were exposed to SV40 (Shah and Nathanson 1976). 
In  addition,  oral  poliovirus  vaccines  contaminated  with  SV40  were  administered  to 
approximately  10,000  people  participating  in  clinical  trials  between  1959  and  1961 
(Stratton et al. 2002). SV40 has been sporadically detected in human tumours since its 
discovery,  however  the  validity  or  consistency  of  detection,  the  significance  of  the 
various  reported  detections  and  the  putative  role  of  SV40  in  the  pathogenesis  of 
neoplasia in humans is somewhat controversial and keenly debated (Wong et al. 2002; 
Shah  2006).  A  recent  review  of  SV40  contaminated  poliovirus  vaccines  found 
insufficient  evidence  to  accept  or  reject  a  causal  relationship  between  SV40- 
contaminated vaccines and cancer in humans (Stratton et al. 2002). Other PyV species 
known  to  infect  primates  include  the  African  green  monkey  or  lymphotropic  PyV 
(LPV)(Pawlita  et  al.  1985)  and  Simian  agent  12  (Sa12)  or  baboon  polyomavirus 
(Cantalupo et al. 2005). 
 
In contrast to the mammalian PyVs, which are generally characterised by subclinical 
persistent infection, the avian PyVs Goose hemorrhagic PyV (GHPyV) and Budgerigar 
fledgling disease virus (BFDV), also known as avian PyV (APV), and possibly the finch 
(FPyV) and crow (CPyV) PyVs, are associated with fatal disease in birds (Muller and 
Nitschke 1986; Guerin et al. 2000; Johne et al. 2006b; Johne and Muller 2007).  In 
young  budgerigars,  BFDV  causes  disease  characterised  by  ascites,  hepatitis  and 
hydropericardium, although other bird species are also susceptible to infection (Muller 
and Nitschke 1986; Ritchie 1995; Johne and Muller 1998). GHPyV is the causative 
agent of haemorrhagic nephritis and enteritis of geese, a disease of high mortality and 
morbidity in geese four to ten weeks of age (Guerin et al. 2000; Lacroux et al. 2004). 
Gross and histological features of disease include interstitial nephritis and necrosis of   67
tubular epithelium, necrosis of intestinal epithelium, haemorrhagic foci in many tissues 
and a moderate to severe lymphocytolysis in both the cortex and medulla of follicles of 
the cloacal bursa suggestive of B-lymphocyte depletion (Lacroux et al. 2004). More 
recently two avian PyVs, the crow PyV (CPyV) and finch PyV (FPyV), have been 
detected in association with fatal disease in their host species respectively (Johne et al. 
2006b). 
 
3.3.2 Polyomavirus structure, genome and life cycle 
PyVs  are  small  non-enveloped  DNA  viruses  with  an  icosahedral  protein  capsid 
approximately 45 nm in diameter. The protein capsid contains the viral genome which 
comprises a single molecule of double stranded circular DNA complexed with cellular 
histones  in  the  form  of  chromatin  (Cole  and  Conzen  2001).  PyV  genomes  range 
between 4697 nt (Schuurman et al. 1990) and 5366 nt (Delmas et al. 1985) in length. 
Like PVs, the position,  size and function of many of the ORFs are well conserved 
among the various PyV types sequenced and studied thus far (Table 3.2), supporting the 
idea  that  all  known  members  of  the  Polyomaviridae  are  descendents  of  a  common 
ancestor (Cole and Conzen 2001).  
 
The  PyV  genome  is  divided  into  early  (transforming  protein)  and  late  (structural 
protein) coding regions: the early region expressed soon after the virus enters the cells 
and continually expressed after the onset of viral replication, the late region expressed 
efficiently only after viral DNA replication begins (Cole and Conzen 2001). The coding 
strands  for  PyVs  comprise  up  to  seven  ORFs,  encoding  VP1,  VP2,  VP3,  large  T 
antigen,  small  t  antigen  and  depending  on  the  species,  the  middle  T  antigen  or 
agnoproteins, as well as a viral regulatory region. The genomic organisation of PyVs, 
unlike  that  of  the  PVs,  is  such  that  ORFs  are  divided  between  both  strands  of  the   68
double-stranded DNA genome: late ORFs (VP1, VP2, VP3 and agnoprotein) located on 
one strand and early ORFs (large T, small t and middle t antigens) encoded on the 
opposite strand (Figure 3.5) (Cole and Conzen 2001). 
 
        
Figure 3.5 Schematic representation of classical Polyomaviridae (human and nonhuman primate 
PyV) genomic organisation 
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Table 3.2 Genome characteristics of PyVs. 
Host 
species 
PyV type  GenBank 
Access. no. 
Proteins encoded  Genome 
size 
Reference 
Mouse  Murine polyomavirus (MPyV)   NC_001515  VP1, VP2, VP3, large T antigen, middle T antigen, small t antigen  5297 nt  (Deninger et al. 1980) 
Murine pneumotrophic disease virus (MptV)   NC_001505  VP1, VP2, VP3, large T antigen, middle T antigen, small t antigen, tiny t 
antigen 
4754 nt  (Mayer and Dörries 1991) 
Hamster  Hamster polyomavirus (HaPyV)   NC_001663  VP1, VP2, VP3, large T antigen, middle T antigen, small t antigen  5366 nt  (Delmas et al. 1985) 
Avian  Budgerigar fledgling disease virus (BFDV)   NC_004764  VP1, VP2, VP3, agno-like protein, large T antigen, small t antigen  4981 nt  (Muller and Nitschke 1986) 
Goose haemorrhagic disease virus (GHDV)   NC_004800  Putative ORF-X, putative protein 2, putative protein 3, putative protein 1, 
putative large T antigen, putative small t antigen 
5256 nt  (Johne and Muller 2003) 
Crow polyomavirus (CPyV)   NC_007922  Putative ORF-X, putative VP1, putativeVP2, putative VP3, putative large T 
antigen, putative small t antigen 
5079 nt  (Johne et al. 2006b) 
Finch polyomavirus (FPyV)   NC_007923  Putative ORF-X, putative VP1, putativeVP2, putative VP3, putative large T 
antigen, putative small t antigen 
5278 nt  (Johne et al. 2006b) 
Bovine  Bovine polyomavirus (BPyV)   NC_001442  VP1, VP2, VP3, large T antigen, small t antigen, agnoprotein  4697 nt  (Schuurman et al. 1990) 
Human  JC polyomavirus  NC_001699  VP1, VP2, VP3, large T antigen, small t antigen, agnoprotein  5130 nt  (Frisque et al. 1984) 
BK polyomavirus   NC_001538  VP1, VP2, VP3, large T antigen, small t antigen, agnoprotein  5153 nt  (Seif et al. 1979) 
WU polyomavirus   NC_009539  VP1, VP2, VP3, large T antigen, small t antigen  5229 nt  (Gaynor et al. 2007) 
KI polyomavirus  NC_009238  VP1, VP2, VP3, large T antigen, small t antigen  5040 nt  (Allander et al. 2007) 
Primate  African green monkey polyomavirus/ 
Lymphotropic polyomavirus (LPyV)  
NC_004763  VP1, VP2, VP3, large T antigen, small t antigen  5270 nt  (Pawlita et al. 1985) 
Baboon polyomavirus/ Simian agent 12 (Sa12)   NC_007611  VP1, VP2, VP3, large T antigen, small t antigen, agnoprotein, microRNA 
precursor 
5230 nt  (Cantalupo et al. 2005) 
Simian virus 40 (SV40)  NC_001669  VP1, VP2, VP3, large T antigen, small t antigen, early leader protein, 
agnoprotein 
5243 nt  (Fiers et al. 1978) 
Squirrel monkey polyomavirus  NC_009951  VP1, VP2, VP3, large T antigen, small t antigen  5075 nt  Unpublished   70
The early coding region comprises the viral regulatory proteins, known as the T antigens (T 
= “tumour”), named so due to their ability to be detected by antisera from animals bearing 
tumours  induced  by  PyVs  (Cole  and  Conzen  2001).  The  T  antigens  are  complex 
multifunctional proteins that perform a diverse array of activities, including alteration and 
recruitment of specific host cell proteins to participate in virus production, blockade of 
cellular antiviral defence systems and direct participation in viral replication (Brodsky and 
Pipas 1998). The T antigens are also responsible for malignant transformation of infected 
cells, mediated through their direct physical association with cellular target proteins such as 
p53  and  the  retinoblastoma  protein family  of  tumour  suppressors  (Rb, p107  and  p130) 
(discussed further below).  
 
PyV T antigens are encoded by a common precursor mRNA that is differentially spliced to 
create  multiple  monocistronic  mature  mRNAs  (Brodsky  and  Pipas  1998).  For  example 
SV40 expresses three such mRNAs, one each for the large T antigen, small t antigen and 
tiny t antigen, whereas murine PyV expresses four mRNAs, one each for large, middle, 
small and tiny t antigens (Kamen and Shure 1976; Berk and Sharp 1978). The large T 
antigen has multiple enzymic activities, interacts with cellular proteins and viral DNA and 
performs several different roles during infection. It is the only protein directly needed for 
viral replication in productive infections, its role being in interacting cellular replication 
factors and the viral origin of replication (Cole and Conzen 2001). Large T antigens also 
demonstrate helicase, a-polymerase, ATPase, and DNA-binding activities (Frisque et al. 
1984;  Dean  et  al.  1987).  PyVs  are  dependent  on  the  host  cellular  machinery,  only 
replicating during the S phase of the cell cycle; the large T antigen stimulating cells to 
move through the cell cycle into S phase (Cole and Conzen 2001). The consensus motif 
required for binding to the tumour suppressor protein Rb and to two structurally related   71
proteins, p107 and p130 present within PyV large T antigen sequences is LXCXE (Hall et 
al. 1999). This pRB binding motif is a common feature of both PyV large T and PV E7 
proteins (DeCaprio et al. 1988; Hall et al. 1999).  
 
The middle T antigen is encoded by MPyV, MPtV and HaPyV.  In these PyV species, 
middle T antigens play important roles in viral replication, persistence, transformation and 
oncogenesis (Freund et  al. 1992). The small t antigen  acts in concert  with the other T 
antigens in gaining control of the host cell cycle. A stretch of cysteine residues (CXCXXC) 
seen at the C-terminal in all PyV small t antigens, excepting BPyV and the avian PyVs, is 
believed to bind with cellular protein phosphatase 2A (Pipas 1992; Johne et al. 2006b).  
 
The small t and large T antigens of characterised PyVs share the N-terminal portion of the 
early domain, inclusive of the DnaJ domain, and with the exception of the bovine PyV 
large T antigen, the conserved HPDKGG motif (Pipas 1992). The DnaJ domain of the T 
antigens plays an essential role in virion assembly, virus DNA replication, transcriptional 
control and oncogenic transformation (Hall et al. 1999). The PyV ATPase binding domain, 
GP(V/I)(N/D)XGKT (Walker et al. 1982), present within T antigen sequences is the most 
highly conserved domain among PyV types. Sequences important for complex formation 
with the cellular p53 protein lie within this domain (Pipas 1992).  
 
PyV ORFs VP1, VP2 and VP3 encode the structural (capsid) proteins of the PyVs which 
arrange to form an icosohedral capsid. This region is highly conserved across PyV types, 
VP1 forming the major capsid protein and VP2 and VP3 the minor capsid proteins. VP1 
proteins are the major component of the virus capsid and can self assemble into icosohedral 
particles independently of both VP2 and VP3 (Chang et al. 1997). VP1 is also responsible   72
for adsorption of virus particles to the host cell and interacts with cell surface receptors in 
order to facilitate cell entry (Bolen and Consigli 1979; Bolen et al. 1981; Nakanishi et al. 
2007). Aside from forming important components of the viral capsid, recently VP2 and 
VP3 have been found to be important in facilitating the entry of PyV genomes into the host 
nucleus (Nakanishi et al. 2007). Late mRNAs are generated from common precursor pre-
mRNA by alternative slicing: the coding regions of VP2 and VP3 overlap (VP3 sequences 
a subset of VP2 sequences) and the coding region for the N-terminus of VP1 overlaps that 
for the C-terminus of VP2  (Cole and Conzen 2001). SV40, JCV and BKV encode a fourth 
late protein, the agnoprotein, which is believed to facilitate the localisation of the VP1 to 
the nucleus (Carswell and Alwine 1986). It is also thought that the agnoprotein may have 
regulatory roles in viral transcription and translation, in virion assembly and maturation and 
in DNA repair (Safak and Khalili 2003; Darbinyan et al. 2004). 
 
The viral regulatory region of the PyVs is located between the early and late regions and 
comprises the origin of replication (ori), the TATA box, T antigen binding sites, cellular 
transcription  factor  binding  sites,  and  bidirectional  promoters  and  enhancers  for 
transcription  of  early  and  late  genes  (Cole  and  Conzen  2001).  Transcription  extends 
bidirectionally from initiation sites near the origin, with early and late mRNAs transcribed 
from opposite strands of the viral genome. The ori of most characterized PyVs consists of 
multiple copies of the GAGGC pentanucleotide, flanked by A/T-rich sequences on the late 
side  and  an  imperfect  palindrome  on  the  early  side,  with  the  exception  of  BFDV  and 
GHDV which do not contain any GAGGC pentanucleotides within the regulatory region 
(Pipas 1992; Cantalupo et al. 2005). In mammalian PyVs, the large T antigen binds to this 
GAGGC pentanucleotide (Tjian 1978). In avian PyVs, however, the binding sequence for   73
the large T antigen has been identified as the palindromic sequence TCC (A/T)6 GGA or 
similar (Luo et al. 1994; Johne et al. 2006b). 
 
Studies with murine PyV and SV40 infection of mammalian cell lines and cultures and 
natural  infection  with  JC  virus  in  human  patients  have  exhibited  the  various  fates  of 
infected cells following virus entry, which appear to be dependent on the host and tissue 
type properties of the cell infected  (Butel  and  Lednicky 1999; Cole and Conzen 2001; 
Khalili et al. 2003).  In cells that are said to be permissive, productive infection will result 
as viral replication can occur, followed by the production of virions and ultimately the 
death  of  the  cell.  Alternatively,  the  infected  cell  may  be  non-permissive  for  viral 
replication, and the infected cell may become transiently or permanently transformed (Cole 
and  Conzen  2001).  Non-productive  infection  occurs  in  cell  types  not  belonging  to  the 
natural PyV host, or for which the virus does not demonstrate tropism (Figure 3.6). In these 
non-productive infections, viral DNA replication is thought not to take place due to an 
inability of the large T  antigen to interact productively with  cellular replication factors 
(Cole and Conzen 2001) and perhaps due to PyV type-specific factors encoded in the viral 
regulatory region (Khalili et al. 2003). 
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Figure  3.6  Mechanisms  of  JC  virus  (JCV)  T-antigen-mediated  demyelination  or  cellular 
transformation in permissive vs. non-permissive cells (Khalili et al. 2003). 
 
In productively infected cells, the replication cycle of PyV can be divided into early and 
late stages (Cole and Conzen 2001). The beginning of the early stage is defined by the 
attachment of the virus to cells and continues until the beginning of viral DNA replication. 
The PyV absorbs to the cell surface is taken up by endocytosis and is transported to the 
nucleus  for  viral  uncoating.  Gangliosides  have  recently  been identified  as  the  host cell 
plasma membrane receptors for entry of mouse PyV, SV40 and BKV (Tsai et al. 2003; 
Low et al. 2006) whereas JC virus is thought to use serotonin receptors (Elphick et al. 
2004). Replication is initiated by transcription  and translation of the T antigens,  which 
stimulates the cell to prepare it for replication of viral DNA. The late stage of infection   75
begins at the onset of viral replication and runs to the end of the infection cycle. It involves 
replication of the viral DNA, expression of viral late gene (capsid) proteins, assembly of 
progeny virus particles in the nucleus of the infected cells and release of the virus by fusion 
of virus containing cytoplasmic vesicles with plasma membrane or via cell lysis (Cole and 
Conzen 2001).  
 
3.3.3 Mechanisms of oncogenesis 
PyVs have been definitely and putatively associated with a broad range of tumour types in 
humans and animals. The oncogenic mechanisms of murine PyV, SV40 and to a lesser 
extent JC and BK viruses, have been extensively studied and reviewed (Butel and Lednicky 
1999; Cole and Conzen 2001; Khalili et al. 2003; Tognon et al. 2003). Transformation of 
(non-productively) PyV infected cells is mediated through direct physical association of the 
T antigens with cellular target proteins, such as p53 and the retinoblastoma protein family 
of tumour suppressors Rb, p107 and p130 (large T antigen), components of the cellular 
signal transduction network (middle T antigen) and cellular protein phosphatase 2A (small t 
antigen) (Brodsky and Pipas 1998). The action of the large T antigen on key proteins such 
as p53 and Rb leads to unregulated cell division (Ludlow and Skuse 1995; Kim et al. 1998; 
Butel and Lednicky 1999; Krynska et al. 2000; Klein et al. 2002). Interference with p53 
assists the PyV to avoid the cell’s normal response to undergo apoptosis in response to 
replication of foreign DNA. By inactivating these proteins, the large T antigen promotes 
both transformation and immortalization of cells. The small t antigen has been shown to 
contribute to transformation by enhancing the actions of the large T antigen by inhibiting 
cellular protein phosphatase 2A (Dixon et al. 1982; Goutebroze and Feunteun 1992). 
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As is sometimes the case for high risk PV infections, integration of PyV DNA into cellular 
DNA is known to occur in malignantly transformed cells. In studies with PyV and SV40, 
integration appears to occur randomly with respect to both the viral genome and host cell 
genomes,  and  if  integration  permits  continued  expression  of  the  T  antigens  then  the 
malignant  phenotype  is  expressed  permanently  (Cole  and  Conzen  2001).  Experimental 
studies with murine PyV have indicated that although the large T antigen is required for the 
initiation of the transformed state, it is not required for its maintenance: the viral DNA is 
integrated  into  the  cellular  genome  to  disrupt  the  early  region,  blocking  continued 
expression of the large T antigen but continuing expression of small and middle T antigens 
(Cole and Conzen 2001). Various PyV T antigens have also been shown to have mutagenic 
activity leading to chromosomal instability (Theile and Grabowski 1990). The induction of 
chromosomal instability in combination with dysregulation of cellular pathways may make 
persistence of T antigen expression unnecessary for maintenance of the transformed state, 
leading to a “hit and run” type scenario (Khalili et al. 2003).     77
3.4 Discussion 
The well recognised association between PVs and PyVs and proliferative epithelial lesions, 
the  pathological  features  of  lesions  induced  by  these  agents  and  knowledge  of  the 
oncogenic  potential  of  these  viruses  led  to  consideration  that  a  PV  or  a  PyV  may  be 
associated with the papillomatosis and carcinomatosis syndrome in the WBB. Molecular 
methods for the detection of both novel and pre-existing members these two virus families 
are discussed in Chapter 4.   78
Chapter 4: A novel virus exhibiting genomic features of both the 
Papillomaviridae and Polyomaviridae is detected in papillomas 
and carcinomas of the western barred bandicoot 
 
Genomic organization of bandicoot papillomatosis carcinomatosis virus type 1 (BPCV1) and image 
of an adult WBB. Image appeared on the cover of the Journal of Virology, Volume 81 Issue 24 
(Woolford et al. 2007).  
Published in: 
Woolford L, Rector A, Van Ranst M, Ducki A, Bennett MD, Nicholls PK, Warren KS, Swan RA, 
Wilcox  GE  &  O’Hara  AJ,  2007.  A  novel  virus  detected  in  papillomas  and  carcinomas  of  the 
endangered western barred bandicoot (Perameles bougainville) exhibits genomic features of both 
the Papillomaviridae and Polyomaviridae. Journal of Virology, 81(24) p 13280-90. 
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Summary: 
Chapter 4 describes the detection of a novel virus, tentatively designated the bandicoot 
papillomatosis carcinomatosis virus type 1 (BPCV1), in lesional tissue and superficial skin 
swabs taken from western barred bandicoots (WBBs) affected by the papillomatosis and 
carcinomatosis syndrome. The use of multiply primed rolling circle amplification (RCA) 
allowed the detection and amplification of the complete double-stranded DNA genome of 
BPCV1, and viral DNA was also detected in lesional tissue using PCR with the FAP59/ 
FAP64  broad  spectrum  cutaneotropic  papillomavirus  primer  pair.  Sequencing  of  the 
BPCV1 genome revealed a novel prototype virus exhibiting genomic properties of both the 
Papillomaviridae  and  the  Polyomaviridae.  Papillomaviral  properties  included  a  large 
genome size (~7.3kb) and the presence of ORFs encoding canonical L1 and L2 structural 
proteins. The genomic organisation in which structural and non-structural proteins were 
encoded  on  different  strands  of  the  double-stranded  circular  DNA  genome,  and  the 
presence of ORFs encoding the non-structural proteins large T and small t antigen were on 
the other hand typical polyomaviral features. BPCV1 may represent the first member of a 
novel  virus  family,  descended  from  a  common  ancestor  of  the  papilloma-  and 
polyomaviruses  recognised  today.  Alternatively  it  may  represent  the  product  of ancient 
recombination  between  members  of  these  two  virus  families.  PCR  screening  of  DNA 
extracted from both lesional and unaffected epithelia, and superficial skin swabs from both 
affected  and  unaffected  WBBs  indicates  that  BPCV1  is  only  detectable  (by  this 
methodology) in individuals clinically affected by the papillomatosis and carcinomatosis 
syndrome,  and  therefore  is  unlikely  to  be  a  commensal  of  normal  WBB  skin.  This  is 
supportive  of  the  hypothesis  that  BPCV1  is  a  necessary  factor  for  development  of  the 
papillomatosis and carcinomatosis syndrome in the WBB.   80
4.1 Introduction 
The  gross,  histological,  ultrastructural  and  immunohistochemical  features  of  the 
papillomatosis and carcinomatosis syndrome in the WBB discussed in Chapter 2 led to the 
consideration that a papillomavirus (PV) or a polyomavirus (PyV) may be involved in the 
pathogenesis of this syndrome. Consequently, molecular investigations carried out during 
the course of this study have focused on screening for the presence of a member of either of 
these two virus families.   
 
Molecular techniques have been utilised extensively by researchers in the detection of both 
recognised and novel viruses. Older and conventional techniques involve cell culture for 
the detection of viruses; however, growing some viruses (e.g. PVs) in cell culture can be 
problematic.  PVs  require  a  stratifying  squamous  epithelium  in  order  to  be  cultured  as 
mature virions are only produced in terminally differentiating epithelia, and the species-
specificity of PVs creates an additional level of complication (Meyers et al. 1997; Sundberg 
et al. 1997; Stanley 2005). 
  
In general, molecular techniques are rapid, sensitive and, once optimised, relatively straight 
forward to perform, with the additional benefit of gaining valuable information about the 
viral  genetic  material.  In  addition,  molecular  techniques  are  also  advantageous  for  the 
detection of viruses such as PVs that do not produce a cytopathic effect in cell culture. The 
polymerase chain reaction (PCR) and multiply-primed rolling circle amplification (RCA) 
discussed  below  are  two  techniques  that  were  employed  in  this  study  to  screen  WBB 
lesional tissue for the presence of papillomaviral and polyomaviral DNA. 
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Polymerase chain reaction (PCR) 
PCR,  first  described  in  1985  (Saiki  et  al.  1985;  Mullis  et  al.  1986),  is  a  widely  used 
technique to detect and amplify viral DNA sequences. PV sequences were first detected by 
PCR by Shibata and others (Shibata et al. 1988), and PyV sequences by PCR by Arthur and 
others (Arthur et al. 1989). PCR is rapid and can detect minute quantities of viral DNA in 
test specimens, making it ideal to screen DNA extracted from lesional tissues for potential 
aetiological agents. 
 
Degenerate PCR assays can be used to detect a broad range of known, as well as novel, PV 
and PyV types. These assays use pools of primers that include most or all of the possible 
nucleotide  sequences  within  a  conserved  region  of  the  respective  viral  genome  or  that 
encode a conserved amino acid motif. The most conserved region of the PV genome across 
all types is the L1 ORF, encoding the major capsid protein. Many degenerate primer sets 
have been designed which detect a broad range of cutaneous and mucosal PVs types in both 
humans and animal species. These include, but are not limited to, the FAP59/64 primer set 
(Forslund et al. 1999); the MY09/11 primer set (Gravitt et al. 2000); the AR-L1F8/AR-
L1R9 primer set (Rector et al. 2005) and the ME/MH primer set (Baines et al. 2005). The 
most conserved region of the PyV genome across all types is the VP1 open reading frame, 
also encoding the major capsid protein. Many degenerate primer sets have been designed in 
this region of the PyV genome, which detect a broad range of PyV types in both humans 
and animals (Volter et al. 1997; Whiley et al. 2004; Del Valle et al. 2005; Johne et al. 
2005).  
 
The advantages of degenerate PCR assays are that they are sensitive, versatile and robust 
and thus can be used to screen samples for known or novel viruses. The disadvantages,   82
however, are that these assays require an educated suspicion of which virus is present in 
lesional tissue and when searching for novel agents can only be performed when sufficient 
sequence information from related viruses is known. Additional pitfalls of PCR include the 
inability to detect DNA in situ, which can potentially give misleading results, and the high 
sensitivity of the assay leading to false positives due to the detection of contaminants. 
 
Multiply-primed rolling circle amplification (RCA)   
Multiply-primed  rolling  circle  amplification  (RCA)  is  a  sequence  independent  and 
isothermal technique for the amplification of circular DNA templates (Dean et al. 2001). 
The technique employs bacteriophage  29 DNA polymerase, a high fidelity enzyme with 
strong strand displacing capability, high processivity and proof reading activity (Dean et al. 
2001). Random hexamers are used to prime template strands (viral DNA) for elongation, 
therefore no prior knowledge of nucleotide sequence is required. This technique has been 
optimised for the amplification of viruses with circular, double-stranded DNA genomes 
(Rector et al. 2004a), such as PVs (Rector et al. 2004b; Rector et al. 2005), PyVs (Johne et 
al.  2006b),  circoviruses  (Johne  et  al.  2006a)  and  anelloviruses  (Niel  et  al.  2005).  The 
advantages of RCA are that it is relatively straight forward to perform, requires no previous 
knowledge of the viral nucleotide sequence, is suitable to screen for both known and novel 
PV  and  PyV  types,  and  will  generate  a  large  number  of  copies  of  the  entire  genomic 
sequence. Disadvantages of the technique are that it can only be used to selectively amplify 
circular DNA genomes, and the sensitivity is decreased when genomic DNA samples are 
used as a template, as cellular DNA is also amplified (Rector et al. 2004a).   83
4.2 Materials and Methods 
4.2.1 Clinical material 
Between 2000 and 2007, cutaneous and muco-cutaneous lesional and non-lesional tissue 
samples from 32 WBBs affected by a papillomatosis and carcinomatosis syndrome and 2 
unaffected  WBBs  were  received  by  the  pathology  section  at  the  Murdoch  University 
School of Veterinary and Biomedical Sciences. Tissue samples collected from 19 WBBs 
were divided in two, one half frozen for molecular techniques and the other half collected 
into  10%  neutral  buffered  formalin  for  histological  evaluation.  Submissions  from  the 
remaining  13  individuals  were  collected  at  a  referring  captive  breeding  centre  and 
submitted as formalin-fixed tissues only. Tissue samples were classified histologically as 
unaffected  (normal)  epithelia,  papillomatous  epithelial  hyperplasia,  carcinoma  in  situ, 
squamous cell carcinoma or adenocarcinoma (detailed in Chapter 2). All submissions were 
received  from  Western  Australian  captive  populations  of  WBBs  held  at  the  Kanyana 
Wildlife Rehabilitation Centre (KWRC), Dryandra Field Breeding Facility or the Peron 
Captive Breeding Centre (PCBC).   
 
Skin  swabs  for  the  purpose  of  viral  DNA  detection  were  collected  from  73  WBBs 
examined  during  field  monitoring  activities  carried  out  between  2005  and  2007.  The 
number and origin of WBBs examined and swabbed for viral DNA during this study and 
the number of individuals with clinical evidence of the papillomatosis and carcinomatosis 
syndrome is presented in Table 4.1. Skin swabs were collected from WBBs as described in 
Section 5.2.2. 
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Table 4.1 WBBs screened for BPCV1 DNA using a skin swab technique. 
Origin  WBBs examined and 
swabbed for viral DNA 
WBBs with clinical evidence 
of skin disease 
Dryandra 
a  18 (6
 b)  6 (5
 b) 
Bernier Island 
c  24  2 
Dorre Island 
c  20  0 
Heirisson Prong Biosphere 
d  11  0 
Total  73  8 
a Field breeding facility, near Narrogin, Western Australia 
b Currently quarantined at Kanyana Wildlife Rehabilitation Centre or deceased 
c Remnant wild populations, Shark Bay, Western Australia 
d Extensive range captive breeding facility, Shark Bay, Western Australia   
4.2.2 DNA extraction from skin lesions 
Sixty three fresh tissues samples from 19 affected and 2 unaffected individuals, and 13 
formalin-fixed  samples  from  13  affected  individuals  were  selected  for  molecular 
techniques. Total genomic DNA was isolated from 25 mg of each tissue sample using the 
DNeasy Tissue Kit (Qiagen) according to the manufacturer’s protocol for either fresh tissue 
or formalin fixed tissues, respectively. Extracted DNA was quantified using the NanoDrop 
Spectrophotometer (NanoDrop Technologies). 
4.2.3 Processing of skin swabs for use with PCR methods 
Microcentrifuge tubes containing the cotton tip swab immersed in saline were thawed at 
room temperature and vortexed for 30 seconds. Each sample was then spun down briefly, 
following which the cotton tipped swab was removed and discarded using sterile forceps 
and the remaining suspension stored at -20°C until further testing. Total DNA within the 
skin swab suspension was quantified using the NanoDrop Spectrophotometer (NanoDrop 
Technologies).    85
4.2.4 Multiply-primed rolling circle amplification (RCA) 
RCA was performed on 15 fresh tissue lesional extracts from seven affected WBBs (Table 
4.2) using the TempliPhi 100 Amplification Kit (Amersham Biosciences) and a modified 
protocol  optimised  for  the  amplification  of  circular  DNA  viral  genomes  (Rector  et  al. 
2004a). One µL of extracted WBB lesional DNA (containing 1-5 µg of total DNA), 2 ng of 
pUC18 (positive control) or water (negative control) were transferred to a 0.5 mL tube with 
5 µL of TempliPhi Sample Buffer, denatured at 95°C for 3 minutes and afterwards placed 
on ice. For each sample, a premix was prepared on ice by mixing 5 µL TempliPhi Reaction 
Buffer, 0.2 µL TempliPhi enzyme mix containing the  29 polymerase, and an extra 450 
µM of each dNTP. After vortexing, 5 µL of the premix was added to each of the cooled 
samples,  reactions  were  gently  mixed  and  incubated  overnight  at  30°C.  Following 
overnight incubation, the reactions were heated to 65°C for 10 minutes to inactivate the φ29 
DNA polymerase and then stored at –20°C. 
4.2.5 Restriction enzyme analysis of RCA products 
To investigate whether viral DNA had been amplified in the reaction, 2  L of the RCA 
product  from  each  sample  was  digested  with  10U  of  BamHI,  SalI,  EcoRI  and  HindIII  
(Promega), respectively, in a total volume of 10 µL for each reaction. Each digest was 
separated via gel electrophoresis in a 0.8% agarose gel and visualised through ethidium 
bromide  staining  to  check  for  the  presence  of  a  DNA  band  consistent  with  full-length 
papillomaviral DNA (circa 8 kb), or multiple bands with sizes adding up to this length. 
4.2.6 DNA transformation and cloning 
Digestion of RCA products amplified from lesional extracts of WBBs B04K02, B05K04, 
B05K10  and  B05DrS04  with  either  BamHI  or  SalI  resulted  in  one  DNA  fragment  of   86
approximately 7.3 kb, respectively (Table 4.2). BamHI - cut and SalI - cut RCA products 
obtained from the lip lesion of B05DrS04 and the eyelid lesion of B05K10 were selected 
for cloning.  
 
Five µL of each RCA product was digested in an overnight incubation with 40 U of BamHI 
or SalI, respectively, in a total volume of 30 µL. In a separate reaction, 1 µg of pUC18 
(Invitrogen) was digested with 5 U of the same restriction enzyme used in the RCA product 
digest in a total volume of 28 µL. Following overnight incubation, 2 U of Calf intestinal 
Alkaline Phosphatase (Invitrogen) was added to the pUC18 digest (to prevent re-ligation of 
the vector) and the sample incubated for 1 hour at 37°C, then for 15 minutes at 85°C to 
inactivate the alkaline phosphatase.  
 
Fragments obtained from the digestion of the RCA products and pUC18 were separated via 
0.8% agarose gel electrophoresis, stained with ethidium bromide and visualised under UV 
light. pUC18 and RCA product fragments were cut from the gel using a sterile scalpel blade 
and purified using the QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s 
protocol.  Extracted  DNA  was  quantified  using  the  NanoDrop  Spectrophotometer 
(NanoDrop Technologies). 
 
Each fragment was then ligated into dephosphorylated BamHI - cut or SalI - cut pUC18 
using the Roche Rapid DNA ligation kit (Roche) according to the manufacturer’s protocol. 
A molar ratio of 5:1 RCA product to pUC18 was used for the ligation reaction. One Shot 
MAX  Efficiency  DH5α  -T1
R  cells  (Invitrogen)  were  used  for  transformation  with  the 
recombinant RCA insert and pUC18 vector according to the manufacturer’s protocol. One 
50 µL vial of One Shot cells was thawed on ice and 4 µL of ligation reaction added and   87
mixed by gentle tapping. The remaining ligation mix was stored at -20°C. The vial was 
then incubated on ice for 30 minutes. Following this incubation cells were heat shocked at 
42°C  for  exactly  30  seconds  and  then  placed  on  ice.  250  µL  of  pre-warmed  (room 
temperature) SOC medium was added and the vial placed in a shaking incubator at 37°C 
for  one  hour  at  225  rpm.  Volumes  of  25,  50,  75  and  150  µL,  respectively,  from  the 
transformation vial was spread onto labelled LB agar plates containing X-Gal (5-bromo-4-
chloro-3-indolyl- -D-galactopyranoside) and ampicillin [50 µg/mL]) and incubated at 37°C 
overnight. 
 
Initial screening of the DH5 -T1R competent cells containing recombinant pUC18 was 
carried  out  with  blue/  white  screening  of  colonies.  Ten  to  twelve  white  colonies  were 
selected  and  placed  separately  in  5  mLs  of  LB  broth  with  ampicillin  [50  µg/mL]  and 
incubated at 37°C for a period of 8-10 hours growth on a mechanical shaker at 225 rpm. 
Following incubation, cultures were centrifuged for 7 minutes at ~ 4000 rpm, and liquid 
media  siphoned  off.    Plasmid  DNA  was  extracted  from  centrifuged  pellets  using  the 
QIAprep Miniprep Kit (Qiagen) according to manufacturer’s protocol. 
 
A restriction enzyme digest was performed on a sample of the extracted plasmid with the 
original RE used in the digestion of the RCA product for cloning purposes. One µL of the 
Miniprep DNA was digested with 5 U of RE in a total volume 20 µL at 37°C for 1 - 4 
hours. Following incubation, 10 µL of each digest was separated via gel electrophoresis in 
a  0.8%  agarose  gel  and  visualised  through  ethidium  bromide  staining  under  UV  light. 
Miniprep DNA whose restriction digests showed vector and insert DNA of appropriate 
sizes were selected for sequencing.   88
4.2.7 Sequencing of plasmid DNA  
Multiple clones containing the BamHI - cut ~7.3 kb DNA fragment or SalI - cut ~7.3 kb 
DNA fragment obtained by digestion of RCA products from the lip lesion of B05DrS04 
and the eyelid lesion of B05K10, respectively, were selected for sequencing. The complete 
genome  of  the  bandicoot  papillomatosis  carcinomatosis  virus  type  1  (BPCV1)  was 
determined by primer-walking sequencing of cloned DNA fragments, beginning by using 
universal primers on the multiple cloning site of pUC18. In total, 21 primers were used to 
cover  the  complete  genome  on  both  strands. Each  clone  was  sequenced  three  times  in 
entirety. Sequencing of the purified plasmids was carried out using the dideoxynucleotide 
chain termination method (Sanger et al. 1977). Sequence was determined using an ABI 
Prism  Applied  Biosystems  377  DNA  sequencer  (Applied  Biosystems)  at  the  State 
Agriculture  and  Biotechnology  Centre,  Perth,  Western  Australia.  Chromatogram 
sequencing files were edited using Chromas Lite version 2.0 (Technelysium Pty Ltd) and 
contigs were assembled using BioEdit v7.0.5 (URL: http://www.mbio.ncsu.edu/BioEdit/). 
4.2.8 DNA sequence submission 
The nucleotide sequence data reported for BPCV1 were deposited in GenBank using the 
National  Center  for  Biotechnology  Information  (NCBI,  Bethesda,  MD)  BankIt  v3.0 
submission  tool  (http://www3.ncbi.nlm.nih.gov/BankIt/)  under  accession  number 
EU069819.   89
4.2.9 PCR detection using broad-spectrum cutaneotropic PV-specific 
primers 
A PCR technique for the detection of a broad range of cutaneous PV types (Forslund et al. 
1999) was used to screen total DNA extracted from lesional and non-lesional cutaneous and 
muco-cutaneous tissue samples and skin swabs collected from WBBs (Table 4.2).  
 
Table 4.2 Degenerate primer set use to screen DNA extracted from cutaneous and mucocutaneous 
lesions and skin swabs collected from WBBs for papillomaviral DNA. 
Primer name    Sequence (5’→ → → →3’)                     Product length (bp) 
FAP59       TAACWGTIGGICAYCCWTATT         450 
FAP64       CCWATATCWVHCATITCICCATC  
R = A,G;  Y = C,T;  M = A,C;  K= G,T;  S = G,C; W = A,T; H = A,C,T; B = G,C,T;  V = A,G, C;  D = A, G, T;  N= A, G, C, T 
 
PCR was carried out in a total reaction volume of 25 µL containing 200 µM of each dNTP, 
0.75 µM of forward and reverse primer (Table 4.2), 1 U of Taq DNA polymerase, 1.5 mM 
MgCl2 [pH 8.5] and 1 X DNA Polymerase Reaction Buffer, with 2 µL of the 1:10 diluted 
RCA product, extracted lesional DNA or 2 µL of skin swab saline suspension as template. 
PCR  reagents  were  supplied  by  Fisher  Biotech  Australia.  PCR  was  carried  out  in  an 
automated  thermocycler  (Perkin  Elmer  Gene  Amp  PCR  System  2400)  programmed  for 
block temperatures, using the following parameters: 10 minutes at 94°C and then 45 cycles 
of  1.5  minutes  at  94°C,  1.5  minutes  at  50°C  and  1.5  minutes  at  72°C,  followed  by  5 
minutes  at  72°C.  Five  µL  of  the  PCR  reaction  was  separated  by  2%  agarose  gel 
electrophoresis  and  visualised  using  ethidium  bromide  staining.  PV-specific  bands 
extracted from the gel using the QIAquick Gel Extraction Kit (Qiagen) and sequenced with 
the same primers used for PCR. The sequence of the PCR products was determined and 
edited as described above for plasmids. Similarity searches were performed using the NCBI   90
BLAST (Basic Local Alignment Search Tool) server (version 2.2.13) on the NIH genetic 
sequence database GenBank (Altschul et al. 1997). 
4.2.10 PCR detection using broad spectrum PyV-specific primers 
Total DNA extracted from lesional and non-lesional cutaneous and muco-cutaneous tissue 
samples  collected  from  affected  WBBs  was  screened  for  the  presence  of  PyVs  with  a 
nested broad spectrum PCR technique for the detection of PyV types (Table 4.3) (Johne et 
al. 2005). Total DNA extracted from the liver of an avian PyV (BFPyV) infected bird was 
used as the positive control. All PCR reagents were supplied by Fisher Biotech Australia.  
 
Table 4.3 Degenerate primer set use to screen DNA extracted from cutaneous and mucocutaneous 
lesions and skin swabs collected from WBBs for polyomaviral DNA. 
Primer name      Sequence (5’→ → → →3’)                      Product length (bp) 
Outer pair       VP1.1f       CCAGACCCAACTARRAATGARAA          829–1137 
             VP1.1r       AACAAGAGACACAAATNTTTCCNCC 
Nested  pair    VP1.2f     ATGAAAATGGGGTTGGCCCNCTNTGYAARG       249–273 
             VP1-2r       CCCTCATAAACCCGAACYTCYTCHACYTG 
R = A,G;  Y = C,T;  M = A,C;  K= G,T;  S = G,C; W = A,T; H = A,C,T; B = G,C,T;  V = A,G, C;  D = A, G, T;  N= A, G, C, T 
 
In the first reaction (outer primer pair), PCR was carried out in a total reaction volume of 
50 µL containing 200 µM of each dNTP, 1 µM of each primer (VP1.1f; VP1.1r), 0.6 U Taq 
DNA Polymerase, 1.5 mM MgCl2 [pH 8.5], and 1X DNA Polymerase Reaction Buffer with 
2 µL of the 1:10 diluted extracted lesional DNA as template. PCR was carried out in an 
automated  thermocycler  (Perkin  Elmer  Gene  Amp  PCR  System  2400)  programmed  for 
block temperatures, using the following parameters: 5 minutes at 95°C and then 45 cycles 
of 30 seconds at 94°C, 1 minute at 46°C and 1 minute at 72°C, followed by 72°C for 5   91
minutes. Five µL of the PCR reaction was separated by 2% agarose gel electrophoresis and 
visualised using ethidium bromide staining.  
 
In the nested reaction, PCR was carried out in a total reaction volume of 50 µL containing 
200  µM  of  each  dNTP,  1  µM  of  each  primer  (VP1.2f;  VP1.2r),  0.6  U  Taq  DNA 
Polymerase, 1.5 mM MgCl2 [pH 8.5], and 1 X DNA Polymerase Reaction Buffer with 4 µL 
of  the  first  PCR  reaction  mixture.  PCR  was  carried  out  in  an  automated  thermocycler 
(Perkin Elmer  Gene Amp PCR System) programmed for block temperatures, using the 
following parameters: 5 min at 95°C and then 45 cycles of 30 seconds at 94°C,  30 seconds 
at 56°C and 30 seconds at 72°C, followed by 72°C for 5 minutes. Five µL of the PCR 
reaction was separated by 2% agarose gel electrophoresis and visualised using ethidium 
bromide  staining.  PyV-specific  bands  extracted  from  the  gel  using  the  QIAquick  Gel 
Extraction Kit (Qiagen) and sequenced with the same primers used for PCR. The sequence 
of the PCR products was determined and edited as described above for plasmids. Similarity 
searches were performed using the NCBI BLAST (Basic Local Alignment Search Tool) 
server (version 2.2.13) on the NIH genetic sequence database GenBank (Altschul et al. 
1997). 
 
4.2.11 PCR detection using primer pairs specific for the detection of 
the bandicoot papillomatosis carcinomatosis virus type 1 (BPCV1) 
Following the determination of the BPCV1 genome genetic sequence, a BPCV1-specific 
PCR protocol was designed and optimised using forward and reverse primers designed 
within the putative L1 ORF to yield a 176 bp amplicon (Table 4.4). Primers were designed 
using Primer 3 v 0.4.0 (http://fokker.wi.mit.edu/primer3/input.htm). All PCR reagents were   92
supplied by Fisher Biotech Australia. PCR was carried out in a total reaction volume of 25 
µL containing 200 µM of each dNTP, 0.3 µM of each primer (LWL1F and LWL1R), 0.5 U 
Taq DNA Polymerase, 1.5 mM MgCl2 [pH 8.5], and 1 X DNA Polymerase Reaction Buffer 
with  2  µL  of  a  1:10  dilution  of  extracted  tissue  DNA  or  2  µL  of  skin  swab  saline 
suspension.  
 
Table 4.4 Primer set use to screen DNA extracted from cutaneous and mucocutaneous lesions and 
skin swabs collected from WBBs for BPCV1 DNA. 
Primer name    Sequence (5’→ → → →3’)                     Product length (bp) 
LWL1F       GAGGAGGGACATCAGGTGAC                            176     
LWL1R       ATTGTTTTGCCCAGTTGCTC 
 
 
PCR was carried out in an automated thermocycler (Perkin Elmer Gene Amp PCR System 
2400) programmed for block temperatures, using the following parameters: 5 minutes at 
94°C and then 25 cycles of 30 seconds at 94°C,  30 seconds at 55°C and 30 seconds at 
72°C, followed by 7 minutes at 72°C. Five µL of the PCR reaction was separated by 2% 
agarose  gel  electrophoresis  and  visualised  using  ethidium  bromide  staining.  Visualised 
bands (BPCV1 specific amplicon 176bp) were extracted from the gel using the QIAquick 
Gel  Extraction  Kit  (Qiagen)  and  sequenced  with  the  same  primers  used  for  PCR.  The 
sequence of the PCR products was determined and edited as described above for plasmids.    93
4.2.12 DNA and protein sequence analysis 
Putative  ORFs  were  predicted  using  the  ORF  Finder  tool  on  the  NCBI  server  of  the 
National  Institutes  of  Health  (http://www.ncbi.nlm.nih.gov/gorf/gorf.htmL).  Similarity 
searches were performed using the NCBI BLAST (Basic Local Alignment Search Tool) 
server (version 2.2.13) on the NIH genetic sequence database GenBank (Altschul et al. 
1997).  Protein  sequence  similarities  between  BPCV1  and  known  PVs  and  PyVs  were 
investigated by pairwise sequence  alignments using the GAP-program  on the Sequence 
Analysis  Server  at  Michigan  Technological  University,  Michigan,  USA 
(http://genome.cs.mtu.edu/align/align.html).    94
4.3 Results 
4.3.1 Detection of a novel virus using RCA and a broad-spectrum PCR 
for the detection of cutaneotropic PV types 
BamH1 or Sal1 digestion of the 15 RCA reactions listed in Table 4.2 revealed one ~7.3 kb 
band in five reactions consistent with full length PV genomic DNA. Digestion of RCA 
products with EcoRI revealed two bands ~5.5 kb and 1.8 kb in size, and with HindIII 
multiple bands ~ 2.5 kb, 2 kb, 1.8 kb, 1.5 kb, 600 bp and 400 bp in size, respectively 
(Figure 4.1).  
 
         
Figure 4.1 Restriction analysis of extracted WBB lesional DNA after multiply-primed RCA. Two 
microlitres of RCA product was digested with each of BamHI (lane 2), SalI (lane 3), HindIII (lane 
4) and EcoRI (lane 5). (1 kb ladder image adapted from www.promega.com) 
 
Sequencing  of  cloned  BamH1  -  cut  and  Sal1  -  cut  ~7.5  kb  fragments  from  WBBs 
B05DrS05 and B05K10 revealed the complete genome of a novel virus had been amplified. 
Sequencing ~450 bp amplicon generated from extracted lesional tissue DNA (Table 4.5) 
using the FAP59/64 primer pair demonstrated they had identical nucleotide sequences and a   95
BLASTX  query  showed  that  these  amplicons  were  homologous  to  papillomaviral  L1 
sequences, yet not identical to any previously identified PV types. No PCR products were 
amplified from lesional tissues using nested PCR for the detection of PyV types.    96
Table 4.5 WBB identity, origin, site of tissue collection and histological classification of tissue screened for BPCV1 DNA by RCA and PCR. 
LRPCR = Long range polymerase chain reaction 
WBB ID  Origin  Lesions 
noted 
Tissue collection site  Histological classification  Results of RCA, RE digest and sequencing  PCR result 
(FAP59/64) 
B04K02  PCBC  KWRC  Skin lesion from digit  Carcinoma in situ  ~7.3 kb DNA fragment.  
BPCV1 genome partially sequenced, by LRPCR 
450 bp, BPCV1 
Right eyelid lesion  Carcinoma in situ  No amplification  450 bp, BPCV1 
Left eyelid lesion  Papillomatous hyperplasia  No amplification  450 bp, BPCV1 
B05DrS05  Dryandra  Dryandra  Skin lesion at right lip muco-
cutaneous junction 
Papillomatous hyperplasia  ~7.3 kb DNA fragment 
BPCV1 genomic DNA (sequenced in entirety) 
450 bp, BPCV1 
Skin lesion from left dorsal fore 
digit 
Papillomatous hyperplasia  No amplification  450 bp, BPCV1 
B05K10  Dryandra  Dryandra  Right eyelid lesion  Carcinoma in situ  ~7.3 kb DNA fragment 
BPCV1 genomic DNA (sequenced in entirety) 
450 bp, BPCV1 
Skin lesion from ventral tail  Papillomatous hyperplasia  ~7.3 kb DNA fragment 
BPCV1 genomic DNA (partially sequenced) 
450 bp, BPCV1 
Right eye peri-ocular skin  Carcinoma in situ  No amplification  450 bp, BPCV1 
B05K04 
 
 
 
PCBC  PCBC  Left eyelid lesion  Papillomatous conjunctival 
hyperplasia 
~7.3 kb DNA fragment 
BPCV1 genomic DNA (partially sequenced)
  
450 bp, BPCV1 
Right eyelid lesion  Papillomatous conjunctival 
hyperplasia 
No amplification  450 bp, BPCV1 
Skin lesion from haired skin of 
body 
Papillomatous hyperplasia  No amplification  450 bp, BPCV1 
B02K04  Kanyana  Kanyana  Skin lesion from right hock  Carcinoma in situ  No amplification  450 bp, BPCV1 
B02K05  Kanyana  Kanyana  Skin lesion from left axilla  Carcinoma in situ  No amplification  450 bp, BPCV1 
B05K09  Kanyana  Kanyana  Skin lesion from right periocular 
region 
Papillomatous hyperplasia  No amplification  450 bp, BPCV1 
Unaffected left eyelid  No significant changes  No amplification  450 bp, BPCV1   97
4.3.2 Analysis of BPCV1 complete genomic sequence and deduced 
amino acid sequences 
The  newly  identified  virus  was  tentatively  named  the  bandicoot  papillomatosis 
carcinomatosis virus type 1 (BPCV1) and its complete genome counted 7295 bp, with a GC 
content  of  37.4%  (GenBank  accession  number  EU069819).  The  genomes  amplified  by 
RCA from the lip lesion of B05DrS05 and an eyelid lesion of B05K10 were sequenced in 
their entirety and found to be identical. ORF analysis and BLASTX searches predicted the 
presence of the two classical papillomaviral late (L) protein ORFs, and two polyomaviral T 
antigen-like  early  region  ORFs  (Figure  4.2).  Putative  T  antigens  were  encoded  on  the 
opposing strand as the late protein ORFs.   98
 
Figure  4.2  Genomic  organisation  of  BPCV1  (A)  and  schematic  representation  of  classical 
Papillomaviridae  (HPV16)  (B)  and  Polyomaviridae  (JCV)  (C)  genomic  organisation.  BPCV1 
ORFs are divided between both strands of the genome, the structural proteins encoded on one strand 
and the non-structural proteins encoded on the other strand. Numbers show the nucleotide positions 
of the putative ORFs’ start and stop codons. BamHI and SalI cut sites are indicated.  
 
The  genome  of  BPCV1  exhibited  two  ORFs  encoding  proteins  demonstrating  greatest 
similarity to PV major (L1) and minor (L2) capsid proteins respectively. The putative L1 
ORF was 1518 bp in length (nt 2240 - 3757) and the putative L2 1409 bp in length (nt 818 - 
2227). The sequence similarity between the respective L1 and L2 ORFs of BPCV1 and 
HPV1a  (a  benign  cutaneous  PV  of  the   -PV  genus;  NC_001356),  HPV5  (an   99
epidermodysplasia verruciformis-associated PV of the  -PV genus; NC_001531), HPV16 
(a mucosal high-risk PV of the  -PV genus; NC_001526), HPV6 (a mucosal low-risk PV of 
the  -PV genus; X00203) and bovine BPV1 (a fibropapillomavirus of the  -PV genus; 
X02346) was investigated by pairwise alignments performed at the amino acid level. The 
similarity of the putative BPCV1 L1 and L2 sequences to those of the PV types listed above 
ranged between 47-51% and 26-33% respectively (Table 4.6). The BPCV1 late ORFs did 
not demonstrate any similarity to classical PyV capsid proteins ORFs VP1, VP2 or VP3. 
 
In  addition to  the  late  proteins  described above,  two  BPCV1  ORFs  coded  for  proteins 
demonstrating greatest similarity to the avian and mammalian PyV T antigens: a putative 
large  T  antigen  (nt  7295  –  5070)  and  putative  small  t  antigen  (nt  7295  -  6621).  The 
sequence similarity between the respective large T antigen and small t antigen ORFs of 
BPCV1 and thirteen known PyVs [Lymphotropic PyV of African Green Monkey (LPyV) 
NC_004763, Simian virus 40 (SV40) NC_001669, Simian agent 12 (Sa12) NC_007611, 
Hamster PyV (HaPyV) NC_001663, Mouse PyV (MPyV) NC_001515, Kilham strain of 
mouse  PyV  (MptV)  NC_001505,  Bovine  PyV  (BPyV)  NC_001442,  JC  virus  (JCV) 
NC_001699, BK virus (BKV)  NC_001538, Budgerigar fledgling disease PyV (BFPyV) 
NC_004764,  Goose  hemorrhagic  PyV  (GHPyV)  NC_004800,  Crow  PyV  (CPyV) 
NC_007922,  Finch  PyV  (FPyV)  NC_007923]  was  investigated  by  pairwise  alignments 
performed at the amino acid level. Due to the dissimilarity of this virus to known PyVs, a 
putative  intron  was  not  able  to  be  predicted  within  the  BPCV1  large  T  antigen  ORF. 
Therefore alignments were performed using the BPCV1 large T protein sequence predicted 
from the unspliced ORF nucleotide sequence.  The similarity of the putative BPCV1 large 
T antigen and small t antigen sequences to those of known PyVs ranged between 19-35% 
and 0-22%, respectively (Table 4.7).    100
Table 4.6 Percentage amino acid similarity of the BPCV1 L1 and L2 ORFs with those of HPV1, HPV5, HPV16, HPV6 and BPV1. 
BPCV1 
ORF 
% amino acid similarity to ORF of: 
HPV1  HPV5  HPV16  HPV6  BPV1 
L1  51  55  48  50  47 
L2  29  33  30  29  26 
 
 
Table 4.7 Percentage amino acid similarity of the BPCV1 large T antigen and small t antigen ORFs with those of known PyVs. 
BPCV1 
ORF 
Predicted 
size (aa) 
Avian    Eutherian 
CyPV  FPyV  GHPyV  BFDV  BPyV  BKV  JCV  SV40  SA12  HaPyV  LPV  PyV  KV 
small t antigen  224  20  16  22  16    6  5  6  6  7  5  4  5  0 
large T antigen  742  35  33  32  32    25  23  24  23  24  27  27  19  24 
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Further  analysis  of  these  proteins  revealed  conserved  PyV  T  antigen  motifs.  A  DnaJ 
domain  was  located  between  aa  8-72  of  BPCV1  large  T  antigen  and  small  t  antigen 
proteins, including the conserved hexapeptide HPDKGG (Table 4.8.A), and an ATPase 
binding domain (GPVNTGKT) was present between aa 543-550. The conserved PyV T 
antigen LXCXE motif, LFCYE, was found located between aa 78 to 82 within both the 
putative large T and small t antigens (Table 4.8.B). A C2H2 zinc finger motif, common to 
all PyV T antigens, was found within the putative large T antigen, C-416, C-419, H-437, H-
441 (Table 4.8.C).  
 
Table 4.8 Conserved polyomavirus T antigen motifs encoded by BPCV1 early domain. 
A. HPDKGG box, large T antigen.  
Virus  GenBank Acc. no.   
     
BPCV1  EU 069819 
34K M H P D K G G S T N A M K R L N E L N Q
54 
CPyV  NC_007922 
37M Y H P D K G G D E E K M K R L N Q L M D
57 
FPyV  NC_007923 
32E F H P D K G G D P E R M K E L N R L M D
52 
GHPyV  NC_004800 
34M F H P D K G G D E E K M K R L N Y L M E
54 
BFPyV  NC_004764 
32K Y H P D K G G D E E K M K E L N T L M E
52 
BKV  NC_001538 
40E F H P D K G G D E D K M K R M N T L Y K
60 
JCV  NC_001699 
40E L H P D K G G D E D K M K R M N F L Y K
60 
SV40  NC_001669 
40E F H P D K G G D E E K M K K M N T L Y K
60 
SA12  NC_007611 
40E F H P D K G G D E D K M K R M N T L Y K
60 
LPyV  NC_004763 
40L Y H P D K G G D S A K M Q R L N E L F Q
60 
HaPyV  NC_001663 
40Q L H P D K G G N E E L M Q Q L N T L W T
60 
MPyV  NC_001515 
40L L H P D K G G S H A L M Q E L N S L W G
60 
MptV  NC_001505 
40I V H P D K G G S D E L S Q E L I S L Y R
60 
   
 
* HPDKGG box not encoded by BPyV 
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Table 4.8 Cont’d.  
B. Cr2 LXCXE Rb binding area 
Virus  GenBank Acc. no.   
     
BPCV1  EU 069819 
 75E D L F C Y E S E G D D E P D T C
91 
CPyV  NC_007922 
 67E T L Q C E E T L Y S S D E E D V
83 
FPyV  NC_007923 
 58Q S L F C D E T L D S D S D D G D
74 
GHPyV  NC_004800 
 63E D L F C D E E L S S S E E E D V
79 
BFPyV  NC_004764 
 58E G L R A D E T L E D S D P E P E
74 
BPyV  NC_001442 
 58Q D L H C D E E L E P S D N E E E
74 
BKV  NC_001538 
103E D L F C H E D M F A S D E E A T
119 
JCV  NC_001699 
103E D L F C H E E M F A S D D E N T
119 
SV40  NC_001669 
101E N L F C S E E M P S S D D E A T
117 
SA12  NC_007611 
103E D L F C H E D M F Q S D E E G T
119 
LPyV  NC_004763 
129D D L F C S E T M S S S S D E D T
145 
HaPyV  NC_001663 
128E D L T C Q E E L S S S E D E F T
144 
MPyV  NC_001515 
140P D L F C Y E E P L L S P N P S S
156 
MptV  NC_001505 
101F D L F C N E A F D R S D D E Q E
117 
     
 
 
C. Zinc finger motifs 
Virus 
GenBank Acc. 
no.                         
                           
BPCV
1  EU 069819 
411N T I Q G C K L C V K D Q L L L T G L H K N H A K D - - H V Q H H E 
N A
444 
CPyV  NC_007922 
293V N P D E C K D C K E D R E N S S L Q R L K R R R P G G H L E D H A 
T H
328 
FPyV  NC_007923 
275R P V E A C P D C A K E R E T A K R Q R T S H L E D - - H P A – H Q 
K N
307 
GHPy
V  NC_004800 
289V P Q E E C A D C Q S Q K E N L C F G Q L K R K W Y G G H L D D H G 
I H
324 
BFPy
V  NC_004764 
253Q P T D K C P E C Q K D K D T V K R K R S T H I D D - - H P R – H Q 
H N
285 
BPyV  NC_001442 
254T A P E A C K V C D N P R R L E H R R H - - - - - - - - H T K D H T 
L N
281 
BKV  NC_001538 
299Y N V E E C K K C Q K K D Q P Y H F K Y - - - - - - - - H E K – H F 
A N
325 
JCV  NC_001699 
298E N P Q Q C K K C E K K D Q P N H F N H - - - - - - - - H E K – H Y 
Y N
324 
SV40  NC_001669 
297Y S F E M C L K C I K K E Q P S H Y K Y - - - - - - - - H E K – H Y 
A N
323 
SA12  NC_007611 
298H N P E E C R K C Q K K E Q P Y H F K F - - - - - - - - H E K – H F 
A N
325 
LPyV  NC_004763 
362V E P G K C G K C E K K Q H K F H Y N Y - - - - - - - - H K A – H H 
A N
388 
HaPy
V  NC_001663 
421Q C E S S C K K C A E A L P R M K V H W A N - - - - - - H S Q – H L 
E N
449 
MPyV  NC_001515 
443K E V P S C I K C S K E E T R L Q I H W K N - - - - - - H R K – H A 
E N
471 
MptV  NC_001505 
314S P V P N C S K C E N R M L T N H F K F - - - - - - - - H K E – H H 
E N
340 
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The  genomic  organisation  of  BPCV1  was  found  to  be  most  similar  to  that  of  the 
Polyomaviridae, therefore based on this knowledge a viral regulatory region, containing the 
origin of replication (ori), was predicted to lie between the shared start codon of the T 
antigens and the start codon of L2 (nt 1-817). Two GAGGC pentanucleotides were located 
within this region and may represent potential T antigen binding sites.  A second non-
coding region was also found to lie between the end of L1 and the end of the large T 
antigen ORFs (nt 3758 – 5069). Both non-coding areas contained A/T rich regions which 
may represent putative TATA box sequences. No other recognisable regulatory or promoter 
elements were identified in these regions, and BLAST searches performed with this region 
did not reveal any similarity to known PVs or PyVs.    104
4.3.3 Screening of WBB papillomas and carcinomas and non-lesional 
epithelia by PCR for the presence of BPCV1 DNA 
The methodology described in Sections 4.2.8 and 4.2.10 was used to screen a range of 
cutaneous  and  muco-cutaneous  lesions  and  unaffected  epithelia  collected  from  both 
affected  and  clinically  normal  WBBs  for  the  presence  of  BPCV1  DNA.  BPCV1  was 
amplified from the skin lesions of 18/19 (94.7%) affected WBBs for  whom DNA was 
extracted from fresh lesional tissue. In affected WBB for whom only formalin-fixed tissues 
were available, BPCV1 was detected in skin lesions from 4/13 (30.7%) WBBs. Histological 
classification of and PCR results for lesions screened for BPCV1 DNA are presented in 
Tables 4.9 and 4.10.  Both FAP59/64 and BPCV1-specific primers pairs were utilised in 
tissue screening and sequencing of amplicons indicated that only viral sequences identical 
to BPCV1 were amplified from these tissue extracts. No viral DNA was amplified from 
cutaneous and mucosal tissue extracts (n = 4) from the two unaffected WBB.     105
Table 4.9 Fresh tissues from affected WBBs screened for BPCV1 DNA by PCR. 
 
 
Table 4.10 Formalin-fixed tissues from affected WBBs screened for BPCV1 DNA by PCR. 
PCR result 
Histological classification of lesions 
Total  Papillomatous hyperplasia +/- 
intranuclear inclusions 
Carcinoma 
in situ 
Squamous cell 
carcinoma 
BPCV1 positive  2 (25.0%)  0 (0.0%)  2 (50.0%)  4 (30.8%) 
BPCV1 negative  6 (75.0%)  1 (100.0%)  2 (50.0%)  9 (69.2%) 
Total  8  1  4  13 
 
PCR result 
Histological classification of lesions 
Subtotal  
(lesional tissue) 
Non-lesional 
skin  
Total tissues 
tested 
Papillomatous hyperplasia 
+/- intranuclear inclusions 
Carcinoma 
in situ 
Squamous cell 
carcinoma 
Adenocarcinoma 
BPCV1 positive  20 (95.2%)  14 (87.5%)  12 (85.7%)  0 (0.0%)  46 (88.5%)  2 (28.6%)  48  
BPCV1 negative  1 (4.8%)  2 (12.5%)  2 (14.3%)  1 (100.0%)  6 (11.5%)  5 (71.4%)  11 
Total  21  16  14  1  52  7  59  
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4.3.3 Screening WBBs for the presence of BPCV1 DNA by swabbing 
lesional and non-lesional epithelia 
Swabs taken from the surface of epithelial lesions from the eight WBBs examined in the 
field found to be clinically affected by the papillomatosis and carcinomatosis syndrome 
tested positively for BPCV1 DNA. Five of these animals were examined and swabbed 
on three occasions; the remaining three were examined and swabbed only once. Both 
FAP59/64 and BPCV1-specific primer pairs were utilised and sequencing of amplicons 
indicated that only viral sequences identical to BPCV1 were amplified from skin swab 
suspensions.  Affected  WBBs  testing  positive  for  BPCV1  originated  from  a  wild 
population on Bernier Island (n = 2) and from a captive breeding colony at Dryandra 
Woodland (n = 6). BPCV1 was not detected in skin swab suspensions taken from the 
surface of normal cutaneous and mucosal epithelia in the 65 clinically normal WBBs 
examined in the field.  
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4.4 Discussion 
BPCV1  was  found  to  possess  a  double-stranded  circular  DNA  genome  7295  bp  in 
length which is consistent with members of the Papillomaviridae. However, its genomic 
organisation comprising ORFs encoding structural proteins located on one strand and 
ORFs encoding non-structural proteins on the opposite strand, is characteristic of the 
Polyomaviridae and unlike that of the Papillomaviridae, in which all ORFs are located 
on  (and  genes  are  subsequently  transcribed  from)  one  DNA  strand  only  (Cole  and 
Conzen 2001; Howley and Lowy 2001).  
 
The putative BPCV1 late region codes for PV-like major (L1) and minor (L2) capsid 
protein genes. The L1 ORF is the most conserved region among different PV types, and 
the currently accepted classification of these viruses is based upon similarities in this 
region (de Villiers et al. 2004). The BPCV1 L1 shared less than 60% identity to the L1 
of other PVs, therefore on the basis of L1 sequence analysis alone it cannot be attributed 
to one of the existing PV genera. However, the BPCV1 L1 sequence was sufficiently 
similar to that of other cutaneous PV types to allow detection with degenerate primer 
pairs designed to detect a broad range of cutaneotropic PV types.  
 
Two predicted BPCV1 ORFs encoded proteins most similar to PyV large T and small t 
antigens. The T antigens are multifunctional proteins that perform a diverse array of 
activities,  including  alteration  and  recruitment  of  specific  host  cell  proteins  to 
participate in virus production, blockade of cellular antiviral defence systems and direct 
participation in viral replication (Brodsky and Pipas 1998). The transforming properties 
of the T antigens are mediated through their direct physical association with cellular 
target proteins, such as the retinoblastoma protein family of tumour suppressors Rb, 
p107 and p130 (large T antigen), components of the cellular signal transduction network  
  108
(middle T antigen) and cellular protein phosphatase 2A (small t antigen) (Brodsky and 
Pipas 1998).  
 
PyV T antigens are encoded by a common precursor mRNA that is differentially spliced 
to create multiple monocistronic mature mRNAs. For example SV40 expresses three 
such  mRNAs,  one  each  for  the  large  T  antigen,  small  t  antigen  and  tiny  t  antigen, 
whereas murine PyV expresses four mRNAs, one each for large, middle, small and tiny 
t antigens (Brodsky and Pipas 1998; Cole and Conzen 2001). Due to the dissimilarity of 
the BPCV1 genome to known PyVs, it was not possible to predict T antigen mRNA 
splice junctions from this sequence analysis alone. Examination of BPCV1 T antigen 
proteins  for  conserved  PyV  motifs  was  therefore  performed  on  translated  unspliced 
mRNAs predicted in the ORF analysis. 
 
A  DnaJ  domain  was  identified  in  the  putative  BPCV1  small  t  and  large  T  antigen 
sequences. In previously characterised PyVs the small t and large T antigens share the 
amino-terminal portion of the early domain, inclusive of the DnaJ domain, due to the 
splicing pattern of early viral mRNAs (Pipas 1992). The DnaJ domain of the T antigens 
plays an essential role in virion assembly, virus DNA replication, transcriptional control 
and oncogenic transformation (Hall et al. 1999), and with the exception of the bovine 
PyV large T antigen, all characterised PyV large T antigens and small t antigens contain 
the  conserved  HPDKGG  motif  (Pipas  1992).  The  PyV  ATPase  binding  domain, 
GP(V/I)(N/D)XGKT (Walker et al. 1982), was also identified within BPCV1 T antigen 
sequences. This is the  most highly conserved  domain among PyV types. Sequences 
important  for  complex  formation  with  the  cellular  p53  protein  also  lie  within  this 
domain (Pipas 1992). A large T antigen consensus motif LXCXE, required for binding 
to Rb, p107 and p130 (Hall et al. 1999), was identified in BPCV1 as LFCYE. BPCV1  
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early ORFs did not demonstrate any similarity to classical PV early region ORFs such 
as E1, E2, E6 or E7 at either a nucleotide or amino acid level, except for the presence of 
the pRB binding motif, which is a common feature of both PyV large T and PV E7 
proteins. 
 
Based on the PyV-like genomic organisation of BPCV1, a viral regulatory region and 
origin of replication (ori) was predicted to lie between the start of L2 and the start of the 
T antigens. The regulatory region of PyVs is located between the early and late regions 
and comprises the origin of replication (ori), the TATA box, T antigen binding sites, 
cellular transcription factor binding sites, and bidirectional promoter and enhancer for 
transcription of early and late genes (Cole and Conzen 2001). Transcription extends 
bidirectionally  from  initiation  sites  near  the  origin,  with  early  and  late  mRNAs 
transcribed from opposite strands of the viral genome. The ori of most characterised 
PyVs consists of multiple copies of the GAGGC pentanucleotide, flanked by A/T-rich 
sequences  on  the  late  side  and  an  imperfect  palindrome  on  the  early  side,  with  the 
exception of BFPyV and GHPyV which do not contain any GAGGC pentanucleotides 
within the regulatory region (Pipas 1992; Cantalupo et al. 2005). In mammalian PyVs, 
the large T antigen binds to this GAGGC pentanucleotide (Tjian 1978). In avian PyVs, 
however,  the  binding  sequence  for  the  large  T  antigen  has  been  identified  as  the 
palindromic sequence TCC (A/T)6 GGA or similar (Luo et al. 1994; Johne et al. 2006b), 
of which related sequences were not identified in the BPCV1 sequence. Two potential 
GAGGC  large  T  antigen  binding  sites  were  identified  in  the  putative  BPCV1  viral 
regulatory region.  
 
The NCR region of PVs typically lies between the stop codon of L1 and the start codon 
of E6. PVs usually contain an E1-recognition site flanked by two E2 binding sites (with  
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the consensus sequence ACCN6GGT), for binding of an E1/E2 complex in order to 
activate the origin of replication. These sites were not identified within the BPCV1 viral 
regulatory region, which was not unexpected since BPCV1 does not appear to encode 
any proteins demonstrating similarity to papillomaviral E1 or E2. 
 
A second non-coding region was located between the ends of the BPCV1 L1 and large 
T antigen ORFs, however no significant homology to known PyV or PV types was 
found in the region and regulatory or promoter elements were not able to be identified. 
A second non-coding region, located between the end of the early and the beginning of 
the late protein regions, has also been characterised in the   PV types, including the 
feline PVs, canine oral PV (COPV) and the Procyon lotor PV (PlPV1) (Delius et al. 
1994; Terai and Burk 2002; Tachezy et al. 2002a; Rector et al. 2005; Rector et al. 2007) 
and in the deer PV (   PV) (Groff and Lancaster 1985). It has been postulated that this 
region may have arisen though an ancient integration event, and may have structural or 
functional importance that is yet unknown (Rector et al. 2007).  
 
Due to the novel nature of this viral genome, concerns were initially raised that there 
may be a dual PV and PyV infection in WBB lesional tissue, or that contamination of 
WBB DNA extracts with either PV or PyV DNA may have occurred in the laboratory, 
and therefore this unique hybrid-like PV- PyV genome may in fact be an artefact of 
RCA.  Sequencing  of  long  range  template  PCR  products  amplified  directly  from 
extracted lesional DNA (Appendix 1) indicated that the PV-like and PyV-like sequences 
were  continuous  with  one  another  on  the  BPCV1  template  DNA.  In  addition,  the 
complete  genomic  sequence  of  BPCV1  generated  using  long  template  PCR 
independently of RCA was found to be identical to that obtained from cloned RCA 
products. The findings of the same size 7.3 kb genome detected in biopsies from four  
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different individuals, as well as the fact that entire genome sequences amplified from 
lesions of two of these individuals and partial sequences amplified from the lesions of 
the remaining two individuals were found to be identical, and that these sequences were 
unlike previously characterised PVs and PyVs, were also supportive of the existence of 
this novel genome.   
 
BPCV1 was detected in 94.7% of individuals from whom fresh lesional tissue extracts 
were screened and in 30.8% of individuals for whom only formalin-fixed tissue extracts 
were  available.  Amplification  of  BPCV1  from  DNA  extracted  from  formalin-fixed 
lesions may not have occurred as readily due to deleterious effects on DNA quality and 
quantity  that  might  be  caused  by  formalin-fixation  of  tissues  (Gilbert  et  al.  2007). 
BPCV1  was  detected  in  the  vast  majority  of  epithelial  lesions  consistent  with  the 
papillomatosis  and  carcinomatosis  syndrome  including  papillomatous  hyperplasia, 
carcinoma in situ and squamous cell carcinomas, however, not in the single case of 
adenocarcinoma.  BPCV1  was  not  detected  in  tissue  samples  taken  from  clinically 
normal individuals. No viral sequences other than BPCV1 were amplified using broad 
spectrum  cutaneotropic  PV  and  BPCV1-specific  primer  pairs.  In  addition,  a  broad 
spectrum  nested  PCR  technique  for  the  amplification  of  PyVs  based  on  conserved 
regions of the major capsid protein (VP1) ORF  (Johne et al. 2005) failed to amplify 
PyV genomic DNA.  
 
BPCV1  was  detectable  in  100%  of  individuals  displaying  clinical  evidence  of  the 
papillomatosis and carcinomatosis syndrome screened by a skin swabbing technique. 
No novel viral sequences other than BPCV1 were amplified from WBB skin swabs 
using broad spectrum cutaneotropic PV and BPCV1-specific primer pairs. BPCV1 was 
not detected in skin and mucosal swabs taken from clinically normal individuals.   
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It  appears  from  screening  of  epithelial  lesions  and  skin  swabs  that  BPCV1  is  only 
detectable in individuals clinically affected by the papillomatosis and carcinomatosis 
syndrome, and therefore is unlikely to be a commensal of normal WBB skin. These 
results  are  supportive  of  the  hypothesis  that  BPCV1  is  a  necessary  factor  for 
development of the papillomatosis and carcinomatosis syndrome, and it appears at this 
stage that only one virus type is associated with this disease in the WBB.  
 
BPCV1 represents a novel prototype virus possessing genomic characteristics of both 
the Polyomaviridae and Papillomaviridae; specifically possessing the genome size and 
encoding  the  structural  proteins  of  the  Papillomaviridae,  and  encoding  the  non-
structural proteins and exhibiting the genomic organization of the Polyomaviridae. A 
quandary  is  created  in  regards  to  the  taxonomic  placement  of  this  virus  based  on 
currently  accepted  classification  systems.  Over  one  hundred  PV  types  have  been 
completely characterised in humans alone (de Villiers et al. 2004). An additional 40 
complete genomes of non-human PVs, retrieved from 31 distinct amniote host species 
(mammals  and  birds),  are  currently  available  in  GenBank.  The  position,  size  and 
function of many of the ORFs are well conserved among the various PV types that have 
been  sequenced  and  studied  thus  far  (Chan  et  al.  1995).  This  conserved  genomic 
organisation  provides  strong  evidence  for  a  monophyletic  origin  of  the  extant  PVs. 
Fourteen PyV species have been characterised to date and similarly the many highly 
conserved regions of PyV genomes support the idea that all known members of the 
Polyomaviridae are descendents of a common ancestor (Cole and Conzen 2001).  
 
Alignment  of  papillomavirus  L1  sequences  inclusive  of  BPCV1  and  subsequent 
phylogenetic  analysis  demonstrated  that  BPCV1  was  most  closely  related  to  the  
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members of the  -PV genus (containing the Epidermodysplasia verruciformis associated 
human PVs), but branching off close to the root of the genus (Appendix 2, Figure A2.2). 
This seems to be an argument for BPCV1 having arisen following  a recombination 
event  between  existent  (but  yet  undiscovered)  or  ancestral  members  of  the 
Papillomaviridae and Polyomaviridae families, in which a PV provided the late region 
structural  genes  cassette  and  a  PyV  delivered  the  early  region  non-structural  genes 
cassette to the recombinant virus. However, although recombination events have been 
suspected  in  PVs  (Narechania  et  al.  2005;  Varsani  et  al.  2006)  these  are  highly 
uncommon and no evidence has yet been found for recombination among the major 
PyV clades (Crandall et al. 2005). As these viruses utilise the host cell polymerase 
during replication, they are relatively stable and slow evolving viruses and evolution is 
thought  to  occur  mainly  through  point  mutations.  PVs  and  PyVs  are  also  species-
specific or show a narrow host range. Various phylogenetic and cophylogenetic studies 
provide  evidence  that  PVs  and  PyVs  are  ancient  viruses  that  originated  early  in 
vertebrate evolution and have co-evolved and speciated in synchrony with their host 
species (Van Ranst et al. 1995; Crandall et al. 2005; Perez-Losada et al. 2006; Rector et 
al. 2007).  
 
Alternatively BPCV1 could be a descendant of a common ancestor to both the modern 
day Polyomaviridae and Papillomaviridae. Alignment of polyomavirus large T antigen 
sequences inclusive of BPCV1 and subsequent phylogenetic analysis revealed BPCV1 
as a close-to-root sequence, branching off from the root between the mammalian and 
avian polyomaviruses (Appendix 2, Figure A2.1). In contrast to the L1 analysis, this 
would be in agreement with the virus being a descendent of a common papilloma- and 
polyomavirus  ancestor,  or  at  least  having  arisen  as  long  ago  as  the  two  major 
phylogenetic clades of polyomaviruses, so in the earliest evolutionary history of the  
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Polyomaviridae. Despite sharing no major nucleotide or amino acid similarity, PVs and 
PyVs encode proteins sharing similar functions and domains.  The actions of PV E7 and 
PyV large T antigen are similar in the host cell, including induction of cellular DNA 
synthesis in growth arrested cells and the ability to immortalise cells (Hall et al. 1999). 
E7  and  the  large  T  antigen  share  a  functional  domain,  with  the  consensus  motif 
LXCXE,  for  binding  of  the  retinoblastoma  gene  product  p105-Rb  (DeCaprio  et  al. 
1988; Hall et al. 1999). Therefore, although overall sequence similarity between PVs 
and  PyVs  is  low,  the  conservation  of  small  functional  domains  and  exploitation  of 
similar cellular regulatory pathways is suggestive of an ancient common evolutionary 
origin for both virus families (Van Ranst et al. 1995).  
 
Due to the novel nature of this virus, it is inappropriate for this virus to be definitively 
classified as a PV or a PyV, and it may in fact represent the first member of a new 
family of viruses. Not only is the detection of BPCV1 important for conservation efforts 
to prevent the extinction of the WBB, it will surely open discussion concerning theories 
on  the  evolution  and  divergence  of  virus  families  previously  belonging  to 
Papovaviridae, as well as the final classification of this virus.  
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Chapter 5: Epidemiological features of the papillomatosis and 
carcinomatosis syndrome in captive and wild populations of 
the western barred bandicoot 
 
 
 
 
 
Western barred bandicoot tracks on dune at sunrise, Red Cliff, Bernier Island. 
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Summary: 
Once  widespread  across  western  and  southern  Australia,  wild  populations  of  the 
western barred bandicoot (WBB) are now only found on Bernier and Dorre Islands, 
Shark  Bay,  Western  Australia.  Conservation  efforts  to  prevent  the  extinction  of  the 
WBB involve captive breeding and reintroduction into predator proof enclosures, or fox 
and cat baited habitat, located in the species’ historic distribution range on mainland 
Western  Australia  and  South  Australia.  Chapter  5  presents  evidence  for  the 
establishment  of  BPCV1  as  the  causative  agent  of  the  papillomatosis  and 
carcinomatosis syndrome. This syndrome and BPCV1 were found to be present only in 
the Bernier Island WBB population at Red Cliff and in captive populations comprising 
all  or  a  proportion  of  founder  WBBs  from  Red  Cliff  (Kanyana,  Dryandra  and  the 
PCBC). This pattern of disease emergence was highly suggestive that BPCV1 and the 
associated  syndrome  originated  at  Red  Cliff  and  were  subsequently  disseminated  in 
mainland WBB populations through the introduction of infected WBBs from this site. 
The severity of lesions and the number of affected animals seen in captivity was greater 
than was observed in wild populations. The presence of BPCV1 and increasing age 
appear to be the most crucial risk factors for the development of the papillomatosis and 
carcinomatosis syndrome in the WBB.  
.  
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5.1 Introduction 
The western barred bandicoot (WBB) was once widespread across western and southern 
Australia. Now extinct on the mainland, wild populations are known only to exist on 
Bernier and Dorre Islands, in the World Heritage Area of Shark Bay Western Australia 
(Seebeck et al. 1990; UNESCO 1991; Short et al. 1997; Richards and Short 2003). 
Conservation efforts to prevent the extinction of the WBB involve captive breeding and 
reintroduction into predator proof enclosures, or fox and cat baited habitat, located in 
the  species’  historic  distribution  range  on  mainland  Western  Australia  and  South 
Australia.  These  efforts  are  compromised  by  the  presence  of  the  bandicoot 
papillomatosis  carcinomatosis  virus  type  1  (BPCV1)-associated  papillomatosis  and 
carcinomatosis syndrome.   
 
Pathological and molecular studies detailed in this thesis and elsewhere (Woolford et al. 
2007;  Woolford  et  al.  2008;  Bennett  et  al.  2008a)  have  demonstrated  a  association 
between  BPCV1  infection  and  the  papillomatosis  and  carcinomatosis  syndrome.  An 
association  between  a  factor  (e.g.  viral  agent)  and  disease  is  necessary  to  establish 
causation;  however,  association  alone  does  not  prove  a  causal  relationship  exists. 
Various criteria have been established, that if fulfilled, are thought to contribute to the 
likelihood that a relationship between a factor and a disease is causal (Rivers 1937; Hill 
1965; Evans 1976; Thrusfield 2005). These criteria include: 
 
1.  Strength of association 
a.  The proportion of individuals with a disease should be significantly higher in 
those exposed to the factor than in those who are not; 
b.  In prospective and experimental studies, the incidence of the disease should be 
higher in those exposed to the factor  than those not exposed;  
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c.  Reduction or elimination of the risk factor should reduce the risk of the disease.  
2.  Time sequence of events  
a.  The causal factor must always precede the disease.  
3.  Dose response and biological gradient 
a.  If a dose response relationship can be found between a factor and disease, the 
plausibility of a factor being causal is increased. 
4.  Consistency 
a.  If an association exists in a number of different circumstances, then a causal 
relationship is probable. 
5.  Compatibility with existing knowledge and biological plausibility 
a.  It  is  more  reasonable  to  infer  that  a  factor  causes  a  disease  if  a  plausible 
biological  mechanism  has  been  identified,  than  if  such  a  mechanism  is  not 
known.   
 
Due  to  its  similarity  to  other  small  DNA  viruses,  BPCV1  is  likely  an  ancient  and 
species-specific virus that has co-evolved with the WBB. A second highly similar but 
distinctly different virus, BPCV2, was recently detected in papillomatous skin lesions 
from a southern brown bandicoot (Isoodon obeselus) (Bennett et al. 2008b). It has been 
proposed  that  the  evolutionary  divergence  of  BPCV1  and  BPCV2  occurred 
approximately 10.2 million years ago, coincident with the divergence of the two extant 
genera  within  the  family  Peramelidae,  Isoodon  and  Perameles  (Nilsson  et  al.  2004; 
Bennett et al. 2008b). This finding is both supportive of the theory of host-virus co-
evolution and suggestive that BPCV1 has been present in the WBB population for at 
least 10 million years (Bennett et al. 2008b). 
 
If a causal relationship between this apparently ancient virus and the papillomatosis and 
carcinomatosis syndrome can be established, factors that may have led to the recent  
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emergence  of  this  debilitating  syndrome  in  select  WBB  populations  need  to  be 
determined. It must be considered that a multifactorial disease pathogenesis may exist, 
in which (recently) introduced environmental, host and/ or viral factors (e.g. mutation to 
a more pathogenic variant) have led to the apparent increase in frequency and severity 
of clinical disease in the WBB.  
 
The main objectives of this Chapter are threefold. Firstly, it aims to address criteria 
thought  necessary  for  the  establishment  of  BPCV1  as  the  causative  agent  of  the 
papillomatosis  and  carcinomatosis  syndrome.  Secondly,  this  Chapter  examines  the 
emergence and frequency of the BPCV1-associated papillomatosis and carcinomatosis 
syndrome in geographically isolated wild and captive populations. Patterns of disease in 
captive populations are examined in order to investigate susceptibility to, transmission 
of and clinical progression of disease. Variables that may be associated with increased 
risk  of  disease  are  also  explored  in  order  to  investigate  a  potentially  multifactorial 
disease  pathogenesis.  Finally,  the  impact  of  the  papillomatosis  and  carcinomatosis 
syndrome on captive and wild populations of the WBB is evaluated. 
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5.1.1 Wild populations of the WBB: Bernier and Dorre Islands 
Bernier and Dorre Islands lie 50 kilometres west of Carnarvon in Shark Bay, Western 
Australia (Figures 5.1 and 5.2), a region inscribed on the World Heritage List in 1991 
(UNESCO 1991; Hancock et al. 2000). These islands are of vital importance in the 
preservation  of  the  only  remaining  wild  populations  of  the  WBB,  along  with  four 
additional species of Australian marsupials also classified as rare and endangered: the 
banded  hare-wallaby  (Lagostrophus  fasciatus);  rufous  hare-wallaby  (Lagorchestes 
hirsutus);  the  burrowing  bettong  (Bettongia  lesueur);  and  the  Shark  Bay  mouse 
(Pseudomys fieldi) (Short et al. 1997).  
 
Bernier and Dorre Islands, 44 km
2 and 53 
km
2  in  area,  respectively,  are  believed  to 
have been separated from the mainland by 
rising sea levels approximately 8000 years 
ago, and from each other between 3000 and 
6000 years ago (Hancock et al. 2000). They 
have  had  many  and  varied  uses  since  the 
first known landing on the islands by Dirk 
Hartog in 1717, including pastoral (for 10 
years on Bernier Island but reportedly not at 
all  on  Dorre  Island),  sandalwood  logging 
and as sites for quarantine hospitals (1904-
1911)  constructed  for  mainland  aborigines 
affected  by  leprosy  and  venereal  disease 
(Hancock et al. 2000; Friend 2007). Currently, Bernier and Dorre Islands are designated 
“Class A Nature Reserves for the Conservation of Flora and Fauna”. Bernier Island is a 
Figure 5.1 View to Bernier Island from the 
northern-most point of Dorre Island.  
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limited access area (day use only) and Dorre Island a prohibited area (authorised access 
only) (Hancock et al. 2000). 
 
Figure 5.2 Location of Bernier and Dorre Islands within the Shark Bay World Heritage Area 
(http://www.deh.gov.au/heritage/worldheritage/sites/shark/index.htmL).  
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Researchers have travelled to Bernier and Dorre Islands on a frequent basis since Ride 
and Tyndale-Biscoe first conducted a population survey of the islands in 1959 (Ride and 
Tyndale-Biscoe  1962).  Numerous  expeditions  to  monitor  resident  fauna  and  collect 
animals for mainland captive breeding colonies have been carried out by the Western 
Australian  Department  of  Environment  and  Conservation  (DEC)  and  the 
Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Tables 5.4 
and 5.7).  
 
White Beach on Dorre Island (Figure 5.3) has been the focus of regular monitoring 
activities  by  DEC,  and  was  the  site  for  collections  of  WBBs  for  translocation  to 
Heirisson  Prong,  the  Kanyana  Wildlife  Rehabilitation  Centre  (Kanyana),  and  the 
Dryandra  Field  Breeding  Centre  (Sims  2002;  Richards  2005)  (Tables  5.4  and  5.5). 
Fauna monitoring activities have been carried out at Red Cliff on Bernier Island (Figure 
5.4)  since  1987.  Red  Cliff  was  also  a  collection  site  for  translocation  of  WBBs  to 
captive breeding colonies at the Peron Captive Breeding Centre (PCBC), Kanyana and 
the Arid Recovery Project (Tables 5.7 - 5.10)(Sims 2002; Richards 2005). 
 
A current and precise estimate of the WBB population on each island is unavailable due 
to the low sample size obtained in a recent survey (L. Reinhold, pers. comm., 2007). In 
1997,  the  estimated  combined  WBB  population  on  both  islands  was  2200-4400, 
however  this  number  was  considered  subject  to  substantial  and  rainfall  dependent 
climatic fluctuations (Short et al. 1997). The major threats to the islands' fauna and 
habitat identified include the inadvertent or deliberate introduction of non-indigenous 
species (predators such  as cats, foxes and rats, and competitors such as rabbits and 
mice);  disease;  fire;  inappropriate  recreational  activity  or  development;  and 
inappropriate management practices (Hancock et al. 2000).  
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Figure 5.3 White Beach, Dorre Island. 
 
 
Figure 5.4 Red Cliff, Bernier Island.  
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5.1.2 Captive and reintroduced WBB populations 
Kanyana Wildlife Rehabilitation Centre 
The WBB captive breeding programme at Kanyana was established in 1994 with 27 
individuals  sourced  from  both  Bernier  and  Dorre  Islands  (Butcher  2007).  DEC 
conducted hybridisation trials with WBBs from each islands at Kanyana between 1994 
and 1997, successfully producing fertile offspring (Friend and Beecham 2004). In 1998, 
another  seven  WBBs  were  translocated  from  Dorre  Island  to  Kanyana.  Over  100 
individuals  were  bred  at  this  facility,  many  of  which  contributed  to  the  founder 
population of the Dryandra Field Breeding Facility (see below) (Friend and Beecham 
2004).  The  WBB  captive  breeding  programme  was  halted  in  2002  following  the 
emergence  of  the  papillomatosis  and  carcinomatosis  syndrome.  From  this  point 
forward,  Kanyana  played  and  still  continues  to  play  a  vital  role  in  the  quarantine, 
housing  and  supportive  treatment  of  animals  affected  by  the  papillomatosis  and 
carcinomatosis syndrome (Figure 5.5).  
 
Figure 5.5 WBB quarantine facility, Kanyana Wildlife Rehabilitation Centre.  
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The Peron Captive Breeding Centre 
The  DEC  initiated  WBB  breeding  programme  located  at  the  PCBC  on  the  Peron 
Peninsula, Shark Bay, was established in 1998 with 12 male and 18 female adult WBBs 
sourced from Red Cliff, Bernier Island (Table 5.8). The first captive birth was recorded 
in September of 1998  and more than 70 offspring  from 50 litters were born in the 
following three years (Noakes 2007). The mean longevity (lifespan) for WBBs held at 
the PCBC  was approximately 3 years for males and 3.5 years for females, the oldest 
animals of both sexes living to approximately 5 years of age (Noakes 2007). Physical 
examination and general health check of WBBs in the PCBC population occurred every 
two  to  four  months.  At  other  times,  feeding  patterns,  behaviour  and  general 
opportunistic sightings were used to monitor the condition of WBBs. 
 
By  mid-2001,  most  breeding  pairs  had  been  separated  due  to  the  emergence  of  the 
papillomatosis and carcinomatosis syndrome and the unsuitability of this species for 
release into François Peron National Park due to inefficient control of feral cats. The 
WBB colony was closed in February 2005 and the remaining animals translocated to 
Kanyana.  WBBs  from  the  PCBC  population  were  not  released  into  free  ranging 
populations.    
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Dryandra Field Breeding Centre 
 
Figure 5.6 Location of the Dryandra Field Breeding Centre (http://www.naturebase.net). 
 
The  Dryandra  Field  Breeding  Centre  is  located  in  the  Dryandra  Woodland, 
approximately 150 km south-east of Perth (Figure 5.6 and 5.7). In 1997, the “Return to 
Dryandra”  initiative  was  instigated  by  DEC  in  order  to  reintroduce  five  threatened 
marsupials now extinct in the south-west of Western Australia (Friend and Beecham 
2004). This area of Western Australia has been listed as one of the top 25 “biodiversity 
hotspots”  for  conservation  priorities  in  the  world,  an  area  that  should  be  allocated 
maximum conservation effort as it possesses unique and endemic species of flora and 
fauna and is a region in which habitat is threatened (Myers et al. 2000).   
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Two  10  hectare  predator-proof  breeding  enclosures  of  natural  vegetation  within  the 
woodland  were  constructed.  In  1998,  27  WBBs  were  released  into  the  northern 
enclosure,  comprising  individuals  from  White  Beach  on  Dorre  Island,  Red  Cliff  on 
Bernier  Island  and  captive  bred  individuals  from  Kanyana  (Table  5.18).  WBBs 
currently  breed  in  both  enclosures, 
which are maintained on a weekly basis 
and  monitored  intensively  every  three 
to four months. Dryandra WBBs have 
been observed to live to over 4.5 years 
of  age  and  females  breed  up  to  three 
times  per  year,  all  year  round, 
producing  1-3  young  per  litter  (N. 
Thomas, pers. comm., 2005). Evidence 
of predation from pythons, various owl 
species  and  wedge-tailed  eagles  has 
been observed within enclosures.   
 
  Figure 5.7 Wandoo Woodland, Dryandra.  
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The Heirisson Prong Biosphere Project 
 
Figure 5.8 Location of Heirisson Prong and Faure Island within the Shark Bay World Heritage 
Area (Richards 2003). 
 
The  Heirisson  Prong  Biosphere  Project,  established  in  1989,  is  an  initiative  to 
reconstruct  an  original  ecosystem  on  the  Heirisson  Prong  Peninsula  in  Shark  Bay 
(Figure  5.8)  (Richards  and  Short  2003).  Sheep  and  feral  goat  removal,  fox  and  cat 
baiting and predator proof fencing were carried out to assist in re-establishing, through 
re-introductions, long-term viable populations of original marsupial species. 
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Three male and nine female adult WBBs sourced from Dorre Island were introduced 
into a seventeen hectare predator refuge on Heirisson Prong in November of 1995, and 
an additional two females were sourced from Dorre Island in 1996 (Richards and Short 
2003). Five of 11 females translocated in 1995 and 1996 were carrying pouch young. In 
May 1997, ten individuals from the predator refuge were released to free range on the 
peninsula (12 km
2), and by mid-1999 the remaining refuge colony had been released to 
free range. Over 730 WBBs have been marked on Heirisson Prong since 1996. The 
population is typically young (mean longevity <1.5 years, maximum recorded age for 
males and females >4.5 years of age), and has undergone many fluctuations since its 
inception  (Short  2006).  In  May  2006,  the  WBB  population  was  estimated  at  485 
individuals (J. Short, pers. comm., 2006). 
 
Faure Island  
Faure Island is a predator free, 60 km
2 island located east of Denham within Shark Bay 
(Figure 5.8) (A.W.C. 2006b).  In 1999, the Australian Wildlife Conservancy (AWC) 
acquired the Faure Island pastoral lease and commenced destocking of sheep and goats 
present on the island (Richards 2005). The AWC is a “national, independent, non-profit 
organisation committed to saving Australia's native wildlife from the very real threat of 
extinction” via a national network of sanctuaries managed for conservation, scientific 
research and public education (A.W.C. 2006a). Low numbers of horses, goats and sheep 
remain  on  Faure  Island,  however  their  eradication  is  planned.  The  founder  WBB 
population was established in October of 2005 by the introduction of 11 male and nine 
female adults sourced from Heirisson Prong.  
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The Arid Recovery Project and the Adelaide and Monarto Zoos 
The  Arid  Recovery  Project  (ARP),  situated  near  Roxby  Downs  in  northern  South 
Australia,  is  a  joint  conservation  initiative  between  Western  Mining  Corporation 
Resources,  the  Department  of  Environment  and  Heritage/  National  Parks  South 
Australia and the University of Adelaide, and is a Natural Heritage Trust-funded project 
(A.R.P 2006). It aims to “restore a portion of South Australia’s arid land to a semblance 
of it’s pre-European state, to conduct research and improve conservation strategies for 
arid  lands,  whilst  increasing  public  awareness  of  arid  zone  environmental  issues” 
(Moseby 2002). The ARP project was initiated in 1997 with the construction of a 14 
km
2 rabbit and predator free enclosure, which was then increased to 60 km
2 in 2001. 
The founder WBB population was sourced from Bernier Island and individuals captive 
bred from Bernier Island stock (Figure 5.14). WBBs at the ARP currently inhabit the 14 
km
2 enclosure. At the beginning of 2007, the ARP WBB population was estimated to 
comprise between 40 and 80 individuals (K. Moseby, pers. comm., 2007). 
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5.2 Materials and methods 
5.2.1 Monitoring of wild, reintroduced and captive WBB populations 
2005-2007 
Wild populations  
WBB  populations  on  Bernier  and  Dorre  Islands  were  monitored  annually  with  the 
assistance of DEC, the Australian Customs Service (Corio Bay) and Spaniard Charters. 
WBBs  were  trapped  overnight  using  Elliot  and  Sheffield  cage  traps  baited  with  a 
mixture of oats, peanut butter and sardines at sites within the species’ preferred habitat 
[coastal sandplain heath and hummock grassland, dunal systems (heath and scrub) and 
travertine heath (Short et al. 1998)] (Figure 5.9). The sites that could be sampled and 
number of nights spent trapping on each island were determined by logistics, available 
time and finances. A limited number of beaches on each island were appropriate for safe 
boat landings and access was often dependent on weather conditions and tides. The 
sampling sites and trapping grids used on Dorre and Bernier Islands during the course 
of this study are detailed in Table 5.1 and Figures 5.10 and 5.11.   
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Figure 5.9 WBB preferred habitat on Bernier and Dorre Islands. 
Table 5.1 Sites and number of individuals examined on Bernier and Dorre Islands 2005 – 2007. 
Island  Year  Month  Location  Total WBB 
examined 
Examined 
previously 
When examined 
Bernier  2005  July  Hospital Bay  0  0  n/a 
2006   August  Red Cliff  11  0  n/a 
2007  April  Red Cliff  9  2  2006 (this study) 
  Hospital Bay  6  0  n/a 
Dorre   2005  July  White Beach  13  1   2000 and 2003 (DEC) 
2006  August  White Beach  11  1   2005 (this study) 
2007  April  White Beach  5  2  2005 and 2006, respectively (this study) 
  Disaster Cove  5  0  n/a 
      DEC = Western Australian Department of Environment and Conservation 
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A. Dorre Island, Shark Bay, WA. 
  
B. Disaster Cove, Dorre Island. 
 
 
C. White Beach, Dorre Island. 
 
 
 
Figure 5.10 Topographical images showing Dorre Island (A), Disaster Cove (B) and White 
Beach (C). Pink lines indicate trap locations. Images courtesy Google Earth v4.1.7076.4458, 
http://earth.google.com/ accessed September 2007.   
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.  
A. Bernier Island, Shark Bay, WA. 
 
 
B. Hospital Bay, Bernier Island. 
 
 
C. Red Cliff, Bernier Island. 
 
 
 
 
Figure 5.11 Topographical images of Bernier Island (A), Hospital Bay (B) and Red Cliff (C). 
Trap  lines  are  indicated  in  pink.  Images  courtesy  Google  Earth  v4.1.7076.4458, 
http://earth.google.com, accessed May 2007.   
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Captive and reintroduced populations  
Captive populations of WBBs in Western Australia are presently located at Kanyana 
and  Dryandra.  These  two  populations  were  monitored  by  the  author  and  Dr  Mark 
Bennett with the assistance of centre staff periodically during 2005, 2006 and 2007 
(Table 5.2). Affected animals detected at Dryandra were removed from breeding stock 
and transferred to Kanyana for further monitoring and quarantine.  
 
Reintroduced populations of WBBs exist on Heirisson Prong, Faure Island, and at the 
ARP.  Population health monitoring exercises at Heirisson Prong were carried out by 
the author and Dr Mark Bennett in conjunction with Dr Jeff Short during September of 
2005 and in May of 2006 (Table 5.2). The Faure Island and ARP populations were 
monitored periodically by each projects’ staff and were not actively monitored by the 
author during the course of this study. 
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Table 5.2 Monitoring exercises conducted with captive and reintroduced WBB populations by 
the author 2005 – 2007, inclusive. 
Location  Year  Month  WBB examined 
Heirisson Prong  2005  September  37 
2006  May  29 
Dryandra North  2005  August  5 
2006  March  6 
July  4 
November  7 
Dryandra South  2005  April  10 
August  5 
December  10 
2006  April  6 
August  1 
December  5 
Kanyana  2005  June  9 
October  5 
2006  February  6 
July  6 
September  2 
October  1 
November  5 
2007  June  5 
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5.2.2 Examination of WBB and sample collection  
WBBs  were  examined  under  mask  delivered  isoflurane  anaesthesia  in  the  field.  A 
general physical examination was carried out for each individual with particular focus 
on the skin and mucosal surfaces for the presence of abnormalities. Morphometric data 
(sagittal  head  length,  pes  length,  scrotal  width  and  length)  was  collected  for  each 
individual and a jugular blood sample taken from adult WBBs and collected into plain 
serum, EDTA anticoagulant and lithium heparin anticoagulant tubes for the purpose of 
haematology,  biochemistry  and  serum  storage.  The  volume  of  blood  collected  was 
maximally 10% of the individual’s circulating blood volume (~1.0-1.25 mLs, based on 
estimated  mammalian  circulating  blood  volume  of  50  mL/kg).  WBBs  examined  on 
Bernier and Dorre Islands were micro-chipped by DEC using Trovan microchips.   
 
 
Figure 5.12 Examination of a WBB under isoflurane anaesthesia. 
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During  physical  examination,  swabs  were  taken  from  epithelial  surfaces  of  both 
clinically  normal  WBBs  and  those  with  evidence  of  epithelial  abnormalities  using 
sterile 0.9% NaCl soaked cotton-tip swabs for the purpose of viral DNA detection, as 
per  as  per  Martens  et  al.  (2001)  and  Antonssen  et  al.  (2002)  (Martens  et  al.  2001; 
Antonsson and Hansson 2002). Swabs were rubbed gently against epithelial surfaces six 
to ten times and then placed into sterile saline within a 1.5 mL microcentrifuge tube. 
Sites swabbed consistently for all individuals examined included the skin of the lateral 
flank, lip commissure and feet and the conjunctival epithelia (sites at which epithelial 
lesions  are  most  commonly  observed).  In  addition,  any  abnormal  (e.g.  alopecic, 
thickened,  inflamed,  eroded  or  ulcerated)  mucosal  or  cutaneous  sites  were  also 
swabbed. Following collection in the field, samples were then stored at -20°C until 
processed in the laboratory and subjected to PCR as described in sections 4.2.2, 4.2.8 
and 4.2.9. 
   
Figure 5.13 Swabbing of WBB skin surfaces for viral DNA under isoflurane anaesthesia. 
 
Dry  swabs  were  also  collected  from  conjunctival,  oral  and  urogenital  mucous 
membranes for detection of Chlamydiales genotypes (P. Timms, Queensland University  
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of Technology) and ectoparasites taken for identification and PCR screening for tick-
borne diseases (Y. Abdad, Murdoch University; M. Bennett, Murdoch University). 
 
5.2.3  Preparation  and  disinfection  of  equipment  used  during  field 
monitoring activities 
Protocols were adopted to minimise the risk of iatrogenic transmission of infectious 
agents  between  individuals  in  a  population,  and  between  populations.  BPCV1 
demonstrates greatest genomic and morphologic similarity to the Papillomaviridae and 
Polyomaviridae. As such, protocols were developed based on viricidal methods known 
to be effective against these two families (i.e. non-enveloped DNA viruses).  
 
Field equipment was sterilized either by autoclaving (handling bags, field drapes and 
surgical  instruments)  or  disinfected  with  chemical  agents  prior  to  each  usage  and 
following sampling of WBBs in the field. Virkon® S (DuPont Animal Health Solutions, 
Suffolk,  United  Kingdom),  active  ingredient  potassium  peroxomonosulfate,  was  the 
disinfectant of choice during field monitoring exercises. Sodium hypochlorite bleaches 
(5.25% solution) or F10SC Veterinary Disinfectant (Health and Hygiene, Roodepoort, 
South Africa), active ingredients polihexanide and benzalkonium chloride, were used 
occasionally  in  this  study.    Anaesthetic  masks,  measuring  callipers  and  surfaces  on 
which WBBs were examined were disinfected with Virkon® S or F10SC between the 
anaesthesia and examination of each individual. The same compounds were also used to 
disinfect the hands of those restraining and examining animals between the examination 
of each animal.  
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5.2.4 Construction of cohort database and statistical analyses 
Records  pertaining  to  observational  studies,  husbandry  and  veterinary  procedures 
carried out prior to commencement of this study were sourced from DEC, Kanyana, Dr 
Jeff  Short  (Heirisson  Prong),  Katherine  Moseby  (ARP),  the  Adelaide  and  Monarto 
Zoological  Gardens,  VETPATH  Laboratory  Services  (VLS),  the  Western  Australian 
Department  of  Agriculture  and  Food  (DAFWA),  IDEXX  Diagnostic  Veterinary 
Pathology  and  the  Conservation  Medicine  and  Pathology  sections  at  the  Murdoch 
University School of Veterinary and Biomedical Sciences. Microsoft Access™ 2003 
and Excel® 2003 databases (Microsoft Corporation, Washington, USA) were utilised to 
collate and analyse records from 375 wild and captive WBBs known to exist between 
1994 and 2007, inclusive.  
 
The information obtained for each individual included (when available) identification 
(DEC ID, Kanyana ID, microchip, ear clip or tag); sex; disease status; location held, 
origin and translocation activities; physical examinations (when, where and by who); 
date  of  birth;  date  deceased;  results  of  pathological  investigations;  results  of  PCR 
testing for aetiological agents using methodologies detailed in sections 4.2.2, 4.2.9 and 
4.2.11; detection of epithelial lesions and time elapsed between lesion detection and 
death  (when  applicable);  longevity  (lifespan);  cause  of  death;  identity,  origin  and 
disease status of dam and sire; ancestry (Bernier Island or Dorre Island descendant or 
“hybrid bred”); siblings; first known contact with affected animals and breeding/ pairing 
history. Results from a study conducted by Bennett et al. (2008) in which formalin-fixed 
paraffin  embedded  sections  of  WBB  papillomas  and  carcinomas  were  screened  for 
BPCV1 DNA by in situ hybridisation (ISH) were also included (Bennett et al. 2008a). 
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Cross  sectional  observational  studies  were  conducted  for  wild  and  reintroduced 
populations  of  WBBs  between  2005  and  2007,  inclusive.  Prevalence  of  the 
papillomatosis and carcinomatosis syndrome in the population sample examined was 
calculated as: 
P =  Number of individuals affected by syndrome at point in time 
       Number of individuals in the population at risk at that point in time 
 
Incidence of disease in wild and reintroduced populations was not able to be calculated. 
Due to the opportunistic nature of sampling in wild populations, it was found that it was 
not possible to resample the same individuals at a particular location each time (most 
individuals were examined on one occasion only). Furthermore, it was not possible to 
determine the age of lesions and therefore distinguish between old and new cases of 
disease. 
 
A retrospective cohort study was conducted examining records from individuals bred 
and/ or held at Kanyana between 1994 and 2005, inclusive (n = 57), and at the PCBC 
between 1998 and 2005, inclusive (n = 70). Individuals who died at 6 months of age or 
younger (n = 10) were excluded from statistical analyses (the youngest recorded WBB 
affected by the papillomatosis and carcinomatosis syndrome was ~10 months of age).  
 
Statistical analyses examining the relationships between disease status and categorical 
variables  (infection  with  BPCV1,  genetic  origin,  sex,  captive  bred  vs.  wild  caught, 
disease status of sire and dam) were performed using Chi-Square and Fisher’s exact 
tests in SPSS 15.0 for Windows® (SPSS Inc., Chicago, Illinois). Odds ratios (ORs) 
were used for the analysis of data when significant differences between groups were 
observed (Table 5.3). OR 95% confidence intervals were calculated using Woolf’s method, e 
(ln(odds ratio) ± 1.96  (Variance of ln(OR) (Kahn and Sempos 1989). ORs (c.f. Relative Risk, RR) were  
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used  selected  as  a  measure  of  association  between  variables  and  disease  in  captive 
populations in order to address selection bias that may have developed secondarily to 
the predominant use of clinical records (disease prevalence may be artificially higher in 
the sample therefore RR not an appropriate measure of strength of association (Dohoo et 
al. 2003)). 
 
Table 5.3 Methodology used for calculation of odds ratios (OR), referent assigned when > 2 
levels of a factor.  
Exposure  Disease +ve  Disease –ve  % +ve  OR  95% CI 
+ve  A  B  A/A+B  (AxD)/(BxC) 
e
(ln(OR)+/ -1.96 √(1/A+1/D+1/C+1/B) 
-ve  C  D  C/C+D  (CxD)/(DxC) 
 
T-tests  were  used  to  examine  differences  between  continuous  data  sets  (longevity/ 
lifespan, age at which disease first detected) and this was also performed using SPSS 
15.0 for Windows® (SPSS Inc., Chicago, Illinois). Distribution of continuous data was 
inspected  for  normality  through  the  generation  of  histograms  and  calculation  of 
skewness and kurtosis values. Levene’s test was performed to examine for homogeneity 
of variance between groups (when applicable).  
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5.3 Results 
5.3.1 Association between BPCV1 and disease 
In order to investigate the strength of the association between BPCV1 infection and the 
papillomatosis and carcinomatosis syndrome, Fisher’s exact tests were performed using 
results presented in Chapter 4 pertaining to the screening of affected and unaffected 
individuals for BPCV1 DNA.   In total, 93 WBBs were tested for BPCV1 infection (26 
affected, 67 unaffected) by screening of DNA extracted from lesional and non-lesional 
epithelia only (n = 20), screening of DNA obtained from surface of lesional and non-
lesional epithelia only (n = 72), or by both methodologies (n = 1). 
 
BPCV1 was amplified from skin lesions of 18/19 (94.7%) affected WBBs for whom 
DNA was extracted from fresh lesional tissue, but not amplified from normal cutaneous 
and mucosal tissue DNA extracts from the two unaffected WBB (Table 5.4). Affected 
WBBs for which only formalin-fixed tissues were available were excluded from this 
analysis due to the likelihood of false negative results secondary to fixation of tissues. 
In WBBs screened by this methodology, the proportion of individuals affected by the 
papillomatosis and carcinomatosis syndrome was found to be significantly higher in 
BPCV1 infected individuals than in their unaffected counterparts (Fisher’s exact test, p 
= 0.014). 
 
Table 5.4 Individuals tested for BPCV1 DNA by screening of DNA extracted from lesional and 
non-lesional epithelia.  
  Disease +ve  Disease -ve  Total 
BPCV1 +ve  18 (94.7%)  0 (0.0%)  18 
BPCV1 -ve  1 (5.3%)  2 (100.0%)  3 
Total  19  2  21 
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BPCV1 was amplified from skin swabs taken from the lesions of 8/8 (100.0%) affected 
WBBs and not at all from swabs taken from the non-lesional cutaneous and epithelial of 
65 clinically normal WBBs (Table 5.5). In WBBs screened by this methodology, the 
proportion of individuals affected by the papillomatosis and carcinomatosis syndrome 
was  found  to  be  significantly  higher  in  BPCV1  infected  individuals  than  in  their 
unaffected counterparts (Fisher’s exact test, p < 0.000). 
 
Table 5.5 Individuals tested for BPCV1 DNA by screening of swabs taken from lesional and 
non-lesional epithelia. 
  Disease +ve  Disease -ve  Total 
BPCV1 +ve  8 (100.0%)  0 (0.0%)  8 
BPCV1 -ve  0 (0.0%)  65 (100.0%)  65 
Total  8  65  73 
 
As expected, combining results obtained using the two screening methodologies (Table 
5.6) confirmed that the proportion of individuals affected by the papillomatosis and 
carcinomatosis syndrome was significantly higher in BPCV1 infected individuals than 
in their unaffected counterparts (Fisher’s exact test, p < 0.000). 
 
Table  5.6  Total  number  of  affected  and  unaffected  individuals  tested  for  BPCV1  DNA 
irrespective of methodology. 
  Disease +ve  Disease -ve  Total 
BPCV1 +ve  25  0  25 
BPCV1 -ve  1  67  68 
Total  26  67  93 
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5.3.2 Frequency of the papillomatosis and carcinomatosis syndrome 
in wild WBB populations 
 
Dorre Island 
Monitoring of population health prior to January 2005 
The results of WBB population monitoring excercises on Dorre Island carried out prior 
to January 2005 are listed in Table 5.7. Epithelial abnormalities were not recorded in 
Dorre Island WBBs prior to the emergence of the papillomatosis and carcinomatosis 
syndrome  in  captive  populations.  The  first  exercise  on  Dorre  Island  to  specifically 
examine for this syndrome was conducted in August of 2001 by DEC. An adult WBB 
was detected at White Beach with a small skin lesion, however the lesion was thought 
not to be typical of the papillomatosis and carcinomatosis syndrome and no further 
testing was performed to characterise the nature of the lesion (Sims 2002). In March 
2003, DEC conducted a second population and disease monitoring expedition to Dorre 
Island.  No  evidence  of  the  papillomatosis  syndrome  was  observed  in  the  animals 
examined, however conjunctival discharge, corneal ulceration or corneal scarring was 
observed in three individuals. 
 
In 2003, Hill examined 33 archival wild caught Dorre Island WBB specimens from 
Australian museums in an attempt to ascertain if the papillomatosis and carcinomatosis 
syndrome was present in WBBs on Dorre Island prior to the detection of the index case 
in captivity (Hill 2003; Hill 2005). No specimens sourced from Dorre Island showed 
evidence of epithelial lesions. 
 
Over 340 Dorre Island WBB were examined between 1987 and 2004 inclusive (the 
number of WBBs examined during CSIRO activities is unknown). Forty WBBs (2001  
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and  2003  DEC  expeditions)  were  examined  specifically  for  epithelial  lesions. 
Conclusive evidence of the papillomatosis and carcinomatosis syndrome was not seen 
in the resident WBB population on Dorre Island prior to 2005. Of the Dorre Island 
WBBs  translocated  to  mainland  captive  breeding  programmes  (n  =  11),  four  were 
observed  to  develop  the  syndrome  whilst  in  captivity  at  Kanyana  and  BPCV1  was 
detected in lesions from two of these individuals (Table 5.5). Disease was first detected 
in these individuals 2 years 4 months, 4 years, 4 years 4 months or 6 years, respectively, 
after their arrival at Kanyana, during which time they participated in captive breeding 
“hybridisation trials” with Bernier Island WBBs.  
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Table 5.7 Monitoring of the Dorre Island WBB population prior to January 2005. Adapted from Richards J (2003) and Friend JA (pers. comm., 2007). 
Location  Date  Examiner  WBBs 
examined 
WBBs with 
skin disease 
Developed skin 
lesions in captivity 
Comments 
NR  1962  Ride and 
Tyndale-Biscoe 
Unknown  0  n/a  Population survey of Bernier and Dorre Islands (Ride and Tyndale-Biscoe 1962) 
NR  1986, June and August  DEC  7  0  n/a  Netting and hand capture, WBB research. 
NR  1987, March  DEC  20  0  n/a  Netting, hand capture and Elliot trapping, WBB research. 
NR  1987, August  DEC  10  0  n/a  Netting and hand capture, WBB research. 
NR  1988, August  DEC  6  0  n/a  Netting and hand capture, WBB research. 
NR  1988, October  CSIRO  Unknown  0  n/a  Threatened Shark Bay marsupial monitoring by trapping and spotlight transects (Short et 
al. 1997). 
NR  1990, June and July  CSIRO  Unknown  0  n/a  Threatened Shark Bay marsupial monitoring by trapping and spotlight transects (Short et 
al. 1997). 
NR  1991, March and 
September 
CSIRO  Unknown  0  n/a  Threatened Shark Bay marsupial monitoring by trapping and spotlight transects (Short et 
al. 1997). 
NR  1992, August  DEC  69  0  n/a  Netting, hand capture, cage and Elliot trapping. WBB research and monitoring, disease 
screening of threatened Shark Bay marsupials (Stephanie Haigh). 
NR  1994, June  DEC  28  0  n/a  Netting, hand capture, cage and Elliot trapping. WBB research and monitoring, disease 
screening of threatened Shark Bay marsupials (Stephanie Haigh). 
NR  1995, August  DEC  25  0  0  Netting, hand capture, cage and Elliot trapping. WBB research and monitoring, 2 WBBs 
(95DM08, 95DF06) translocated to Kanyana. 
White 
Beach 
1995, October and 
November 
CSIRO  12  0  0  12 WBBs (3 male, 9 female [5 with pouch young]) translocated to Heirisson Prong to form 
founder population (Richards and Short 2003). 
NR  1996, August  DEC  26  0  n/a  Netting, hand capture, cage and Elliot trapping. WBB research and monitoring. 
2 female WBBs translocated to Heirisson Prong (Richards and Short 2003). 
NR  1997, August  DEC  30  0  n/a  Netting, hand capture, cage and Elliot trapping. WBB research and monitoring. 
NR  1998, March and April  DEC  17  0  Kanyana = 4/7 
Dryandra = NR 
Netting, hand capture, cage and Elliot trapping. 14 WBBs translocated to mainland 
breeding colonies: Kanyana (7) and Dryandra (7). 
NR = Not recorded 
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Table 5.7 Cont’d. 
Location  Date  Examiner  WBB 
examined 
WBB with 
skin disease 
Developed skin 
lesions in captivity 
Comments 
NR  1999, September  DEC  30  0  n/a  Netting, hand capture, cage and Elliot trapping. WBB research and monitoring. 
NR  2000, September  DEC  19  0  n/a  Netting, hand capture, cage and Elliot trapping. WBB research and monitoring.  
White 
Beach 
2001, August  DEC  8  1  n/a  1 WBB with suspicious, but atypical, solitary skin lesion detected. No further testing conducted.  
1 WBB detected with corneal opacity and conjunctivitis.  
Castle 
Point 
2001, August  DEC  2  0  n/a  No clinical evidence of skin disease. 1 WBB detected with conjunctivitis only. 
White 
Beach 
2003, March  DEC  21  0  n/a  Netting and cage trapping. No clinical evidence of skin disease. 
1 WBB with mild conjunctival discharge. 
Disaster 
Cove 
2003, March  DEC  9  0  n/a  Netting and cage trapping. No clinical evidence of skin disease.  
1 WBB with corneal ulceration, 1 WBB with corneal scarring. 
NR = Not recorded  
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Table 5.8 Wild caught Dorre Island WBBs translocated to the Kanyana Wildlife Rehabilitation Centre. Individuals who subsequently developed the papillomatosis 
and carcinomatosis syndrome are indicated in red. 
Date of arrival to 
Kanyana 
WBB ID  Sex  Age 
caught 
Skin 
disease 
Date lesions 
noted 
Results of diagnostic investigations  Date died  Cause of death 
1992  92DKF01  F  Adult  NR  n/a  n/a  1996, January  Infection, unknown 
1995, August  95DM08  M  Adult  NR  n/a  n/a  1998, 
December 
Toxoplasmosis 
95DF06  F  Adult  NR  n/a  n/a  1998, 
December 
Toxoplasmosis 
1996, September  96BM19  M  Adult  NR  n/a  n/a  1999, July  Not specified 
1998, May  98DM42  M  Adult  NR  n/a  n/a  2000, May  Injuries sustained during fighting 
98DF43  F  Adult  NR  n/a  n/a  2000, June  Not specified 
98DM48  M  Adult  NR  n/a  n/a  1999, July  Not specified 
B02K03 
(98DM44) 
M  Adult  Yes  2000, September  Clinical evidence and histological confirmation of syndrome, 
BPCV1 detected in lesions by PCR 
2002, April  Euthanased due to severe skin 
lesions 
B04K01 
(98DM46) 
M  Adult  Yes  2004, April  Clinical evidence and histological confirmation of syndrome, 
BPCV1 detected in lesions by PCR & ISH 
2004, April  Natural death following  weight loss 
98DM47 
(1D2FA94) 
M  Adult  Yes  2002, October  Clinical evidence only  2003, May  Not specified 
B06K08 
(98DF45) 
F  Adult  Yes  2002, May  Clinical evidence and histological confirmation of syndrome, 
no further testing performed 
2004, August  Not specified 
NR = not recorded; PCR = polymerase chain reaction; ISH = in situ hybridisation.  
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Monitoring population health January 2005 to December 2007 
The results of WBB population monitoring on Dorre Island that was carried out by 
the author between January 2005 and December 2007 are presented in Table 5.9. 
Twenty  eight  WBBs  were  examined  on  one  occasion  and  three  WBBs  were 
examined twice during two annual disease monitoring expeditions to Dorre Island 
The oldest known WBB examined was at least five years of age. All individuals were 
found to be clinically free of the papillomatosis and carcinomatosis syndrome. Swabs 
collected  from  the  skin  and  mucosal  surfaces  of  20  WBBs  (2006  and  2007 
expeditions) were negative for BPCV1. No clinical evidence of the papillomatosis 
and  carcinomatosis  syndrome  or  BPCV1  was  found  in  the  Dorre  Island  WBB 
population during the course of this study. 
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Table 5.9 Monitoring of the Dorre Island WBB population 2005 – 2007. 
Location  Date  Examiner  WBB 
examined 
WBB with skin 
disease 
Comments 
White 
Beach 
2005, 
July 
Murdoch 
University 
and DEC 
13  0  Three nights trapping, 50 cage traps and 100 Elliot traps. 
WBBs examined: B05Do01-B05Do13 (6 adult males, 5 adult females & 2 juvenile females). 
B05Do03 examined previously by DEC in 2000 (est. age 5 yo). 
No clinical evidence of papillomatosis.  
Epithelial swabs not collected (prior to detection of BPCV1 and development of testing protocol). 
 
White 
Beach 
2006, 
August 
Murdoch 
University 
and DEC 
11  0  Four nights trapping, 50 cage traps and 100 Elliot traps. 
WBB examined: B05Do07 and B06Do01-B06Do10 (6 adult males, 3 adult females & 2 juvenile females). 
No clinical evidence of papillomatosis.  
Epithelial swabs from all individuals negative for BPCV1 DNA. 
White 
Beach 
2007, 
April 
Murdoch 
University 
and DEC 
5  0  Two nights trapping, 25 cage traps and 25 Elliot traps. 
WBB examined: B05Do05, B06Do03 and B07Do01-B07Do03 (3 adult males, 1 adult female and 1 juvenile female). 
No clinical evidence of papillomatosis, WBB in poor to average physical condition. 
Epithelial swabs from all individuals negative for BPCV1 DNA. 
Disaster 
Cove 
2007, 
April 
Murdoch 
University 
and DEC 
5  0  Three nights trapping, 25 cage traps and 25 Elliot traps.  
WBB examined: B07Do04-B07Do08 (2 adult males & 3 adult females). 
No clinical evidence of papillomatosis, WBB in poor to average physical condition. 
Epithelial swabs from all individuals negative for BPCV1 DNA. 
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Bernier Island 
Monitoring of population health prior to January 2005 
The  results  of  WBB  population  monitoring  on  Bernier  Island  carried  out  prior  to 
January 2005 are listed in Table 5.10. The papillomatosis and carcinomatosis syndrome 
had not been observed by researchers on this island prior to its emergence in captive 
breeding colonies. The first population health monitoring exercise on Bernier Island 
after this syndrome was identified in the captive population was conducted in August of 
2001 by DEC.  Five WBBs examined at Red Cliff demonstrated clinical evidence of 
epithelial lesions. Histological evaluation of skin biopsies collected from 2/5 individuals 
found  lesions  to  be  consistent  with  those  of  the  papillomatosis  and  carcinomatosis 
syndrome.  When  screened  in  2007,  ISH  demonstrated  BPCV1  DNA  in  archival 
histological  sections  from  these  two  individuals  (Bennett  et  al.  2008a).  During  this 
expedition, WBBs were also observed with conjunctivitis, both alone or in conjunction 
with skin lesions (Sims 2002; Warren et al. 2005). 
 
In  an  attempt  to  ascertain  if  the  papillomatosis  and  carcinomatosis  syndrome  was 
present in WBBs on Bernier Island prior to the detection of the first case in captivity, 
Hill  examined  26  archival  wild  caught  Bernier  Island  WBB  specimens  from  the 
Western Australian Museum (Hill 2003; Hill 2005). Three WBBs collected from Red 
Cliff in 1982 (n = 2) and 1988 (n = 1) were found to have macroscopic skin lesions 
consistent with the syndrome.  
 
In March and April of 1998, 30 WBBs were collected from Red Cliff and translocated 
to the PCBC (Table 5.11). WBBs were recorded as clinically normal at the time of 
collection, however, skin lesions were noted to appear in an adult male (B07K01) in 
September of the same year, five months following arrival at the PCBC. An additional  
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14 WBBs collected during this expedition subsequently displayed clinical evidence of 
papillomatosis syndrome whilst in captivity. Lesional biopsies from seven individuals 
examined  histologically  were  consistent  with  the  syndrome,  and  BPCV1  DNA  was 
detected in lesions from three of four individuals screened by PCR and/ or ISH. 
 
In September of 2000, 19 WBBs were collected from Bernier Island by DEC to form 
the founder population of the ARP’s breeding programme (Figure 5.14; Tables 5.12 and 
5.13). Two WBBs exhibited clinical evidence of papillomatosis at the time of collection 
(602F2D4 on arrival to the ARP and 6031E6D on arrival to Kanyana) and a further two 
WBBs were observed to develop clinical disease whilst held at Kanyana (602FC39) or 
Monarto  Zoo  (B02M01).  Lesions  from  602F2D4,  6031E6D  and  B02M01  were 
examined  histologically  and  found  to  be  consistent  with  the  papillomatosis  and 
carcinomatosis syndrome.  
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Table 5.10 Examination of the Bernier Island WBB population prior to 2005. Adapted from Richards J (2003) and Friend JA (pers. comm., 2007). Individuals 
detected with or which subsequently developed the papillomatosis and carcinomatosis syndrome are indicated in red. 
Location  Date  Examiner  WBB 
examined 
WBB with 
skin disease 
Prevalence of 
papillomatosis  
syndrome 
Developed skin 
lesions in 
captivity 
Comments 
NR  1962  Ride and 
Tyndale-Biscoe 
NR  n/a  n/a  n/a  Population survey of Bernier and Dorre Islands (Ride and Tyndale-Biscoe 
1962) 
NR  1987, March  DEC  5  0  0.0%  n/a  Netting, hand capture and Elliot trapping, WBB research. 
NR  1987, August  DEC  10  0  0.0%  n/a  Netting and hand capture only, WBB research. 
NR  1988, August  DEC  NR  n/a  n/a  n/a  WBB research. 
NR  1989, July/ 
August 
CSIRO  NR  n/a  n/a  n/a  Threatened Shark Bay marsupial monitoring by trapping and spotlight transects 
(Short et al. 1997). 
NR  1992, July/ 
August 
CSIRO  NR  n/a  n/a  n/a  Threatened Shark Bay marsupial monitoring by trapping and spotlight transects 
(Short et al. 1997). 
NR  1993, 
September 
DEC  13  0  0.0%  n/a  Netting and hand capture only. Shark Bay mouse research. 
NR  1994, 
November 
DEC?  NR  NR  n/a  NR  Not specified 
NR  1995, August  DEC  1 adult + 3 
pouch young 
0  0.0%  1  Netting, hand capture and Elliot trapping. WBB research. 1 female WBB 
(95Bf07) with 3 pouch young to translocated to Kanyana (95BKM9-11). 
NR  1996, 
September 
DEC  1  0  0.0%  0  Shark Bay Mouse monitoring (Peter Speldewinde). 1 male WBB (96BM19) 
translocated to Kanyana. 
Red Cliff  1998, March/ 
April 
DEC  30  0  0.0%  14  30 WBBs translocated to PCBC (Table 9), 12 males, 18 females. 2/30 sent to 
Dryandra 5 months later.  
Red Cliff   2000, 
September 
DEC  19  2  10.5%  2  Netting, hand capture, cage and Elliot trapping. 
19 WBBs trapped and translocated to the mainland.  
12 transported to ARP, remaining 7 WBB translocated to Kanyana (due to 
presence of conjunctivitis and skin lesions).  
2 WBBs diagnosed with papillomatosis on arrival to Kanyana (Table 5.9) or 
ARP (Table 5.10) 
2 WBBs subsequently developed papillomatosis at Kanyana or Monarto Zoo 
(Table 5.10). 
 
Red Cliff   2001, August  DEC  12  5  41.7%  n/a  5 WBBs detected with wart-like lesions. 
Histological confirmation of papillomatosis in B02P02a and B02P02b and 
lesions from both animals positive for BPCV1 DNA by ISH.  
Red Cliff disease prevalence 5/12 = 42%.  
3 WBBs detected with ruptured globes, 4 WBBs with corneal opacity, 2 WBBs 
with conjunctivitis. 
 
Hospital 
Bay 
2001, August  DEC  2  0  0.0%  n/a  No clinical evidence of papillomatosis or conjunctivitis. 
NR = not recorded; PCR = polymerase chain reaction; ISH = In situ hybridisation  
  155
Table 5.11 Wild caught Bernier Island (Red Cliff) WBBs translocated to the PCBC in March and April of 1998. Individuals who subsequently developed the 
papillomatosis and carcinomatosis syndrome are indicated in red. 
WBB ID  Sex  Age 
caught 
Skin 
disease 
Date lesions 
noted 
Results of diagnostic investigations  Date died  Cause of death 
B07K01  M  Adult  Yes  1998, September 
a  Clinical evidence and histological confirmation of syndrome (Murdoch),  
BPCV1 detected in lesions by PCR 
2002, March  NR 
1E039F9  F  Adult  Yes  2000, April  Clinical evidence only  2001, February  NR 
1DFC64A  M  Adult  Yes  2000, September 
a  Clinical evidence and histological confirmation of syndrome (DAFWA)  2003, April  Euthanased, exophthalmia 
126B7CE  M  Juvenile  Yes  2000, October  Clinical evidence only  2001, August  Natural death, severe wart lesions 
125F83F   F  Juvenile  Yes  2001, February  Clinical evidence and histological confirmation of syndrome (DAFWA)  2002, May  NR 
B03P02  M  Juvenile  Yes  2001, February  Clinical evidence and histological confirmation of syndrome (Murdoch)  2003, July  Found dead, thin, skin lesions 
B03P03  F  Juvenile  Yes  2001, June  Clinical evidence and histological confirmation of syndrome (Murdoch), 
BPCV1 detected in lesions by ISH 
2003, July  Euthanased (severe skin lesions) 
B03P04  F  Juvenile  Yes  2003, February  Clinical evidence and histological confirmation of syndrome (Murdoch), 
BPCV1 detected in lesions by PCR 
2003, July  Euthanased (severe skin lesions) 
B03P01  F  Juvenile  Yes  2003, July  Clinical evidence and histological confirmation of syndrome (Murdoch), 
BPCV1 detected in lesions by ISH 
2003 (1/10/03)  Euthanased (severe skin lesions) 
126B6D5  F  Adult  Yes  NR  Clinical evidence only  2002, February  NR 
1E02E9A  M  Adult  Yes  NR  Clinical evidence only  2002, November  NR 
125DABC  M  Adult  Yes  NR  Clinical evidence only  2001, February  NR 
1262CC0  F  Adult  Yes  NR  Clinical evidence only  2002, July  NR 
125EDA1  M  Adult  Yes  NR  Clinical evidence only  2000, June  NR 
126B491  F  Adult  NR  n/a  n/a  1998, May  NR 
125FB67  F  Adult  NR  n/a  n/a  2000, March  NR 
1DFCC8  F  Adult  NR  n/a  n/a  1998, May  NR 
a Translocated to Kanyana September 2000; NR = not recorded; PCR = polymerase chain reaction; ISH = in situ hybridisation  
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Table 5.11 Cont’d. 
WBB ID  Sex  Age 
caught 
Skin 
disease 
Date lesions 
noted 
Results of diagnostic investigations  Date died  Cause of death 
125BCF1  F  Adult  NR  n/a  n/a  NR  (Sent to Dryandra 
14/10/98) 
NR 
125F3A9  F  Adult  NR  n/a  n/a  2002, March  NR 
1E03296  F  Adult  NR  n/a  n/a  1999, June  NR 
1DFBD69  F  Adult  NR  n/a  n/a  2001, January  NR 
125B790  F  Adult  NR  n/a  n/a  2000, March  NR 
1E02970  F  Adult  NR  n/a  n/a  Unknown  NR 
125A396  F  Adult  NR  n/a  n/a  1998, May  NR 
126B41E  F  Adult  NR  n/a  n/a  NR (To Dryandra 14/10/98)  NR 
126A950  M  NR  NR  n/a  n/a  2000, October  NR 
125A402  M  Adult  NR  n/a  n/a  2000, June  NR 
125FDEC  M  Adult  NR  n/a  n/a  2001, July  NR 
1E05B47  M  Juvenile  NR  n/a  n/a  2002, May  Infection post eye ablation 
1BCD463  M  Adult  NR  n/a  n/a  2001, July  NR 
NR = not recorded; PCR = polymerase chain reaction; ISH = in situ hybridisation  
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Table 5.12 Wild caught Bernier Island WBBs translocated to Kanyana Wildlife Rehabilitation Centre. Individuals who subsequently developed the papillomatosis 
and carcinomatosis syndrome are indicated in red. 
Arrival  ID  Sex  Age caught  Skin 
disease 
Date lesions 
noted 
Results of diagnostic investigations  Date died  Cause of death 
1994, 
November 
94BKM04  M  Pouch young  Yes  2000, August  Clinical evidence only  2002, May  Natural/ old age 
94BM02  M  Adult  NR  n/a  n/a  1997, December  Respiratory problems 
94BF03  F  Adult  NR  n/a  n/a  1995, June  Not specified 
94BKM05  M  Pouch young  NR  n/a  n/a  1995, July  Not specified 
1995, August  95BF07  F  Adult  NR  n/a  n/a  1998, December  Toxoplasmosis 
95BKM10   M  Pouch young  NR  n/a  n/a  2000, March  Not specified 
95BKM09  M  Pouch young  NR  n/a  n/a  1998, December  Toxoplasmosis 
B06K02  F  Pouch young  Yes  2000, August  Clinical evidence and histological confirmation of 
syndrome (Murdoch), BPCV1 detected in lesions by PCR 
2001, August  Euthanased (severe skin lesions) 
1996, 
September 
96BM19  M  Adult  NR  n/a  n/a  1999, July  Unknown 
2000, 
September   
602F11A  F  Adult  NR  n/a  n/a  NR  Pneumonia 
  6031B6F 
a
  M  Adult  NR  n/a  n/a  NR  Not specified   
  6031E6D  M  Adult  Yes  2000, 
September 
Clinical evidence and histological confirmation of 
syndrome (DAFWA) 
2000, 
September 
Trauma 
  602FC39  M  Adult  Yes  2001, 
February 
Clinical evidence only  2002, March  Euthanased (severe skin lesions) 
  6030A87 
a
  F  Adult  NR  n/a  n/a  NR  Not specified 
  6077288 
a
  F  Adult  NR  n/a  n/a  NR  Not specified 
  B02M01
 a
  F  Adult  Yes  2002, July  Clinical evidence and histological confirmation of 
syndrome (Murdoch) 
2002, October  Euthanasia 
 a Translocated to Monarto Zoo in August of 2001. NR = not recorded; PCR = polymerase chain reaction; ISH = in situ hybridisation   
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Figure 5.14 Translocation history of WBBs collected from Red Cliff, Bernier Island, in September 2000. CB = captive bred; WC = wild caught.
 
7 WBBs translocated to 
Kanyana due to presence 
of conjunctivitis and/ or 
papillomatosis (6031E6D)  
2000, September: 
19 WBBs collected 
from Red Cliff, 
Bernier Island 
10 WBBs 
released at ARP 
2 WBBs died on arrival, 1 of these WBB (602F2D4) 
exhibited papillomatosis and conjunctivitis  
2001, February: 1 WBB (602FC39) 
developed papillomatosis 
2001, August: 4 WC WBBs sent to 
Monarto Zoo for captive breeding  
12 WBBs translocated to ARP 
2002, May: 3 WBBs (CB 
at Monarto Zoo) 
translocated to ARP  
2002, October: 1 WC WBB (B02M01) 
developed papillomatosis, leading to 
cessation of captive breeding activities. 
ARP founder 
WBB population 
2000, November: 10 WBBs 
re-trapped due to 
emergence of papillomatosis 
syndrome in WA and 
quarantined at Adelaide Zoo. 
2 died (causes unknown), 
2 young born in captivity.  
2001, May: 10 WBBs (2 CB, 8 original 
WC) released into ARP. Conjunctivitis 
observed in some WBB, 2 WBBs died 
during recapture and radio-collaring  
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Table 5.13 Wild caught Bernier Island WBB translocated to the ARP in September 2000. 
ID  Sex  Age  Skin  
disease 
Date 
lesions 
noted 
Results of diagnostic 
investigations 
Date died  Cause of death 
602F2D4  F  Adult  Yes  2000, 
September 
Clinical evidence and 
histological confirmation 
of syndrome (IDEXX) 
2000, 
September 
Died on arrival, 
stress 
NB: records from only 1/12 animals translocated to ARP in 2000 available for use in this study. 
 
More than 96 WBBs were examined on Bernier Island between 1987 and 2004 (the 
number of WBBs examined during CSIRO activities remains unknown), and 19 were 
examined  specifically  for  epithelial  lesions  (2001  DEC  expedition)  following  the 
identification  of  the  papillomatosis  and  carcinomatosis  syndrome  in  captive 
populations. The papillomatosis and carcinomatosis syndrome was only detected in the 
WBB population at Red Cliff. This occurred in 2000 and 2001, and the prevalence of 
disease in the trapped sample from the population was 10.5% and 41.7%, respectively.  
 
Five resident individuals at Red Cliff were detected with evidence of the syndrome in 
2001,  and  BPCV1  DNA  was  detected  in  lesional  tissue  taken  from  two  affected 
animals.  Of  Bernier  Island  WBBs  translocated  to  mainland  captive  breeding 
programmes  (n  =  58),  19  were  observed  to  develop  clinical  evidence  of  the 
papillomatosis syndrome whilst in captivity and two WBBs were noted to have skin 
lesions  at  the  time  of  collection  in  2000  (all  WBBs  collected  from  Red  Cliff). 
Histological evaluation of lesions from 11/21 individuals confirmed the papillomatosis 
and carcinomatosis syndrome in each animal. BPCV1 was detected in lesional tissue 
from three of four WBBs screened using molecular techniques.  
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Monitoring of population health January 2005 to December 2007 
The details of the WBB population monitoring activities carried out on Bernier Island 
2005 to 2007, inclusive, are listed in Table 5.14. Twenty four WBBs were examined by 
the  author  on  one  occasion  only,  and  two  WBBs  were  examined  in  consecutive 
monitoring expeditions to Bernier Island in 2006 and 2007. Two adult WBBs examined 
in 2006 at Red Cliff displayed clinical evidence of the papillomatosis syndrome (disease 
prevalence  in  trapped  sample  of  population  at  Red  Cliff  =  18.2%).  One  individual 
(B06B02) demonstrated mild papillomatous thickening of the right and left palpebrae, 
the right lip commissure and skin of the lateral aspects of the left radius and the right 
hind  metatarsus  (Figure  5.15).  A  second  individual  demonstrated  papillomatous 
thickening of the right palpebrae alone (B06B08). BPCV1 DNA was detected in swabs 
taken from the lesional surfaces of both individuals. These WBBs were not trapped 
again in 2007. Viral DNA was not amplified from swabs taken from the epithelia of 
clinically normal individuals. Unilateral mucopurulent conjunctivitis was seen in six 
adult WBBs (five trapped at Red Cliff, one trapped at Hospital Bay) examined in 2007.  
 
Figure  5.15  Adult  WBB  (B06B02)  detected  at  Red  Cliff  on  Bernier  Island  in  2006  with 
papillomatous skin lesions (visible on lateral aspect of the right hind). BPCV1 detected in swabs 
taken from lesional surfaces.  
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Table 5.14 Monitoring of the Bernier Island WBB population 2005 – 2007. 
Location  Date 
examined 
Examiner  WBB 
examined 
WBB with 
skin 
disease 
Prevalence of 
papillomatosis  
syndrome 
Comments 
Hospital 
Bay 
2005, July  Murdoch 
University/ 
DEC 
0  0  0.0%  Three nights, 50 cage traps and 100 Elliot traps. No WBBs trapped. 
 
 
Red Cliff  2006, 
August 
Murdoch 
University/ 
DEC 
11  2  18.2%  Three nights, 50 cage traps and 100 Elliot traps.  
WBB examined: B06B01-B06B11 (4 adult males, 4 adult females, 2 juvenile females & 1 adult male). 
B06B02 and B06B08 demonstrated skin lesions, swabs taken from lesional skin positive for BPCV1. 
 
Red Cliff  2007, 
April 
Murdoch 
University/ 
DEC 
9  0  0.0%  Three nights, 25 cage traps and 50 Elliot traps.  
WBB examined: B06B01, B06B07, B07B01- B07B07 (4 adult females, 3 adult males & 2 juvenile 
females) 
No clinical evidence of skin disease. Skin swabs from all individuals negative for BPCV1 DNA. 
Unilateral mucopurulent conjunctivitis observed in B06B07 and WBBs B07B01-B07B04.  
 
Hospital  
Bay 
2007, 
April 
Murdoch 
University/ 
DEC 
6  0  0.0%  Three nights, 25 cage traps and 50 Elliot traps.  
WBB examined: B07B08- B07B13 (4 adult males, 1 adult female & 1 juvenile female). 
No clinical evidence of skin disease. Skin swabs from all individuals negative for BPCV1 DNA. 
Unilateral mucopurulent conjunctivitis observed in B07B10 
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5.3.3 Frequency of the papillomatosis and carcinomatosis syndrome 
in captive and reintroduced populations 
 
Kanyana Wildlife Rehabilitation Centre 
The WBB population at Kanyana was founded by wild caught individuals from both 
Bernier and Dorre Islands (Tables 5.8 and 5.12; Figure 5.14). Adequate archival records 
were available for 62 WBBs bred or housed at Kanyana between 1994 and 2005 for use 
in  this  study.  The  emergence  of  the  papillomatosis  and  carcinomatosis  syndrome  at 
Kanyana between 1994 and 2005 is presented in Figure 5.16. The first clinical case was 
detected in a 3 year 6 month old breeding female (95BKF14) in April of 1999, and was 
confirmed through histological examination of multiple skin biopsies at DAFWA and 
VLS. This animal was the captive bred offspring of two wild caught Bernier Island 
WBBs translocated to Kanyana in 1994 and 1995, respectively. The dam (95BF07) died 
during an outbreak of toxoplasmosis at Kanyana in 1998 and did not develop clinical 
evidence  of  the  papillomatosis  syndrome.  The  sire  (94BKM04)  developed  the 
papillomatosis syndrome in August of 2000. 
 
If it is assumed that the BPCV1-associated papillomatosis syndrome was introduced to 
the Kanyana population by founder (wild caught) WBBs, it is unlikely that the captive 
bred 95BKF14 was the first animal in this population to be affected. WBBs known to 
have contact with 95BKF14 prior to April 1999 are detailed in Table 5.15 and Figure 
5.16.  Wild  caught  individuals  listed  here  were  not  observed  to  develop  the 
papillomatosis syndrome.  
 
Following the detection of first case, an additional 29 WBBs displayed clinical evidence 
of the papillomatosis and carcinomatosis syndrome whilst housed at Kanyana (Table  
  163
5.16).  Surgical  biopsies  and/  or  post  mortem  and  subsequent  histopathological 
evaluation confirmed the syndrome in 21/30 affected WBBs. BPCV1 was detected in 
skin lesions from all ten WBBs tested for the presence of viral DNA using PCR with 
BPCV1-specfic  and/  or  FAP59/64  primer  pairs,  or  ISH.  Thirty  two  WBBs  held  at 
Kanyana remained unaffected by clinical skin disease for the duration of their natural 
lives (5/ 32 WBBs died at less than six months of age and so were excluded from 
statistical analyses below). 
 
The mean longevity (when known) for WBBs bred or held at Kanyana was 3 years 8 
months of age (n = 41, range 1y – 8y6m, std. dev. 1.8), 4 years 5 months of age in 
WBBs  affected  by  the  papillomatosis  and  carcinomatosis  syndrome  (n  =  25,  range 
1y4m – 8y6m years, std. dev. 1.7) and 2 years 7 months of age in unaffected WBBs (n = 
16, range 1y – 4y10m years, std. dev. 1.2). The difference in mean longevities between 
unaffected and affected groups was significant (t(41) = -3.79, p = 0.001 ).  
 
The mean age at which skin lesions were detected in affected WBBs bred or held at 
Kanyana (known for 23 WBBs) was 3 years 1 month of age (range 1y – 6y6m years, 
std. dev. = 1.4). Detection of lesions in Kanyana-held WBBs translocated from Bernier 
Island (n = 3) occurred between 5 months and 6 years post-arrival, for Dorre Island 
WBBs (n = 4) between 2 years 4 months and 6 years post-arrival, in PCBC WBBs (n = 
5) between 1 year and 3 years 6 months post-arrival and at 3 years 4 months post-arrival 
in the single WBB translocated from Heirisson Prong in 1997.  Mean survival time 
following diagnosis of the papillomatosis and carcinomatosis syndrome was 1 year 2 
months (range 0y – 5y, std. dev. = 1.0).  
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As the Kanyana captive breeding colony contained WBBs from both islands as well as 
“hybrid-bred” individuals, it was possible to investigate if a genetic susceptibility to 
developing  the  papillomatosis  and  carcinomatosis  syndrome  existed  (based  on  the 
genetic stock from which the animal was bred, e.g. Bernier Island vs. Dorre Island vs. 
hybrid bred). Ancestry for 57 individuals held at Kanyana was available, 30 of which 
developed the syndrome whilst at Kanyana (individuals diagnosed at other locations are 
not included in this analysis) and 27 unaffected individuals.  
 
Univariant  analyses  revealed  that  no  significant  differences  in  susceptibility  to 
developing the papillomatosis and carcinomatosis syndrome existed based on genetic 
origin (Bernier vs. Dorre vs. hybrid) (n = 57, Chi-Square test, p = 0.709), whether the 
dam and/ or sire developed skin disease (n = 33, Chi-Square test, p = 0.955) or between 
the sexes (n = 57, Fisher’s exact test, p = 0.793). However, the papillomatosis syndrome 
was observed more frequently in individuals captive bred at Kanyana than in their wild 
caught counterparts (n = 57, Fisher’s exact test, p = 0.03; OR = 3.54, 95%CI 1.14-
11.00). 
 
Following the cessation of captive breeding activities, the role of Kanyana in the WBB 
conservation programme changed to that of quarantine facility for diseased WBBs.  An 
additional  16  WBBs  displaying  skin  lesions  consistent  with  the  papillomatosis 
syndrome were transferred to Kanyana from other populations following detection of 
skin disease (Table 5.17).  
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Figure 5.16 New cases of the papillomatosis syndrome diagnosed at Kanyana Wildlife Rehabilitation Centre between July 1994 and July 2004 (n = 27, disease onset 
unknown for 3 affected WBBs). Introductions of wild caught (Bernier Island, Dorre Island) and captive bred (Heirisson Prong) WBBs that contributed to the captive 
breeding population prior to the detection of the index case are indicated. NB: number of “new cases’ per month are presented rather than ‘incidence’ due to the 
unavailability of data pertaining to size of the susceptible population at each time point. 
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a Subsequently developed the papillomatosis and carcinomatosis syndrome 
b WBBs known to have contact with the first case recorded at Kanyana prior to April 1999 
c WBBs known to have contact with the second case recorded at Kanyana prior to December 1999 
94BM02 
94BF03 
94BKM04 
a, c 
94BKM05 
95DM08 
b 
95DF06 
c 
95BF07 
b 
95BKM09
 c 
95BKM10 
95BKM11
a 
 
97DLM30 
97DLM37 
a 
96BM19
 b 
98DM42 
98DF43 
98DM44
 a 
98DF45 
a 
98DM46 
a 
98DM47 
a 
98DM48  
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Table 5.15 Individuals who had contact with 95BKF14 prior to April 1999. 
Date of contact  Type of 
contact 
ID  Captive bred (CB) or 
wild caught (WC) 
Skin disease  Date lesions 
noted 
Date died  Cause of death 
1995, December  Dam  95BF07  WC adult female 
Bernier Island in 1995 
NR  n/a  1998, December  Toxoplasmosis 
1996, June  Mating  95DM08  WC juvenile male, 
Dorre Island in 1995 
NR  n/a  1998, December  Toxoplasmosis 
1996, September 
& November 
Mating  96HKM18  CB male Kanyana born 1996, 
Dorre dam and Bernier sire 
NR (released into Dryandra in 1998)  n/a  Not specified  NR 
1997, March  Mating  96HKM22  CB male Kanyana born 1996, 
Dorre dam and Bernier sire 
NR (released into Dryandra in 1998)  n/a  Not specified  NR 
1997, October  Mating  95DKM13  CB male Kanyana born 1996, 
Dorre dam and sire 
Yes  2000, December  2001, July  NR 
1998, April  Mating  97HBKM31  CB male Kanyana born 1997, 
hybrid dam and Bernier sire 
NR  n/a  1998, December  Died whilst radio collar being 
fitted 
1998, April  Mating  98HKM49  CB male Kanyana born 1998, 
Dorre dam and Bernier sire 
NR (released into Dryandra in 1998)  n/a  NR  NR 
1999, March  Mating  96BM19  WC adult male 
Bernier Island in 1996 
NR  n/a  1999, July  NR 
NR = not recorded 
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Table 5.16 WBBs which developed papillomatosis syndrome whilst at Kanyana (n = 30).  
CB or WC  WBB ID  t (yrs) at 
Kanyana 
pre-disease 
Age 
lesions 
detected 
Results of diagnostic 
investigations 
BPCV1 
WC Dorre Is. 
(n = 4) 
B02K3  2y4m  Adult  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR) 
B04K01  6y  Adult  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR, ISH) 
B06K08  4y  4y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested* 
98DM47  4y4m  Adult  Clinical evidence only  n/a 
WC Bernier 
Is. (n = 3) 
B06K02  5y  5y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR) 
94BKM04  6y6m  6y6m  Clinical evidence only  n/a 
602FC39  5m  Adult  Clinical evidence only  n/a 
CB Kanyana 
(n = 17) 
B07K03  n/a  3y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR) 
B06K03  n/a  2y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR) 
B05K09  n/a  2y6m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR, ISH) 
B02K04  n/a  5y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR) 
B02K05  n/a  1y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR) 
B06K07  n/a  5y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested 
B06K05  n/a  3y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested 
B06K09  n/a  2y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested 
B02K08  n/a  1y6m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested 
B00K01  n/a  3y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested 
B02K07  n/a  2y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested 
B02K06  n/a  3y6m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested 
95BKF14  n/a  3y6m  Clinical evidence and histological 
confirmation of syndrome (DAFWA) 
Not tested 
B07K04  n/a  1y6m  Clinical evidence only  n/a 
97DKF29  n/a  3y6m  Clinical evidence only  n/a 
96HKF20  n/a  Adult  Clinical evidence only  n/a 
99HDKF73  n/a  1y3m  Clinical evidence only  n/a 
CB PCBC 
(n = 5) 
B04K02  3y6m  4y6m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR, ISH) 
B02K02  1y  1y6m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR) 
B02K01  2y6m  2y6m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested 
99PF70  NR  Adult  Clinical evidence only  n/a 
1E59C8B  NR  Adult  Clinical evidence only  n/a 
CB Heirisson  97DLM37  3y  3y6m  Clinical evidence and histological 
confirmation of syndrome (DAFWA) 
Not tested 
CB = captive bred; WC = wild caught; NR = not recorded; PCR = polymerase chain reaction; ISH = in situ hybridisation  
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Table 5.17 WBBs held at Kanyana detected with the papillomatosis syndrome at other locations. 
Lesions 
detected 
WBB ID  Date of arrival at 
Kanyana 
Results of diagnostic investigations  BPCV1 
PCBC  B07K01 
(PCBC index case) 
2000, September  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR) 
00P80  2000, September  Clinical evidence only  n/a 
1DFC64A  2000, September  Clinical evidence and histological 
confirmation of syndrome (DAFWA) 
n/a 
B02P01  NR  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested 
WC Bernier Is.  6031E6D  2000, September  Clinical evidence and histological 
confirmation of syndrome (DAFWA) 
n/a 
Dryandra   B06K01  2000, September  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR) 
B05K10  2000, October  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR, ISH) 
97HBKF36  2000, September   Clinical evidence and histological 
confirmation of syndrome (DAFWA) 
Not tested 
98HBKM55  2000, September  Clinical evidence only  n/a 
B05K07  2004, July  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR, ISH) 
B05DrS10  2005, April  Clinical evidence but lesions regressed  Negative
 a 
B05DrN3  2005, July  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR, ISH) 
B05DrS11  2005, November  Clinical evidence  Positive (PCR)
 b 
B05DrS02  2005, December  Clinical evidence  Positive (PCR)
 b 
B05DrS09  2006, August  Clinical evidence  Positive (PCR)
 b 
B05DrN5  2006, November  Clinical evidence  Positive (PCR)
 b 
a = Skin swabbed for viral DNA after lesions had regressed. B = BPCV1 DNA detected by lesion swabs only. 
PCR = polymerase chain reaction; ISH = in situ hybridisation; NR = Not recorded  
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Peron Captive Breeding Centre (PCBC) 
The  PCBC  contained  an  additional  focus  of  WBBs  affected  by  the  papillomatosis  and 
carcinomatosis syndrome. Adequate archival records were available for 75 WBBs bred or 
housed at this facility. The monthly incidence of the papillomatosis and carcinomatosis 
syndrome at PCBC between 1998 and 2005 is presented in Figure 5.17.  
 
The first case at PCBC was detected in 1999, shortly following the detection of the index 
case  at  Kanyana.  However,  a  retrospective  search  of  clinical  records  revealed  early 
indication of skin lesions (‘moist dermatitis’) in this individual (B07K01) in September of 
1998. B07K01 (126277A, WB20), a wild caught adult male from Red Cliff used in captive 
breeding  activities,  was  paired  numerous  times  between  1998  and  2000  before  being 
translocated  to Kanyana  for quarantine. This  animal  died  in  March  of  2002,  following 
which the body was placed in storage (-20°C) until necropsy was performed in 2007. Skin 
lesions  were  grossly  and  histologically  consistent  with  the  papillomatosis  and 
carcinomatosis syndrome, and BPCV1 DNA was amplified from multiple lesions by PCR. 
One of three females known to have contact with B07K01 subsequently developed skin 
lesions 2 years 3 months following first known contact with this male (Table 5.18). The 
number of individuals exposed to this animal, directly or indirectly (e.g. via fomites), may 
be greater than that recorded here.   
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Figure 5.17 New cases of the papillomatosis syndrome at PCBC between 1998 and 2005 (n = 24; unknown for 19 individuals). NB: number of “new 
cases’ per month are presented rather than ‘incidence’ due to the unavailability of data pertaining to size of the susceptible population at each time point. 
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Table 5.18 Individuals known to have contact with the index case (B07P01) at PCBC between 1998 and 2000. 
ID  CB or 
WC 
Type of 
contact 
Date of contact  Skin 
lesions 
Date lesions noted  t onset post 
first contact 
with B07K01 
Date died  Cause of death 
125F3A9, WB15  WC  Mating  1998, September & 
1999, August 
NR  n/a  n/a  2002, March  Not recorded 
1E02970, WB07  WC  Mating  1998, December & 
1999, February 
NR  n/a  n/a  Not recorded   Not recorded 
1CDC750, WB66  CB  Mating  2000, June  Yes  2002, October  2y3m  2004, April  Euthanased, severe skin lesions 
CB = captive bred; WC = wild caught; NR = not recorded  
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Following the detection of the first case, an additional 42 WBBs developed clinical 
evidence of the papillomatosis and carcinomatosis syndrome whilst housed at PCBC 
(Tables 5.19 and 5.20). Thirty two WBBs held at PCBC remained unaffected by clinical 
skin disease for the duration of their natural lives (5/ 32 WBBs died at less than six 
months of age and so were excluded from statistical analyses below). Surgical biopsies 
and/  or  necropsy  and  subsequent  histopathological  investigation  confirmed  the 
syndrome in 20/43 affected WBBs and BPCV1 was detected in skin lesions from 12/16 
WBBs  screened  for  viral  DNA  using  PCR  with  BPCV1-specfic  and/  or  FAP59/64 
primer pairs, or ISH. Thirty two WBBs held at PCBC remained unaffected by skin 
disease for the duration of their natural lives.  
 
The mean longevity (lifespan) for all individuals was 3years 8 months of age (n = 48, 
range 1y – 6y6m, std. dev. = 1.6), for affected WBB 4 years 1 month of age (n = 32, 
range 1y – 6y, std. dev. = 1.4) and for unaffected WBB 2 years 11 months of age (n = 
16, range 1y – 6y6m, std. dev. = 1.7). There was a significant difference between the 
mean longevities for unaffected and affected groups (t(48) = -2.58 p = 0.013).  
 
The mean age at which skin lesions were detected (when available, n = 21) in affected 
WBBs bred or held at PCBC was 3 years 4 months of age (range 10m – 5y9m, std. dev. 
= 1.1). In wild WBBs translocated from Bernier Island to the PCBC that were clinically 
normal on arrival  yet subsequently  developed the syndrome, the mean time elapsed 
between arrival at the PCBC and lesion detection (known for 10/15 WBBs) was 2 years 
11 months (range 5m – 5y, std. dev. = 1.4). Mean survival time following diagnosis was 
1 year 6 months (range 0y – 3y, std. dev. = 1.0).  
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Univariant analyses revealed no significant difference in susceptibility to developing the 
papillomatosis and carcinomatosis syndrome existed based on sex (n = 70, Chi-Square 
test, p = 0.938), whether the dam and/ or sire developed skin disease (n = 40, Chi-
Square test, p = 0.15), or between individuals bred in captivity vs. those caught at Red 
Cliff and introduced into the breeding colony (n = 70, Chi-Square test, p = 0.394). 
 
Table  5.19  Wild  caught  WBBs  which  developed  the  papillomatosis  and  carcinomatosis 
syndrome whilst at the PCBC (n = 14). 
 
Lesions noted  WBB ID  Age 
lesions 
detected 
t at PCBC pre- 
disease 
Results of diagnostic investigations  BPCV1 
1998, September  B07K01, 
WB20 (A) 
Adult  5m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
 
Positive 
(PCR) 
2000, April  1E039F9,  
WB03 (A) 
Adult  2y  Clinical evidence only  n/a 
2000, September  1DFC64A,  
WB30 (J) 
2y6m  2y6m  Clinical evidence and histological 
confirmation of syndrome (DAFWA) 
 
n/a 
2000, October  126B7CE,  
WB28 (J) 
2y6m  2y6m  Clinical evidence only  n/a 
2001, February  B03P02,  
WB12 (J) 
3y  3y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
 
Negative 
(F) 
2001, February  125F83F,  
WB27 (J) 
3y  3y  Clinical evidence and histological 
confirmation of syndrome (DAFWA) 
 
n/a 
2001, June  B03P03,  
WB13 (J) 
3y6m  3y6m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
 
Positive 
(F, ISH) 
2003, February  B03P04,  
WB16 (J) 
5y  5y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
 
Positive 
(F, PCR) 
2003, July  B03P01,  
WB11 (J) 
5y  5y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
 
Positive 
(F, ISH) 
NR  125DABC,  
WB19 (A) 
Adult  NR  Clinical evidence only  n/a 
NR  1262CC0,  
WB23 (A) 
Adult  NR  Clinical evidence only  n/a 
NR  125EDA1, 
WB24 (A) 
Adult  NR  Clinical evidence only  n/a 
NR  1E02E9A,  
WB25 (A) 
Adult  NR  Clinical evidence only  n/a 
NR  126B6D5,  
WB29 (A) 
Adult  NR  Clinical evidence only  n/a 
PCR = polymerase chain reaction; ISH = in situ hybridisation; NR = not recorded; F = formalin-fixed tissues tested only; 
A = adult when caught; J = juvenile when caught.  
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Table  5.20  Captive  bred  WBBs  which  developed  the  papillomatosis  and  carcinomatosis 
syndrome whilst at the PCBC (n = 28). 
WBB ID  Lesions noted  Age 
lesions 
detected 
Results of diagnostic 
investigations 
BPCV1 
1EDA62A, WB71  2000, May  10m  Clinical evidence only  n/a 
00P80  2000, 
September 
NR  Clinical evidence only  n/a 
1BDCF3E, WB41  2001, May  2y6m  Clinical evidence only  n/a 
B04P03, WB49  2001, June  2y3m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (F, PCR, 
ISH) 
B03P06, WB39  2001, June  3y6m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (F, PCR) 
B03P07, WB40  2001, November  2y9m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Negative (F) 
B04P01, WB33  2001, November  3y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (ISH) 
B04P02, WB45  2002, May  3.25  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (F, PCR) 
B03P08, WB61  2002, May  3  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (F, PCR) 
B05K04, WB67  2002, October  3y3m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (PCR, ISH) 
B03P05, WB31  2002, October  4y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (F, PCR) 
B03P09, WB66  2002, October  2y3m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Negative (F) 
B03P10, WB77  2003, February  2y5m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (F,  ISH) 
B05K03, WB82  2003, November  4y  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Negative 
B04P04, WB50  2003, November  4y6m  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Positive (F, PCR) 
1CF5C5F, WB559  2004, June  5y  Clinical evidence only  n/a 
1C5B6AB, WB34  NR  NR  Clinical evidence only  n/a 
1CEE278, WB36  NR  NR  Clinical evidence only  n/a 
1F7C9C4, WB37  NR  NR  Clinical evidence only  n/a 
1CEE067, WB53  NR  NR  Clinical evidence only  n/a 
1CE5138, WB54  NR  NR  Clinical evidence only  n/a 
1CE340C, WB57  NR  NR  Clinical evidence only  n/a 
1CEED60, WB65  NR  NR  Clinical evidence only  n/a 
B02P01  NR  NR  Clinical evidence and histological 
confirmation of syndrome (Murdoch) 
Not tested 
1CF005F, WB72  NR  NR  Clinical evidence only  n/a 
5FD6FDF, WB73  NR  NR  Clinical evidence only  n/a 
5FD5D6D, WB75  NR  NR  Clinical evidence only  n/a 
5FD58F8, WB79  NR  NR  Clinical evidence only  n/a 
PCR = polymerase chain reaction; ISH = in situ hybridisation; NR = not recorded; F = formalin-fixed tissues tested only 
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Analyses of combined captive PCBC and Kanyana WBB populations 
Further analyses were performed using pooled records from both PCBC (n = 70) and 
Kanyana (n = 57) to investigate factors common to both populations. Of the 127 WBBs 
for which records were available, 73 WBBs (57.5%) developed the papillomatosis and 
carcinomatosis syndrome. The mean lifespan of WBBs affected by the papillomatosis 
syndrome,  when  known,  (n  =  57,  mean  =  4y3m,  std.  dev.  =  1.5)  was  found  to  be 
significantly higher in captive individuals than in unaffected WBBs (n = 32, mean = 
2y9m, std. dev. = 1.50; t(89) = -4.46, p < 0.000). The magnitude of difference between 
the unaffected and affected groups was found to be large (eta squared = 0.19). Causes of 
death in affected animals, known for 34 WBBs, were euthanasia due to severe skin 
disease (n = 25), presumed natural death/ old age (n = 5), haemorrhagic gastroenteritis 
(n = 2), fighting (n = 1) and following manual restraint (n = 1). Causes of death in 
unaffected animals, known for 11 WBBs, were presumed natural death/ old age (n = 3), 
fighting (n = 1), infection post eye ablation (n = 1), manual restraint during fitting of 
radio collar (n = 2) and toxoplasmosis (n = 4). The mean age at which skin lesions were 
detected (when available, n = 44) in affected WBBs bred or held at a captive breeding 
facility was 3 years 2 months (range 10m – 6y6m, std. dev. = 1.3). 
 
In  captive  individuals  affected  by  the  syndrome,  both  lifespan  and  age  at  disease 
detection were known for 44/73 individuals, and in unaffected animals, the lifespan was 
known for 32/ 54 individuals. These 76 animals were matched for age and the number 
of new cases recorded and the proportion of individuals affected were determined for 
each  age  group  (grouped  at  six  monthly  intervals)  (Tables  5.18  and  5.19).  The 
proportion of individuals affected was observed to increase as the animals aged (Table 
5.21  and  Figure  5.18).  The  highest  attack  rates  (new  cases)  were  seen  to  occur  in 
individuals greater than 2 years of age (Table 5.22 and Figure 5.19).  
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Table 5.21 Frequency of the papillomatosis syndrome in captive held WBBs grouped for age.  
Age range (yrs)  Total WBBs 
KTBA 
WBBs KTBA affected by 
papillomatosis (cumulative) 
% WBB affected within age range 
(prevalence) 
>0.5-1  76  2  2.6% 
>1-1.5  71  6  8.5% 
>1.5-2  66  8  12.1% 
>2-2.5  58  14  24.1% 
>2.5-3  55  21  38.2% 
>3-3.5  49  25  51.0% 
>3.5-4  41  23  56.1% 
>4-4.5  30  17  56.7% 
>4.5-5  26  20  76.9% 
>5-5.5  18  14  77.8% 
>5.5-6  11  9  81.8% 
>6-6.5  3  2  66.7% 
>6.5  1  1  100.0% 
KTBA = known to be alive. 
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Figure 5.18 Proportion of captive WBBs affected by the papillomatosis and carcinomatosis 
syndrome  as  grouped  by  age.  The  proportion  of  captive  held  individuals  affected  by  the 
syndrome was observed to increase with age. 
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Table 5.22 New cases of the papillomatosis syndrome detected in captive held WBBs grouped 
for  age.  Individuals  greater  than  2  years  of  age  were  at  greatest  risk  of  developing  the 
papillomatosis and carcinomatosis syndrome.  
Age range  Susceptible population  
(total KTBA – affected WBBs) 
New cases   Attack rate*  OR  95% CI 
>0.5-1  76  2  2.6%  Referent (1.0)  0.1 – 7.3 
>1-1.5  69  4  5.8%  2.3  0.4 – 12.8 
>1.5-2  61  3  4.9%  1.9  0.3 – 11.8 
>2-2.5  51  7  13.7%  5.9  1.2 -29.6 
>2.5-3  42  8  19.0%  8.7  1.8 – 43.2 
>3-3.5  32  8  25.0%  12.3  2.5 – 62.1 
>3.5-4  21  3  14.3%  6.2  0.9 – 39.7 
>4-4.5  15  2  13.3%  5.7  0.7 – 44.1 
>4.5-5  11  5  45.5%  30.8  4.9 – 193.9 
>5-5.5  4  0  n/a  n/a  n/a 
>5.5-6  3  1  33.3%  18.5  1.2 – 298.6 
>6-6.5  2  1  50.0%  37.0  1.7 – 827.4 
>6.5  0  0  n/a  n/a  n/a 
KTBA = known to be alive. 
* Attack rate = number of new cases of disease in animals within age range 
     population at risk in age range 
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Figure 5.19 Attack rate (new cases) of the papillomatosis and carcinomatosis syndrome in the 
captive population grouped for age. 
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Transmissibility of the papillomatosis and carcinomatosis syndrome from dam to pouch 
young was investigated by comparing the frequency of the syndrome in WBBs whose 
dam  developed  papillomatosis  and  those  whose  dam  did  not.  Univarient  analysis 
revealed  no  significant  difference  between  the  two  groups  (Fisher’s  exact  test,  p  = 
0.422). No breeding females were recorded as exhibiting clinical disease whilst carrying 
pouch  young.  In  individuals  whose  dam  developed  the  syndrome,  no  significant 
difference  in  disease  risk  was  observed  between  individuals  whose  dam  developed 
warts less than 2 years after the individual was born vs. those whose dam developed 
warts two years or more after the individual was born (Fisher’s exact test, p = 0.72).  
 
The youngest recorded animal in a captive breeding colony to develop clinical evidence 
of the syndrome, 1EDA62A (WB71), began to show lesions at 10 months of age. She 
died at 3.5 years of age of unknown causes and records indicated that no pathological 
investigations  were  conducted.  The  only  animal  recorded  as  having  contact  with 
1EDA62A prior to lesion onset was her dam, B03P01, a wild caught adult female which 
develop the papillomatosis syndrome in July of 2003, 3 years following detection of 
disease in 1EDA62A. B03P01 was euthanased in October of the same year, skin lesions 
were histologically consistent with the syndrome and BPCV1 DNA was amplified from 
lesional tissue. 1EDA62A may have been exposed to BPCV1 by her dam, who was not 
expressing noticeable lesions at the time of birth. If this is true then the time period 
following infection with BPCV1 and prior to the onset of clinical disease (incubation 
period) may be 10 months or less. Alternatively, she may have been exposed to BPCV1 
via  another  individual  not  listed  in  archival  records.  Unfortunately  no  pathological 
studies were performed when 1EDA62A died, therefore lesions could not be examined 
for  the  presence  of  BPCV1  DNA,  to  confirm  or  refute  the  presence  of  the 
papillomatosis and carcinomatosis syndrome.   
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Dryandra Field Breeding Facility 
Monitoring of population health prior to January 2005 
The  Dryandra  WBB  population  was  founded  in  1998  with  27  WBBs  sourced  from 
Dorre  Island  (White  Beach),  Bernier  Island  (Red  Cliff)  and  Kanyana  Wildlife 
Rehabilitation Centre (Table 5.23).  The papillomatosis and carcinomatosis syndrome 
was  first  detected  in  2000  in  two  adults  sourced  from  Kanyana,  B06K01  and 
97HBKF36.  Disease  was  suspected  in  a  third  individual  98HBKM55,  also  from 
Kanyana.  Affected  WBBs  were  subsequently  removed  from  the  enclosures  and 
translocated back to Kanyana. Disease was not detected again until 2004, in B05K07, 
which  was  also  translocated  to  Kanyana.  Pathological  investigations  confirmed  the 
papillomatosis and carcinomatosis syndrome in B05K07, B06K01 and 97HBKF36, and 
BPCV1 DNA was detected in lesions from both B05K07 and B06K01 
 
Figure 5.20 Animal processing area, Dryandra Field Breeding Centre, North enclosure. 
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Table 5.23 Founding members of the Dryandra WBB population. Individuals who subsequently developed the papillomatosis and carcinomatosis syndrome are 
indicated in red. 
 
Origin  WBB ID  Lesions noted  Age lesions 
detected 
t at Dryandra prior to 
disease detection 
Results of diagnostic investigations  BPCV1 
Dorre Island 
White Beach 
1214C12  NR  n/a  n/a  n/a  n/a 
1D2333E  NR  n/a  n/a  n/a  n/a 
12A3CAA  NR  n/a  n/a  n/a  n/a 
1D320D9  NR  n/a  n/a  n/a  n/a 
1D330A4  NR  n/a  n/a  n/a  n/a 
1D2A015  NR  n/a  n/a  n/a  n/a 
12A40E5  NR  n/a  n/a  n/a  n/a 
Bernier Is. 
Red Cliff 
126B41E  NR  n/a  n/a  n/a  n/a 
125BCF1  NR  n/a  n/a  n/a  n/a 
Kanyana  96HKM22  NR  n/a  n/a  n/a  n/a 
97HBKF38  NR  n/a  n/a  n/a  n/a 
97HBKF39  NR  n/a  n/a  n/a  n/a 
97HDKM34  NR  n/a  n/a  n/a  n/a 
97HBKM27  NR  n/a  n/a  n/a  n/a 
98HBKF51  NR  n/a  n/a  n/a  n/a 
98HBKM53  NR  n/a  n/a  n/a  n/a 
97HBKF40  NR  n/a  n/a  n/a  n/a 
97HBKM28  NR  n/a  n/a  n/a  n/a 
98HBKF58  NR  n/a  n/a  n/a  n/a 
96HKM18  NR  n/a  n/a  n/a  n/a 
95DKM12  NR  n/a  n/a  n/a  n/a 
97HBKM26  NR  n/a  n/a  n/a  n/a 
96HKF17  NR  n/a  n/a  n/a  n/a 
97HBKF36   2000, September  3y3m  2y6m  Clinical evidence and histological confirmation of syndrome (DAFWA)  Not tested 
98HBKM55   2000, September  2y  1y9m  Clinical evidence only  n/a 
B06K01   2000, September  3y6m  2y6m  Clinical evidence and histological confirmation of syndrome (Murdoch)  Positive (PCR) 
NR = not recorded 
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Monitoring of population health prior to January 2005 to December 2007 
WBB  at  Dryandra  were  monitored  periodically  for  disease  by  the  author  with  the 
assistance of DEC in 2005 and 2006 (Table 5.24). During this period, six individuals 
from the south enclosure and two individuals from the north enclosure were detected 
with  clinical  evidence  of  the  papillomatosis  and  carcinomatosis  syndrome  and 
subsequently  translocated  to  Kanyana  for  quarantine.  The  prevalence  of  the 
papillomatosis and carcinomatosis syndrome in the North and South ranged between 0 - 
25% and 0 – 20%, respectively. Results of pathological investigations carried out with 
these individuals are presented in Table 5.24. 
 
Table 5.24 Examination of WBBs at Dryandra in 2005 and 2006. 
Location  Date 
examined 
WBBs 
examined 
New WBBs 
detected with 
disease 
Disease 
prevalence 
Comments 
North 
Enclosure 
2005 
August 
5  1  20.0%  B05DrN03 detected with skin lesions and 
translocated to Kanyana 
2006 March  6  0  0.0%  No clinical abnormalities detected 
2006 July  4  1  25.0%  Commenced skin swab testing. 
B05DrN05 detected with skin lesions, 
lesional swabs BPCV1 positive 
2006 
November 
6  0  0.0%  B05DrN05 caught at this trapping session 
and translocated to Kanyana. 
South 
Enclosure 
2005 April  10  2  20.0%  B05DrS05 euthanased due to severe skin 
lesions. Skin lesions noted on B05DrS10 by 
DEC staff post trapping, translocated to 
Kanyana 
2005 
August 
5  1  20.0%  Skin lesions detected on B05DrS11 by DEC 
staff post trapping, translocated to 
Kanyana. 
2005 
December 
10  1  10.0%  Skin lesions detected on B05DrS02, 
translocated to Kanyana. 
2006 April  6  0  0.0%  No clinical abnormalities detected. 
2006 
August 
0  1  n/a  Skin lesions detected on B05DrS09 by DEC 
staff post trapping, translocated to 
Kanyana. 
2006 
December 
5  1  20.0%  Skin lesions detected on B06DrS02, 
lesional swabs BPCV1 positive, remains in 
enclosure. 
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Table  5.25  WBBs  affected  by  the  papillomatosis  and  carcinomatosis  syndrome  detected  at 
Dryandra (n = 8). 
WBB ID  Lesions noted  Age lesions 
detected 
Pathological Investigations  BPCV1 
B05DrS05 
(Vincent) 
2005, April  5y  Gross and histopathology (Murdoch)  Positive (Lesion PCR, 
ISH) 
B05DrS10  2005, April  ~1y6m  Clinical evidence but lesions 
regressed 
Swab of normal skin 
negative by PCR 
B05DrN03  2005, August  >3y  Gross and histopathology (Murdoch)  Positive (Lesion PCR, 
ISH) 
B05DrS11  2005, August  ~1y6m  Clinical evidence only  Positive (PCR skin swab) 
B05DrS02  2005, December  >3y  Clinical evidence only  Positive (PCR skin swab) 
B05DrN05  2006, July  2y  Clinical evidence only  Positive (PCR skin swab) 
B05DrS09  2006, August  >3y  Clinical evidence only  Positive (PCR skin swab) 
B06DrS02  2006, December  1y  Clinical evidence only  Positive (PCR skin swab) 
PCR = polymerase chain reaction; ISH = in situ hybridisation 
 
 
The course of lesion progression was recorded for six affected individuals sourced from 
Dryandra and held at Kanyana during the course of this study (Table 5.25). Surgical 
biopsies of lesions and necropsy were performed for one individual (B05DrN3). The 
remaining five WBBs presented below resided at Kanyana at the time of writing and 
have  not  been  subjected  to  serial  lesional  biopsies.  Schematic  diagrams  of  lesion 
distribution and size are presented below and results of pathological investigation and 
virological testing are detailed. 
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Table 5.26 Clinical charts for affected Dryandra WBBs quarantined at Kanyana. 
A. B05DrN3 
  Comments    Lesion map 
19/07/2005, Dryandra. 
 
Multifocal wart-like lesions of varying sizes 
first noted.  
 
Translocated to Kanyana for further 
monitoring. 
 
   
17/10/2005, Kanyana. 
Increase in size and number of wart-like 
lesions. 
 
27/02/2006, Kanyana.  
 
More lesions noted and pre-existing lesions 
observed to have increased in size. 
Cutaneous lesions from head and muco-
cutaneous lesion from pouch biopsied: 
 
Head lesion: Carcinoma in situ (CIS) 
 
Pouch lesions: Squamous cell carcinoma 
(SCC) 
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03/07/2006, Kanyana.  
 
Wart-like lesions more numerous. Pouch 
mass very large and appears infected. 
Pedunculated lesion at medial canthus of 
right eye biopsied. 
Right eyelid lesion: CIS  
 
Swabs taken from the surface of lesions 
positive for BPCV1 DNA by PCR 
 
14/9/2006, Kanyana 
 
Lesions increased in severity and many 
appear infected. Translocated to Murdoch 
University and euthanased on welfare 
grounds on the 20/09/2007 
 
Final Diagnosis:                       
Skin and subcutis 
1.  Left eyelid: Mild epithelial 
hyperplasia 
2.  Right eyelid: moderate to marked 
irregular epidermal and conjunctival 
hyperplasia/ CIS 
3.  Chin: SCC  
4.  Right shoulder: SCC 
5.  Right hind paw: CIS 
6.  Head mass: SCC 
7.  Left shoulder: SCC 
8.  Pouch: SCC 
 
DNA extracted from fresh lesional tissue 
positive for BPCV1 by PCR. 
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B. B05DrN5 
Comments  Lesion map 
14/03/2006, Dryandra 
 
Small scabs noted adherent to the skin of 
the dorso-medial aspect of the lateral 
digit on the right hind and lateral aspect 
of right carpus. Sites of previous trauma? 
 
12/7/2006, Dryandra 
 
Two ~5mm diameter areas of skin on the 
dorso-lateral aspect of right carpus and 
dorso-lateral right metatarsus noted to be 
alopecic and slightly thickened.  
 
Swab taken from the surface of right 
dorsal carpus positive for BPCV1 DNA 
by PCR 
 
15/11/2006, Dryandra 
 
Alopecic area with mild papillated 
thickening right metatarsus and right 
carpus increased in size and thickness. 
 
New alopecic region on papillated 
epidermal thickening has appeared on the 
right ventro-lateral thorax. 
  
Translocated to Kanyana. 
 
Swabs taken from the surface of lesions 
on the right carpus, right metatarsus and 
thorax positive for BPCV1 DNA by PCR 
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21/6/2007, Kanyana. 
 
Lesions on right carpus, right metatarsus 
and right ventral thorax largely 
unchanged. 
 
A new lesion has appeared on the dorso-
medial aspect of the medial digit of the 
left hind. 
  
Swabs taken from the right carpus, right 
metatarsus, right thorax and medial digit 
of the left hind positive for BPCV1 DNA 
by PCR 
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C. B05DrS2 
Comments  Lesion map 
12/04/2005, Dryandra   No visible lesions 
 
06/12/2005, Dryandra 
 
Mild thickening of the left eyelids noted. 
 
Translocated to Kanyana. 
 
27/02/2006, Kanyana 
 
Thickening of the left eyelids unchanged. 
 
Alopecic spot noted on right hind toe. 
 
03/07/2006, Kanyana 
 
Thickening of the left eyelids unchanged. 
 
Swab taken from left eyelid lesion positive 
to BPCV1 DNA by PCR. 
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29/11/2006, Kanyana 
 
Mild increase in thickening of the left 
eyelids and a small wart lesion now evident 
at the medial canthus.  
 
Swab taken from left eyelid lesion positive 
for BPCV1 DNA by PCR. 
 
21/6/2007 
 
Further increase in thickening of the left 
eyelids and wart lesion at medial canthus.  
 
Swab taken from left eyelid lesion positive 
for BPCV1 DNA by PCR. 
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D. B05DrS9 
Comments  Lesion map 
06/12/2005, Dryandra.  No visible lesions 
 
04/04/2006, Dryandra. 
 
Bald patch dorsal right hind.  
 
Detected by DEC staff and translocated to 
Kanyana on the 16/08/2006. 
 
29/11/2006, Kanyana 
 
Patchy alopecia and thickening of the skin 
over the right dorsal metatarsus extending up 
to the hock.  
Alopecia, erythema and skin thickening over 
the dorsal left metacarpus extending in 
between digits.  
 
Swabs taken from lesional surfaces of left 
metacarpus and right metatarsus positive for 
BPCV1 DNA by PCR. 
 
21/06/2007 
 
Lesions over left metacarpus and right 
metatarsus increased in size.  
Additional areas of alopecia and papillated 
thickening of skin now also noted over the 
right stifle, the medial digit of the right fore, 
the medial aspect of the left elbow and the 
lateral aspect of the left metatarsus. 
 
Swabs taken from lesional surfaces of left 
carpus, right hind digits, right stifle and right 
carpus positive for BPCV1 DNA by PCR. 
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E. B05DrS10 
Comments  Lesion map 
20/4/2005, Dryandra 
 
Translocated to Kanyana 
 
Regions of alopecia and papillated thickening 
of the skin over the dorsal left metacarpus and 
dorso-lateral left metatarsus.  
 
 
 
7/06/2005, Kanyana 
 
Lesions over the left metacarpus and metatarsus 
unchanged.  
 
17/10/2005, Kanyana 
 
Lesions no longer apparent. 
Lesion regression? 
 
22/02/2006, Kanyana 
 
No visible lesions 
03/07/2006, Kanyana 
 
Skin swabs negative for BPCV1 DNA by PCR. 
 
No visible lesions 
29/11/2006, Kanyana 
 
Skin swabs negative for BPCV1 DNA by PCR. 
 
No visible lesions 
21/06/2007, Kanyana 
 
Skin swabs negative for BPCV1 DNA by PCR. 
No visible lesions 
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F. B05DrS11 
Comments  Lesion map 
17/10/2005, Kanyana. 
 
At the base of left ear an area 2x3 mm of skin 
demonstrated papillomatous thickening with 
an alopecic margin. 
27/02/2006, Kanyana. 
 
Wart surgically removed and tissue processed 
for molecular techniques. 
 
03/07/2006, Kanyana. 
 
Focal irregular thickening of the skin 5 mm in 
diameter noted at the site of previous 
venipuncture (27/02/2006)   
 
Swab taken from the lesional surface in the 
jugular region positive for BPCV1 DNA by 
PCR. 
 
  
  191
29/11/2006, Kanyana. 
 
No skin lesions observed, small lesion in 
jugular region seen on the 03/07/2006 no 
longer present. 
 
 
 
 
 
 
 
 
 
 
Photograph of jugular region showing site of 
previous skin thickening (present on 
3/7/2006) which is no longer present. 
 
 
 
 
21/6/2007 
 
Skin thickening over jugular region has 
returned.  
 
Small areas (5 x 5 mm) of alopecia and 
papillomatous thickening now noted also over 
the right medial metacarpus, the left medial 
metacarpus and the right dorsal metatarsus. 
 
Swabs taken from the lesional surfaces of the 
right eyelids and left metacarpus positive for 
BPCV1 DNA by PCR. 
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BPCV1 DNA was readily detectable on the lesional surfaces of 5/6 WBBs monitored in 
this  study.  B05DrS10  was  not  screened  for  BPCV1  DNA  at  the  time  of  lesion 
expression  as  testing  was  unavailable;  however,  no  viral  DNA  was  amplified  from 
clinically normal epithelia in subsequent testing (following disappearance of lesions).  
 
In four WBBs (B05DrN3, B05DrS9, B05DrN5 and B05DrS11), epithelial lesions were 
noted to have a multicentric distribution, and both the number of lesions and size of area 
affected were observed to increase with time. Secondary lesions were noted to appear 7-
8 months following the appearance of the primary lesion/s in B05DrS9, B05DrN5 and 
B05DrS11. A single  conjunctival lesion was observed in B05DrS9, which appeared 
clinically to increase in size with time. No additional lesions were observed to develop 
in this WBB during the 18 month monitoring period. 
 
 In two individuals (B05DrN5 and B05DrS11), BPCV1 positive lesions were seen to 
develop at sites at which epidermal trauma was known to occur (on digits with history 
of previous abrasion and at the site of jugular venipuncture). Grossly apparent lesions 
were observed to regress in two WBBs (B05DrS10 and B05DrS11). Swabs taken from 
the surface of the jugular papilloma of B05DrS11 tested positive for BPCV1 DNA, 
however  viral  DNA  was  not  amplifiable  from  the  same  region  of  skin  following 
disappearance  of  the  lesion.  Testing  was  unavailable  at  the  time  B05DrS10  was 
expressing skin lesions, and no pre- or post-lesional biopsies were taken in order to 
characterise the lesions histologically.   
  
  193
Heirisson Prong 
Monitoring of population health prior to January 2005 
The Heirisson Prong WBB population was monitored four times per year between 1995 
and 2002, and subsequent to this twice annually by the project’s manager and chief 
research  scientist,  Dr  Jeff  Short.  No  signs  of  the  papillomatosis  and  carcinomatosis 
syndrome were detected during this time. This population provided WBBs for breeding 
populations at the ARP, Dryandra and Kanyana. One WBB subsequently developed the 
papillomatosis and carcinomatosis syndrome whilst at Kanyana, three years following 
introduction into the colony (Table 5.13).    
 
Monitoring of population health January 2005 to December 2007 
Monitoring exercises with the Heirisson Prong WBB population carried out in 2005 and 
2006  are  presented  in  Table  5.22.  All  WBBs  examined  during  the  course  of  these 
investigations were found to be normal on physical examination and clinically free of 
the papillomatosis and carcinomatosis syndrome. In 2005, 20 of the 37 WBBs examined 
were translocated by light aircraft to Faure Island to form the founding members of a 
new breeding colony. Swabs taken from the skin surfaces (non-lesional) of 11 WBBs on 
Heirisson Prong in 2006 tested negatively for BPCV1.  
 
Table 5.27 Monitoring of the Heirisson Prong WBB population 2005 – 2007. 
Date examined  WBB 
examined 
Comments 
2005, September  37  Two nights of cage trapping, no clinical abnormalities detected. 
20 adult WBBs translocated to Faure Island. 
2006, May  29  One night of cage trapping, no clinical abnormalities detected.  
Swabs taken from non-lesional epithelia of 11 WBBs, BPCV1 not detected. 
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Faure Island 
The founding members of the Faure Island population were examined immediately prior 
to  translocation  from  Heirisson  Prong  in  September  of  2005.  All  were  found  to  be 
clinically normal on physical examination and visibly free of the papillomatosis and 
carcinomatosis syndrome disease.  Molecular tests for the detection of BPCV1 were not 
available at the time of examination. 
 
The Arid Recovery Project  
The  founder  WBB  population  at  the  ARP  was  formed  in  2000  by  wild  caught 
individuals from Red Cliff at Bernier Island (n = 9) and captive bred individuals (n = 3) 
from  Monarto  Zoo  (Figure  5.14).  Following  release  of  founder  animals  into  the 
enclosures,  no  further  capture  and  release  exercises  were  performed  and  therefore 
subsequent records for these animals were unavailable. Some WBBs in the founder 
population  sourced  from  Bernier  Island  (via  Kanyana)  were  recorded  as  exhibiting 
conjunctivitis  at  the  time  of  release;  however,  no  skin  lesions  were  recorded.  The 
papillomatosis and carcinomatosis syndrome has not been detected in this population by 
the project’s managers, however, no monitoring activities or virological testing of ARP 
WBBs were carried out in this study. Monitoring activities carried out by the ARP’s 
managers  were  restricted  by  logistical  difficulties  in  capturing  animals  (competition 
with other species for traps, meaning WBBs often excluded from traps), individuals 
rarely underwent physical examination and not at all under anaesthesia (K. Moseby, 
pers. comm. 2006). The fate of the founder  animals was unknown. As 4/19 WBBs 
translocated  from  Bernier  Island  in  the  September  2000  expedition  developed  the 
papillomatosis and carcinomatosis syndrome, founder ARP WBBs collected during the 
same expedition may also have subsequently developed this disease.  Therefore, the 
disease status of this population should be considered unknown and potentially infected.  
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5.4 Discussion 
A major objective in this study was to explore a causal relationship between BPCV1 
and  the  papillomatosis  and  carcinomatosis  syndrome.  BPCV1  was  only  detected  in 
individuals affected by the papillomatosis and carcinomatosis syndrome, and almost all 
WBBs affected by the syndrome were infected with BPCV1. Furthermore, BPCV1 was 
detected in the vast majority of epithelial lesions consistent with the papillomatosis and 
carcinomatosis syndrome using both PCR and in situ hybridisation, but not at all in 
normal  epithelia  from  unaffected  individuals  (Woolford  et  al.  2007;  Bennett  et  al. 
2008a). At the population level, both the papillomatosis and carcinomatosis syndrome 
and BPCV1 were found to be present in the Bernier Island WBB population at Red Cliff 
and in captive populations comprising all or a proportion of founder WBBs from Red 
Cliff (Kanyana, Dryandra and the PCBC). In these affected and geographically isolated 
populations, the syndrome did not exist independently of the presence of the virus (and 
vice-versa).  Neither  BPCV1  nor  clinical  evidence  of  the  papillomatosis  and 
carcinomatosis syndrome were observed in WBBs examined from the Dorre Island or 
Heirisson Prong (Dorre Island derived founder stock) populations. No agents other than 
BPCV1 (viral or otherwise) were detected in association with this disease using the 
pathological and molecular methodologies described in Chapters 2 and 4, respectively. 
 
On the basis of strength of association, these findings provide strong evidence for the 
existence  of  causal  relationship  between  BPCV1  and  the  papillomatosis  and 
carcinomatosis syndrome. The association between virus and disease was found to be 
consistent, irrespective of the methodology used for detection of viral infection (PCR 
screening of tissue DNA extracted, PCR of skin swabs and in situ hybridisation with 
formalin-fixed paraffin-embedded sections) or whether association was measured at the 
level of the individual or the population.  
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Based on the knowledge of other small DNA virus families such as Papilloma- and 
Polyomaviridae  (families  to  which  the  unclassified  BPCV1  demonstrates  greatest 
similarity) the proposed causal relationship between BPCV1 and the papillomatosis and 
carcinomatosis  syndrome  makes  biological  sense.  These  families  comprise 
transmissible epitheliotropic viruses that are associated with both benign and malignant 
disease  of  cutaneous  and  mucosal  epithelia  (Graffi  et  al.  1968;  Dawe  et  al.  1987; 
Brandsma 1994; Stanley et al. 1997; Sundberg et al. 1997; Cole and Conzen 2001; 
Lowy and Howley 2001; Khalili et al. 2003). A point of particular importance is that 
BPCV1  encodes  polyomavirus-like  small  and  large  T  antigen-like  proteins.  The  T 
antigens encoded by polyomaviruses are known to cause malignant transformation of 
cells  through  physical  association  with  cellular  target  proteins  such  as  p53,  the 
retinoblastoma protein family of tumour suppressors (Rb, p107 and p130) and cellular 
protein phosphatase 2A (Dixon et al. 1982; Goutebroze and Feunteun 1992; Ludlow and 
Skuse  1995;  Brodsky  and  Pipas  1998;  Kim  et  al.  1998;  Butel  and  Lednicky  1999; 
Krynska et al. 2000; Klein et al. 2002). In light of the oncogenic properties of the T 
antigens, it is appropriate to consider BPCV1 as the inciting cause for a spectrum of 
cutaneous and muco-cutaneous lesions resembling the stepwise progression of epithelia 
from pre-malignant stages into invasive squamous cell carcinomas. 
 
A  range  of  disease  severity  was  observed  across  BPCV1  infected  individuals,  with 
variation in the number, size and malignant progression of lesions observed (Woolford 
et al. 2008), reflecting a range of host responses along a biological gradient from mild to 
severe. As no experimental studies were conducted, BPCV1 dose-response could not be 
determined. In regards to time sequence of events, BPCV1 was not detectable on the 
skin of individuals prior to developing clinical evidence of the syndrome. However,  
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viral DNA was readily detectable during the early appearance of lesions (e.g. in regions 
of alopecia) prior to the development of overt papillomatous thickenings. 
 
As  this  was  not  a  prospective  study  and  no  experimental  work  was  performed,  the 
incidence  of  disease  in  individuals  following  exposure  to  BPCV1  could  not  be 
determined. Retrospective analysis did not allow the identification of the time point at 
which  individuals  were  exposed  to  BPCV1.  As  such,  an  accurate  measure  of  the 
incubation period of disease could not be determined (discussed further below).  
 
Various  hypotheses  were  considered  to  explain  the  pattern  of  disease  emergence  in 
WBB populations. Firstly, the author considered that BPCV1 was present (endemic) in 
the Bernier Island (Red Cliff) WBB population only, and subsequently disseminated in 
mainland WBB populations through the introduction of infected animals collected from 
Red Cliff. Findings from a recent study suggest that BPCV1 has been present in the 
WBB population for at least 10 million years (Bennett et al. 2008b). Consequently, the 
papillomatosis and carcinomatosis syndrome may have been present in Bernier Island 
WBBs for equally as long, and went undetected, or was thought to be innocuous, by 
researchers prior to 2001. If Dorre Island is truly free of disease, it is plausible that 
BPCV1 has simply been isolated in the Bernier Island WBB population. This may have 
occurred through a combination of rising sea levels (leading to the separation of the 
islands 3000 years ago) and a substantial population decline on Dorre Island, leading to 
the loss of BPCV1 infected animals, and hence BPCV1.  
 
Alternatively, it was considered that BPCV1 might be present in both the Bernier and 
Dorre Island populations, but individuals sourced from Dorre Island or descended from 
Dorre WBBs might exhibit resistance (genetically determined or otherwise) to infection  
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with BPCV1 and/ or the development of clinical disease.   Host  genetics have been 
shown to be influential in the outcome of papillomavirus infection. There are various 
major histocompatibility complex (MHC) polymorphisms associated with susceptibility 
to infection and/ or the development of malignant disease recorded in humans (Wank 
and Thomssen 1991; Apple et al. 1994; Majewski et al. 1997; Gelder et al. 2003) and 
rabbits (Han et al. 1992; Breitburd et al. 1997). Reduced genetic diversity has been 
proposed in the pathogenesis of papillomavirus-associated disease in other endangered 
animal species (Tachezy et al. 2002b). Examination of clinical records from captive 
breeding facilities and subsequent statistical analyses revealed that although  BPCV1 
and the disease have not yet been detected on Dorre Island, individuals sourced from 
and descendent from this population are as equally susceptible to the papillomatosis and 
carcinomatosis syndrome as their Bernier Island or hybrid bred counterparts.  
 
This finding was not surprising when genetic variation between geographically isolated 
WBB  populations  was  considered,  specifically  in  regards  to  MHC  diversity.  The 
Bernier and Dorre Island WBB populations have been separated from one another for 
approximately 3000 years (Hancock et al. 2000). A recent study by Smith and Hughes 
(2007a) found diversity levels in the WBB, estimated by genotyping six microsatellite 
loci across 134 individuals from 5 populations (Bernier and Dorre Islands, Heirisson 
Prong,  the  PCBC  and  Dryandra),  to  be  amongst  the  lowest  ever  recorded  for  a 
population of marsupials (Smith and Hughes 2007a). Furthermore, Smith and Hughes 
(2007b) found no variation in the DAB gene of the  1 domain (antigen binding region) 
of  the  MHC  class  II  region  across  142  WBBs  from  five  populations  (island, 
reintroduced and captive populations) (Smith and Hughes 2007b). Class I and other 
MHC class II loci have not yet been examined in this species, however it appears at this 
stage  that  susceptibility  to  the  papillomatosis  and  carcinomatosis  syndrome  is  not  
  199
influenced  by  MHC  polymorphism.  The  lack  of  MHC  diversity  in  the  WBB  was 
considered unusual for mammalian populations, but similar to other endangered species, 
and  it  is  thought  that  this  may  increase  the  vulnerability  of  this  species  to  novel 
pathogens and parasites arising in the environment (Smith and Hughes 2007b).  
 
Although it is presently considered to hold an unaffected population, it plausible that 
BPCV1 and the papillomatosis and carcinomatosis syndrome may simply have gone 
undetected on Dorre Island due to the small sample sizes and limited sites examined in 
this study and in previous exercises. A suitable sample size to detect the presence of 
disease in a population can be calculated using the following formula (Thrusfield 2005): 
n = [1-(1-p1)
1/d] [N-d/2]+1 
where: 
N = population size; 
d = minimum number of affected animals expected in the population; 
n = the required sample size; 
p1 = probability of finding at least one case in the sample. 
 
A recent and accurate population estimate for island WBBs is unavailable due to the 
low  sample  size  obtained  in  a  recent  survey  (L.  Reinhold,  pers.  comm.,  2007). 
However,  the  population  of  WBBs  on  Dorre  Island  has  previously  been  estimated 
between  1100  and  2200  (Short  et  al.  1997).  If,  for  arguments  sake,  the  minimum 
number of affected animals in a population of 2000 on Dorre Island (equally dispersed 
over the island) is assumed to be the similar to that detected at Red Cliff (e.g. 10%), i.e. 
N = 2000 and d = 200, 31 WBBs would need to be sampled to detect at least one 
affected animal with probability 0.95. The maximum number of individuals examined 
during each expedition to Dorre Island during the course of this study was only 13. It is  
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therefore plausible that disease on this island went unnoticed due to insufficient sample 
sizes. Furthermore, a pocket of infected animals could exist on Dorre Island, which was 
excluded from the sampling sites chosen.   
 
During this study, sample sizes were small and only a few sites sampled on each island 
due  to  time,  logistical  and  financial  restrictions.  Sampling  sites  were  chosen  that 
supported WBB preferred habitat, yet were also safe and convenient for boat landings 
(non-random/ convenience sampling). Due to this sampling bias, the cohort is not likely 
representative  of  and  cannot  reliably  be  extrapolated  to  reflect  the  entire  WBB 
population on each island. Disease prevalence rates are only indicative for the sample 
population at a particular site. However, if theses areas are to remain collection sites for 
mainland translocations, it is important that they are prioritised in population health 
monitoring  exercises.  Only  unaffected  sites  should  be  used  for  future  WBB 
translocations. 
 
The  development  of  malignancy  involves  a  complex  interaction  between  both 
exogenous and endogenous factors. In attempts to elucidate the pathogenesis of this 
syndrome in the WBB, it was considered that a complex interaction between BPCV1 
and other factors [e.g. compromise of the host immune system (Boules Bavinck and 
Berkhout 1997; Palefsky 1998; Nicholls et al. 1999; Major 2001; Berger 2003) or host 
genetics (Wank and Thomssen 1991; Han et al. 1992; Apple et al. 1994; Breitburd et al. 
1997; Majewski et al. 1997; Tachezy et al. 2002b)] may be driving the development of 
clinical disease.  This study did not find variation in disease susceptibility on the basis 
of  genetic  origin,  familial  disease  history  or  sex.  In  the  Kanyana  population,  the 
papillomatosis and carcinomatosis syndrome was observed with greater frequency in 
captive bred individuals than in wild caught WBBs, however this was not found to be  
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true  in  the  PCBC  population.  Analysis  of  captive  breeding  records  did  not  reveal 
evidence  for  the  vertical  transmission  of  BPCV1  (and  papillomatosis)  from  dam  to 
offspring; however, this cannot be ruled out due to the paucity of information presently 
available on host-virus (WBB-BPCV1) interactions, WBB immunology, the life stages 
of BPCV1 in infected epithelia and the possibility that a latent or dormant phase in 
BPCV1 infection may exist, as reported for papillomavirus and polyomavirus infections 
in other species (Major 2001; Frazer 2004). 
 
The  papillomatosis  and  carcinomatosis  syndrome  appears  to  affect  mature  WBBs 
predominantly. Disease attack rate in captive individuals was observed to be greatest in 
individuals 2 years of age and older, and the mean age of lesion onset was 3 years 2 
months of age.  Curiously, the mean longevity in WBBs affected by the syndrome was 
found to be quite significantly higher than their unaffected counterparts. Indeed, mean 
longevity  in  unaffected  animals  was  found  to  be  less  than  the  mean  age  of  lesion 
detection in affected WBBs. This prompts one to consider that if many of the unaffected 
WBBs  had  lived  longer,  they  too  may  have  developed  the  papillomatosis  and 
carcinomatosis syndrome.  
 
The comparatively higher frequency of this syndrome in older animals may be reflective 
of  a  long  incubation  period,  or  long  period  of  latent  viral  infection.  Alternatively, 
additional factors, endogenous or exogenous, may be introduced as a WBB ages that 
increase  susceptibility  to  BPCV1-infection,  or  trigger  the  development  of  clinical 
disease following a period of viral latency. Activation of papillomavirus infections can 
occur through immunosuppression of the host (Benton et al. 1992; Campo et al. 1994) 
or through mechanical trauma (Siegsmund et al. 1991). Intact cell mediated immunity 
has been shown to be essential for lesion regression and clearance of papillomavirus  
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infection (Nicholls and Stanley 2000), and immunosuppression has been associated with 
the persistence of lesions and increased severity of papillomavirus-associated disease 
(Majewski and Jablonska 1995; Bouwes Bavinck and Berkhout 1997; Palefsky 1998). 
Evidence for lesion regression was observed in two individuals monitored at Kanyana 
during  the  course  of  this  study.  A  cutaneous  papilloma  in  the  jugular  region  of 
B05DrS11 was observed to regress, prior to reforming concurrently with lesions (non-
regressing) at other epithelial sites. This scenario of events may indicate that WBBs are 
capable of clearing lesions (and potentially clearing viral infection or inducing latency), 
yet  some  change  in  the  competence  of  the  host’s  immunity  may  occur  leading  to 
reformation and persistence of lesions.  
 
No evidence of concurrent disease or immunosuppression was observed through routine 
physical  examination,  haematology  and  clinical  chemistry  analyses  (Bennett  et  al. 
2007), but cannot be ruled out on the basis of these investigations alone. Exploration of 
potential co-factors such as concurrent disease (e.g. retroviral infection), chemical (e.g. 
plant (Jarrett et al. 1978)) or physical agents (e.g. UV) that might be involved in the 
pathogenesis of such a disease was beyond the scope of this study and not performed. 
Due to the nocturnal nature of these animals it is unlikely that UV light plays a role in 
lesion pathogenesis, as has been reported in other PV infections (Tilbrook et al. 1989; 
Jablonska and Majewski 2003). 
 
A potential source of BPCV1 in the PCBC population was identified as the wild caught 
Bernier  Island  adult  male  B07K01.  As  this  animal’s  lesions  were  noted  only  five 
months  following  its  introduction,  it  is  plausible  that  this  animal  was  infected  with 
BPCV1  on  arrival.  Captive  breeding  activities  carried  out  with  this  animal  between 
1998  and  2000  may  have  facilitated  the  spread  of  BPCV1  in  this  population.  Two  
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females  known  to  have  contact  with  this  male  developed  the  syndrome  two  years 
following first contact. This two year period may represent an incubation period, which 
may or may not include a period of latency. The youngest animal recorded to develop 
clinical evidence of the papillomatosis syndrome was 10 months of age (pathological 
and molecular investigations not performed). Therefore, 10 months may serve as the 
minimum recorded incubation period until further experimental studies are performed.   
 
The first two affected WBBs detected at Kanyana were captive bred (detected in April 
and December of 1999, respectively). If it is assumed that BPCV1 and the syndrome 
were introduced to this population by wild caught WBBs (founder members sourced 
from wild populations only and BPCV1 appears to be a species-specific virus), it is 
highly probable that BPCV1 and the papillomatosis and carcinomatosis syndrome were 
present in the Kanyana population prior to April 1999. Other individuals may have been 
showing subtle lesions or potentially carrying latent infections at the time of arrival 
from Bernier Island. It was not possible to determine for certain the source of disease in 
the Dryandra WBB population, however the first three affected animals detected, and 
therefore the most likely candidates, were captive bred WBBs sourced from Kanyana. 
This syndrome was not observed in the Heirisson Prong population; however, it should 
be considered that the  mean lifespan of Heirisson Prong WBBs is 1.5  years of age 
(Short 2006), which is less than the mean age at which disease was detectable in captive 
populations.  
 
Monitoring of affected  WBBs held at Kanyana revealed that epithelial lesions most 
commonly increased in number and size with time, concurring with anecdotal findings 
discussed in Chapter 2. Lesions were observed to develop at sites of recent trauma, an 
event which may have facilitated virus access to basal keratinocytes (Longworth and  
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Laimins  2004).  The  increasing  number  and  distribution  of  lesions  may  result  from 
repetitive  trauma  and  “auto-inoculation”,  as  has  been  reported  in  papillomavirus 
infection  (Howley  and  Lowy  2001;  Bossart  et  al.  2002),  alternatively  mechanical 
trauma to epithelia may lead to activation of latent virus infection (Siegsmund et al. 
1991). 
 
The severity of lesions and the number of affected animals seen in captivity was vastly 
greater than that observed in wild populations. In evaluating the significance of this 
finding, it must be taken into consideration that the majority of individuals in captive 
breeding facilities were observed for the entirety of their natural lives, as apposed to 
wild populations where almost all individuals were examined on one occasion only. 
More importantly still, it must be noted that WBBs in captivity appear to live longer 
than those in the wild (N. Thomas pers. comm. 2005, J. Butcher pers. comm. 2005). 
This  study  found  the  papillomatosis  and  carcinomatosis  syndrome  to  affect  mature 
individuals predominantly; the risk of developing the syndrome was seen to increase 
with age, and the clinical severity of disease was seen to increase as the affected animal 
aged. Therefore, the reason why the prevalence and severity of disease seen in captivity 
is greater than in the wild may simply be because captive animals are living longer. 
Many wild WBBs may not have lived long enough to become at risk of developing the 
syndrome (death perhaps resulting from risks not present in captivity, e.g. predation, 
nutritional  stressors).  This  observation  may  analogous  to  an  interpretation  of  the 
increasing rates of human cancer, a disease almost exclusively of old age. Lomborg 
proposed that the increasing prevalence of cancer may in fact not be an indication of 
any higher risk, but merely a consequence of people living longer and therefore falling 
into  higher  risk  age  groups  (Lomborg  2001).  Due  to  the  debilitating  nature  of  this 
disease,  it  should  also  be  considered  that  affected  wild  WBBs  are  more  prone  to  
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predation and environmental stressors than their unaffected counterparts, therefore less 
frequently  observed  in  trapping  exercises.  WBBs  are  territorial  and  largely  solitary 
animals,  therefore  it  must  be  considered  whether  captivity  may  facilitate  more 
prolonged  and  frequent  contact  between  individuals  than  occurs  in  the  wild,  more 
readily  facilitating  spread  of  infectious  agents  such  as  BPCV1.  Other  diseases  of 
marsupials  known  to  infect  both  wild  and  captive  animals,  such  as  herpesvirus 
infections  and  salmonellosis,  have  also  been  observed  with  greater  frequency  and 
severity in captive populations, perhaps secondary to stress associated with captivity 
(Young and Deane 2003).  
 
The  clinical  implications  for  individuals  affected  by  the  papillomatosis  and 
carcinomatosis  syndrome  are  certainly  unpleasant  and  debilitating  in  the  advances 
stages  of  disease,  and  a  considerable  proportion  of  WBBs  held  in  captive  breeding 
facilities  developed  the  syndrome.  This  study  was  unable  to  measure  precisely  the 
impact of the syndrome on the wild WBB population due to the low numbers of animals 
and few sites examined on each island. However, the papillomatosis and carcinomatosis 
syndrome was only observed at Red Cliff on Bernier Island in this and previous studies, 
the disease prevalence in trapped individuals at this site found to range between 0.0% 
and 41.7%. Similar numbers of WBBs (~30) were examined on each island during the 
course of this particular study, and only two animals were detected (on Bernier Island) 
with  clinical  evidence,  albeit  mild,  of  the  papillomatosis  syndrome  and  BPCV1 
infection.  
  
A  quantitative  measure  of  impact  of  this  syndrome  on  the  fecundity,  recruitment, 
survival, and hence size, of wild populations was not determined. However, no apparent 
difference  was  observed  between  the  number  of  WBBs  trapped  or  sighted  during  
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spotlighting activities on Bernier Island (affected population) vs. that on Dorre Island 
(putatively unaffected population) in this study or previous studies (Short et al. 1997; 
Short et al. 1998).  WBBs reach sexual maturity at less than 6 months of age (females 3 
- 5 months, males 4 - 6 months) (Short et al. 1998), mean longevity (lifespan) in wild 
and reintroduced populations may be as low as 1.5 years of age (Short 2006) and the 
oldest known animals in reintroduced or wild populations have been 4-5 years of age 
(author  observation;  N.  Thomas  and  J.  Short  pers.  comm.,  2006).  Breeding  occurs 
throughout  the  year  with  seasonal  peaks  in  reproduction  dependent  on  rainfall  and 
associated  food  availability  (Short  et  al.  1998).  Females  may  produce  litters  of  1-3 
young following a one of the shortest recorded gestation in a mammalian species of 
12.5  days  and  pouch  young  are  thought  to  independent  at  60  days  of  age  or  less 
(Seebeck  et  al.  1990;  Short  et  al.  1998).  As  the  papillomatosis  and  carcinomatosis 
syndrome most commonly affects WBBs 2 years or older, it would appear that many 
wild  WBBs,  if  subsequently  affected,  would  have  had  time  to  utilise  reproductive 
opportunities  and  contribute  genetically  and  numerically  to  the  population  (given 
appropriate  climatic  conditions)  before  onset  of  disease.  Females  affected  by  the 
syndrome, sometimes displaying quite advanced lesions, have been observed by the 
author both carrying pouch  young and lactating, therefore the presence of epithelial 
lesions may not significantly affect reproductive ability (author observation). On the 
basis  of  these  observations,  the  impact  of  the  papillomatosis  and  carcinomatosis 
syndrome on the  wild WBB population may be low. Nevertheless, the syndrome is 
certainly  an  animal  welfare  issue  in  captive  breeding  facilities  and  for  that  reason 
remains a hindrance to the mainland WBB reintroduction programme.   
 
In summing up the main findings presented in Chapter 5, there is strong evidence for 
the  existence  of  a  causal  relationship  between  BPCV1  and  the  papillomatosis  and  
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carcinomatosis syndrome of the WBB. This recently emerged syndrome appears to have 
originated  on  Bernier  Island  and  subsequently  disseminated  in  mainland  WBB 
populations through the introduction of infected WBBs from Bernier Island. No major 
predisposing or co-factors were identified during the course of this study; however, the 
full range of potential factors was not exhausted. The severity of lesions and the number 
of  affected  animals  seen  in  captivity  was  vastly  greater  than  was  observed  in  wild 
populations. The presence of BPCV1 and increasing age appear to be the most crucial 
risk factors for the development of the papillomatosis and carcinomatosis syndrome in 
the WBB.   
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Chapter 6: General discussion and future directions 
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6.1 The major findings of this study 
The  papillomatosis  and  carcinomatosis  syndrome  of  the  western  barred  bandicoot 
(WBB) was characterised by multicentric proliferative lesions involving cutaneous and 
muco-cutaneous  surfaces,  seen  clinically  to  increase  in  size  with  time.  Grossly  and 
histologically the smaller epithelial lesions resembled papillomas, whereas the larger 
lesions were most  commonly carcinoma in situ and squamous cell carcinomas. The 
discernable  stages  of  lesion  development,  from  pre-malignant  stages  into  invasive 
carcinomas, and the progression in lesion size and malignancy seen with increasing age 
were  consistent  with  a  multistage  model  of  carcinogenesis  (Weinstein  et  al.  1995; 
Hanahan and Weinberg 2000).  
 
Pathological  features  of  pre-malignant  lesions,  such  as  the  presence  of  large 
amphophilic intranuclear inclusion bodies in hyperplastic conjunctival epithelia, were 
suggestive  of  a  viral  aetiology.  Ultrastructural  examination  of  conjunctival  lesions 
revealed a crystalline array of spherical electron dense particles ~ 45 nm in diameter 
within  the  nucleus  of  these  epithelial  cells,  consistent  with  a  papillomavirus  or 
polyomavirus,  and  positive  intranuclear  staining  was  also  observed  in  the  same 
conjunctival  lesions  following  immunohistochemistry  for  papillomavirus  structural 
antigens. 
 
Screening of a broad range of benign and malignant squamous epithelial lesions from 
affected WBBs using multiply-primed rolling circle amplification (RCA) and PCR with 
broad  spectrum  cutaneotropic  papillomavirus  primer  pairs  (FAP59/64)  led  to  the 
detection  of  a  novel  virus,  tentatively  designated  the  bandicoot  papillomatosis 
carcinomatosis virus type 1 (BPCV1).  Sequencing of the BPCV1 genome revealed a 
prototype  virus  exhibiting  genomic  properties  of  both  the  Papillomaviridae  and  the  
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Polyomaviridae. Papillomaviral properties included a large genome size (~7.3kb) and 
the presence of ORFs encoding canonical L1 and L2 structural proteins. The genomic 
organisation in which structural and non-structural proteins were encoded on different 
strands  of  the  double-stranded  circular  DNA  genome,  and  the  presence  of  ORFs 
encoding the non-structural proteins large T and small t antigen were on the other hand 
typical  polyomaviral  features.  It  was  thought  that  BPCV1  may  represent  the  first 
member of a novel virus family, descended from a common ancestor of the papilloma- 
and  polyomaviruses  recognised  today.  Alternatively  it  may  represent  the  product  of 
ancient recombination between members of these two virus families. BPCV1 DNA was 
amplified by RCA and/ or PCR (entire genome or L1 ORF fragment, respectively) from 
the  vast  majority  of  epithelial  lesions  consistent  with  the  papillomatosis  and 
carcinomatosis syndrome, but not at all from the normal epithelia of unaffected WBBs.  
 
Evidence  for  the  existence  of  a  causal  relationship  between  BPCV1  and  the 
papillomatosis  and  carcinomatosis  syndrome  was  presented  in  Chapter  5.  Cross-
sectional  and  retrospective  studies  showed  the  papillomatosis  and  carcinomatosis 
syndrome and BPCV1 to be present in the Bernier Island WBB population at Red Cliff 
and in captive populations comprising all or a proportion of founder WBBs from Red 
Cliff (Kanyana Wildlife Rehabilitation Centre, Dryandra Field Breeding Facility, and 
Peron Captive Breeding Centre). BPCV1 was not detected in, and clinical evidence of 
the papillomatosis and carcinomatosis syndrome was not observed in, WBBs examined 
from the Dorre Island or Heirisson Prong populations. 
 
The  BPCV1-associated  papillomatosis  and  carcinomatosis  syndrome  observed  to 
emerge in mainland WBB populations in recent times appears to have originated on 
Bernier  Island  at  Red  Cliff  and  disseminated  in  mainland  colonies  through  the  
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introduction of infected WBBs from Red Cliff. Although BPCV1 and the syndrome 
have not yet been detected on Dorre Island, this study found individuals sourced from 
and descendent from this population to be as equally susceptible to the papillomatosis 
and  carcinomatosis  syndrome  as  their  Bernier  Island  or  “hybrid”  counterparts.  The 
presence of BPCV1 and increasing age appeared to be the most crucial risk factors for 
the development of the papillomatosis and carcinomatosis syndrome in the WBB. The 
loss of MHC diversity in the WBB, arising through isolation and inbreeding, may have 
increased the vulnerability of this species to pathogens, such as BPCV1 (O'Brien and 
Evermann  1988;  Smith  and  Hughes  2007b),  increased  incidence  of  similar, 
papillomavirus-associated, disease also reported in other endangered species (Joslin et 
al. 2000; Bossart et al. 2002).  
 
The severity of lesions and the number of affected animals seen in captivity was vastly 
greater than was observed in wild populations. The greater impact of the syndrome in 
captivity may be simply because captive animals are living longer (therefore falling into 
higher risk age groups) than their wild counterparts, rather than a direct consequence of 
the captive environment itself. Alternatively, affected wild WBBs may be more prone to 
predation and environmental stressors and therefore less frequently observed in trapping 
exercises. WBB are territorial and largely solitary animals, therefore it must also be 
considered  whether  captivity  may  facilitate  more  prolonged  and  frequent  contact 
between individuals than occurs in the wild, more readily facilitating spread of BPCV1.   
 
The major findings of this study have implications for the management of the remaining 
WBB population in addition to, in a much broader sense, the wider research community 
in  regards  to  virus  taxonomy,  virus-host  relationships  and  mechanisms  of  viral 
carcinogenesis. A vast array of important, and no doubt exciting, findings regarding the  
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novel virus BPCV1, such as host-virus interactions, biological behaviour, transmission 
and oncogenic mechanisms remain to be unearthed. Consequently the recommendations 
discussed below are based on information extrapolated from that which is known of the 
two most similar virus families, the Papillomaviridae and Polyomaviridae.   
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6.2 Future management of remnant WBB populations in light of 
the papillomatosis and carcinomatosis syndrome 
From  the  perspective  of  minimising  or  eliminating  the  papillomatosis  and 
carcinomatosis syndrome, the absence of observable clinical disease and the failure to 
detect BPCV1 in Dorre Island WBBs makes this population the preferred source for 
mainland reintroductions. Due to the presence of BPCV1 and the papillomatosis and 
carcinomatosis syndrome at Red Cliff, this site (and hence Bernier Island) is a much 
less ideal source and further use of this population in captive breeding activities will 
likely contribute to the persistence of the syndrome in mainland populations. However, 
an  important  argument  exists  for  maintaining  the  use  of  the  Bernier  Island  WBB 
population for mainland reintroductions and captive breeding activities. A recent study 
by  Smith  and  Hughes  (2007a)  found  diversity  levels  in  the  WBB,  estimated  by 
genotyping six microsatellite loci across 134 individuals from 5 populations (Bernier 
and Dorre Islands, Heirisson Prong, the PCBC and Dryandra), to be amongst the lowest 
ever recorded for a population of marsupials (Smith and Hughes 2007a). It was found 
that the contemporary isolation of the two island populations has acted to maintain a 
higher  combined  effective  population  size  than  would  be  expected  from  either 
population  on  its  own,  and  the  authors  proposed  that  future  use  of  both  genetic 
reservoirs would act to maximise genetic diversity for mainland reintroductions. The 
IUCN has recognised genetic diversity as one of three levels of biological diversity 
requiring conservation (McNeely et al. 1990). Island populations display less genetic 
variation than their mainland counterparts and are also more susceptible to extinction 
(World  Conservation  Monitoring  Centre  1992;  Frankham  1997).  Genetic  factors 
believed  to  contribute  higher  extinction  rates  include  inbreeding  depression,  loss  of 
genetic variation, accumulation of mildly deleterious mutations, and genetic adaptations 
to  island  environments  (limited  ability  to  avoid  predators  and  diseases)  (Frankham  
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1997). Herein a quandary is created: continued use of the Bernier Island population for 
mainland  reintroductions  may  lead  to  propagation  of  the  papillomatosis  and 
carcinomatosis syndrome, yet failure to do so may further contribute to the demise of an 
already genetically impoverished species.   
 
It must now be determined by those responsible for designing future WBB conservation 
initiatives whether the benefits gained from minimising the propagation of a debilitating 
disease outweigh the potential loss of genetic diversity within an endangered species. 
Although it appears likely that BPCV1 has co-evolved with and been present in the 
WBB  population  for  at  least  10  million  years,  and  that  the  papillomatosis  and 
carcinomatosis syndrome may not be having a significantly deleterious impact on the 
wild population, it is without a doubt a disease of welfare significance in captive WBB 
populations. For this reason, if it is decided to use Bernier Island sourced individuals in 
captive  breeding  and  reintroduction  activities,  significant  efforts  should  be  made  to 
minimise  the  risk  of  translocating  BPCV1-infected  WBBs.  Ideally,  the  following 
criteria should be met in the selection of WBBs from Bernier (and Dorre) Island: 
 
1.  WBBs should be collected from sites where disease has not been detected: 
a.  Red Cliff should no longer be used as a site for collection of WBBs from 
Bernier Island, alternative locations should be explored; 
2.  WBBs must not display clinical evidence of epithelial abnormalities (including 
conjunctivitis); 
3.  If possible, juvenile WBBs should be collected in preference to adults: 
a.  Juveniles  less  likely  to  be  have  been  involved  in  fighting  or  mating 
activities  with  BPCV1-infected  WBBs  (infectious  pathogenesis 
assumed);  
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4.  Cutaneous and mucosal epithelia should be negative for BPCV1 by molecular 
techniques (e.g. skin swab PCR); 
5.  Serology should not indicate previous exposure to BPCV1: 
a.  NB: suitable immunoassay not yet developed (see below). 
 
These measures are of course fallible. A BPCV1 infected individual may not display 
clinical  lesions  in  the  early  stages  of  infection  or  if  it  is  a  latently  infected  carrier, 
therefore would likely test negatively for BPCV1 DNA by swabbing of epithelia (only 
overt lesions reliably tested positive for BPCV1 DNA in this study). It is yet to be 
determined if BPCV1-infected WBBs seroconvert, which in turn may be an unreliable 
indicator of exposure given the apparently exclusively epitheliotropic BPCV1 lifecycle. 
Whether transfer of anti-BPCV1 immunoglobulins from dam to pouch young occurs 
would  also  need  to  be  investigated.  Consequently,  the  risk  that  BPCV1-infected 
individuals will enter mainland populations can only be minimised, not eliminated. Due 
to the nature of the testing required, a quarantine facility would need to be established 
near the islands (e.g. at the PCBC) where animals could be held pending the results of 
diagnostic  testing,  and  the  fate  of  any  BPCV1-infected  animals  translocated  to  the 
mainland would need to be determined.  
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6.3 Future research directions 
During the course of this study, much has been learned regarding the nature of the 
papillomatosis  and  carcinomatosis  syndrome  and  the  novel  viral  agent  BPCV1. 
However,  far  greater  is  the  wealth  of  information  potentially  gained  through  the 
continuation  of  research  with  BPCV1  and  the  associated  syndrome.  Keys  areas  for 
prioritisation in future research efforts include: 
 
1.  Clinical trial of antiviral compounds in affected WBBs; 
2.  Development  of  immunoassays  and  application  of  methodologies  to  increase 
knowledge of WBB humoral and cell-mediated immune responses, in particular 
to BPCV1 infection; 
3.  Production of a BPCV1 vaccine (e.g. VLP or pseudovirion - based); 
4.  Further genetic characterisation of putative marsupial papillomaviruses; 
5.  Increasing knowledge of the BPCV1 lifecycle in differentiating epithelia and 
mechanisms of oncogenesis. 
 
6.3.1 Clinical trial of antiviral compounds in affected WBBs 
Cidofovir  [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)  cytosine],  an  acyclic 
nucleoside phosphonate, has a broad spectrum antiviral activity against DNA viruses, 
including  herpesviruses,  poxviruses,  polyomaviruses,  papillomaviruses,  adenoviruses 
and iridoviruses (Andrei et al. 1997; Snoeck 2006; De Clercq 2007; Lebeau et al. 2007). 
The  known  mechanism  of  action  of  cidofovir  is  based  on  DNA  chain  termination 
following the intracellular conversion of cidofovir to its diphosphate and the successive 
incorporation  of  two  cidofovir  units  into  the  growing  viral  DNA  chain  (De  Clercq 
2007). Unlike the other DNA viruses targeted by this compound, papillomaviruses and  
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polyomaviruses  do  not  encode  for  their  own  DNA  polymerase,  the  final  target  of 
cidofovir diphosphate. The mechanism of activity of cidofovir against theses two virus 
families is not yet understood; however, it has been suggested that cidofovir interferes 
directly with viral proteins involved in the control of cellular replication (i.e. the early 
proteins  of  papillomaviruses  and  the  T  antigens  of  polyomaviruses,  respectively) 
(Andrei et al. 1997; Snoeck 2006; Lebeau et al. 2007). As BPCV1 encodes T antigen-
like  non-structural  proteins,  cidofovir  may  effectively  inhibit  replication  of  and 
potentially clear infection with this virus. Cidofovir has been used successfully in the 
treatment of papillomavirus-related diseases by both topical application (Davis et al. 
2000; De Rossi and Laudenbach 2004) and intralesional injection (Van Cutsem et al. 
1995; Snoeck et al. 1998) and been used intravenously, mostly with success, in the 
treatment of BK and JCV related disease in immunosuppressed people (Osorio et al. 
2002; Shitrit et al. 2005; Josephson et al. 2006). 
 
Imiquimod,  a class of imidazoquinoline, has demonstrated potent immunomodulating, 
antiviral  and  antitumour  activities  in  different  animal  models  (Snoeck  2006).  These 
effects  are  believed  to  be  mediated  by  the  induction  or  upregulation  of  cytokine 
production (IL-1, IL-2, IL-6, IL-8, TNF- , IFN-  , and PGE2) and through direct effects 
on Langerhans cells (altered cell morphology, enhanced migration to draining lymph 
nodes  and  enhanced  allergic  contact  hypersensitivity)  ((Suzuki  et  al.  2000)  and 
references  therein).  The  antiviral,  antitumour  and  antiproliferative  properties  of 
imiquimod  lead  it  to  be  considered  in  the  treatment  of  WBBs  affected  by  the 
papillomatosis  and  carcinomatosis  syndrome.  Treatment  success  may  depend  on 
whether the marsupial immune system responds to imiquimod in a similar fashion to 
that of eutherian mammals. Treatment of affected WBBs with imiquimod may also be 
unsuccessful if this species has a yet to be determined defect in cell-mediated immunity.    
  218
A  recent  case  report  described  the  unsuccessful  treatment  of  an  epidermodysplasia 
verruciformis patient with imiquimod, treatment failure proposed to occur due to the 
underlying defect in the patient’s cell mediated immunity (Janssen et al. 2007).  
 
6.3.2 WBB immunology 
Vaccination (discussed below) may be a viable means of preventing BPCV1 infection, 
and assumingly the papillomatosis and carcinomatosis syndrome, in the WBB. Before 
such an initiative can proceed, it must be determined whether the WBB immune system 
is able to generate a protective immune response following vaccination. It should also 
be  determined  whether  the  BPCV1-associated  papillomatosis  and  carcinomatosis 
syndrome  is  an  expression  of  an  underlying  and  more  consequential  (genetically 
determined or otherwise) immunological defect in this species, for example along the 
lines of epidermodysplasia verruciformis (Cooper et al. 1990; Majewski et al. 1990). It 
has recently been suggested that the debilitating devil facial tumour disease (DFTD) of 
the Tasmanian devil (Sarcophilus harrissi) arose as a direct result of loss of genetic 
diversity  (specifically  MHC  diversity)  within  the  species,  which  facilitated  natural 
transmission of tumour cells between individuals (Siddle et al. 2007). In a similarly 
fashion to the WBB, the Tasmanian devil is restricted to an island off the coast of 
mainland Australia and demonstrates low genetic diversity at microsatellite and MHC 
loci (Jones et al. 2004). The lack of genetic diversity and the emergence of debilitating 
diseases  within  both  the  WBB  and  Tasmanian  devil  populations,  respectively,  is 
consistent with findings from other studies demonstrating that island populations have 
reduced  genetic  variation  (Frankham  1997)  and  are  more  vulnerable  to  novel 
environmental  stresses,  such  as  disease  (O'Brien  and  Evermann  1988;  Siddle  et  al. 
2007).  
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Therefore,  it  is  important  that  future  work  be  dedicated  towards  assessing  the 
competence of the WBB humoral and cell-mediated immune responses. The production 
of BPCV1 virus like particles (VLPs, L1 proteins produced in vitro that self-assemble to 
form empty viral capsids) (Trus et al. 1997; Stanley 2006) and/ or pseudovirions (Buck 
et al. 2005) would facilitate the development of immunoassays in order to determine if 
(protective) seroconversion occurs in BPCV1-infected individuals (e.g. ELISA, virus 
neutralisation assay). In most people with papillomavirus infection, humoral immunity 
is generated against conformational epitope(s) on the major coat or capsid protein L1 
displayed  on  the  outer  surface  of  the  intact  virus  particle,  however,  titres  of  virus 
neutralising antibodies are generally low (Wikstrom et al. 1995; Dillner 1999; Stanley et 
al. 2006). This low response is probably reflective of the exclusively intra-epithelial 
infectious cycle of the papillomaviruses, and because L1 protein and the virus particles 
produced in the surface cell layers of the epithelium are shed in the absence of cytolysis 
and  inflammation,  far  from  most  antigen  presenting  cells  (APCs)  and  patrolling 
macrophages  (Stanley  et  al.  2006).  Serum  has  been  collected  from  the  majority  of 
WBBs examined in this study and is currently archived pending further analysis. 
 
Alternatively, in vivo tests, such as the Mantoux/ tuberculin test, may be a simple and 
effective method for assessing competent immune responses (cutaneous Mycobacteria 
marinum infections recorded in captive WBBs). In addition, evaluation of CD4
+ T-cell 
responses to VLPs or pseudovirions may allow an indirect measure of MHC II antigen 
presentation (Williams et al. 2002; Gelder et al. 2003). Technical difficulties will likely 
be encountered in the development of immunoassays for the WBB due to the small 
volumes of blood that can safely be collected from each individual, the geographical 
isolation of populations from laboratory facilities, the endangered nature of the species  
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and  the  unavailability  of  species-specific  reagents;  hopefully  these  factors  will  not 
preclude their development.  
6.3.3 Vaccination 
As BPCV1 encodes structural proteins analogous to the major (L1) and minor (L2) 
capsid proteins of papillomaviruses, adopting the methodologies used in the production 
of papillomavirus vaccines may lead to the successful production of a vaccine against 
BPCV1 for use in for the WBB. Human vaccination programmes against type-specific 
high risk HPV types associated with cervical cancer have recently been shown to be 
safe,  immunogenic  and  highly  effective  (Frazer  2002;  Frazer  2004;  Stanley  2006; 
Stanley  2007).  These  vaccines  comprise  VLPs,  which  exhibit  morphological  and 
antigenic  properties  that  are  virtually  identical  to  native  virions  (Trus  et  al.  1997). 
Protection,  although  not  completely  understood,  is  believed  to  occur  through  the 
generation of serum neutralising Immunoglobulin G (Stanley et al. 2006). VLP-based 
vaccines have also been shown to induce protective immunity in rabbits against CRPV 
(Breitburd et al. 1995), dogs against COPV (Suzich et al. 1995) and cattle against BPV 
infection (Kirnbauer et al. 1996). In addition to the VLP-based vaccines, intracutaneous 
gene gun delivery of plasmid DNA containing individual viral genes has been shown to 
trigger effective protective immunity to papillomavirus infections (Donnelly et al. 1996; 
Ulmer et al. 1996; Sundaram et al. 1997; Stanley et al. 2001; Liu et al. 2004). 
 
Commercially available  VLP vaccines currently in use against high risk HPV types 
comprise  L1  proteins  expressed  via  a  recombinant  baculovirus  vector  (Cervarix 
TM, 
GlaxoSmithKline  Biologicals,  Rixensart,  Belgium)  or  a  via  a  recombinant 
Saccharomyces  pombe  vector  (Gardasil®,  Merck  and  Co.  Inc.,  West  Point, 
Pennsylvania,  USA),  and  are  delivered  intramuscularly  in  preparation  with  an 
aluminium hydroxide and 3-deacylated monophosphoryl lipid A or a proprietary alum  
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adjuvant, respectively (Stanley et al. 2006). L1 capsid proteins have also been expressed 
in transgenic plants (Biemelt et al. 2003; Kohl et al. 2006). These vaccines are highly 
immunogenic,  as  unlike  natural  PV  infections,  intramuscular  delivery  allows  them 
access the draining lymphatics and small vessels at the injection site, initiating antibody 
responses in lymph nodes and the spleen effectively by mimicking a viraemia (Stanley 
et al. 2006).   
 
Parenteral vaccines against BPCV1 may be most beneficial in intensive WBB captive 
breeding facilities, where the syndrome is observed most frequent and is most severe. In 
extensive ranging populations (wild and reintroduced) however, parenteral delivery of 
vaccines to an effective proportion of the population would not be feasible. Potentially 
an oral vaccine, delivered via an aerial drop of immunogen-laden baits, may be suitable 
for use in these populations. Oral vaccines have been successful in the control of rabies 
in wildlife reservoirs in Europe and North America (Pastoret and Brochier 1996), and 
vaccines against other diseases that persist in a wildlife reservoir such as Lyme disease 
(Borrelia burgdorferi), Plague (Yersinia pestis), Tuberculosis (Mycobacterium bovis), 
Brucellosis  (Brucella  abortus),  Pseudorabies  (porcine  herpesvirus),  Pasturellosis 
(Mannheimia  haemolytica)  and  Anthrax  (Bacillus  anthracis)  are  currently  in  the 
experimental stages of development (reviewed by Cross et al. 2007). For an oral vaccine 
programme is to be successful in a wildlife population the following requirements must 
be met (Cross et al. 2007): 
1.  A  safe  and  effective  immunogen  must  be  able  to  be  mass-produced 
inexpensively; 
2.  The immunogen should be highly protective, administrable by several routes, in 
particular the oral route, making it suitable for field delivery;  
  222
3.  The immunogen must be robust, stable and compatible with a species-specific 
bait delivery system. 
 
The successful rabies vaccine comprised a recombinant vaccinia virus producing rabies 
virus glycoprotein G, and was found to be potent, stable, deliverable to a single target 
species (red fox, Vulpes vulpes) via the oral route, compatible with existent wildlife 
baiting  systems,  safe  in  non-target  species  and  non-transmissible  within  species 
(Blancou et al. 1986; Brochier et al. 1989). Recombinant vaccinia virus expressing HPV 
oncoproteins have been developed for use as therapeutic vaccines in the treatment of 
cervical cancer  (Boursnell et al. 1996; Baldwin et al. 2003; Davidson et al. 2003; Liu et 
al. 2004) and prophylactic vaccines for rabbits have also been protected against CRPV 
infection following vaccination with  L1 expressing vaccinia virus  (Lin  et al. 1992). 
Recombinant vaccinia virus expressing capsid proteins L1 or L1/ L2 in combination 
have also been successfully produced, and it was demonstrated that these proteins then 
self assembled to form capsid structures (Zhou et al. 1991; Hagensee et al. 1993).   
 
A similar methodology used for rabies vaccination in wildlife could be adopted for the 
WBB  potentially,  to  control  or  reduce  the  spread  of  BPCV1:  specifically  the  oral 
delivery of a recombinant vaccinia virus vector expressing L1 (VLP), or L1 and L2 in 
combination (pseudovirion), within a species-specific bait that is immunogenic, safe in 
non-target species and non-transmissible within species. Alternatively, the oral delivery 
of  BPCV1  VLPs  may  prove  an  effective  vaccination  strategy  in  the  WBB.  Oral 
administration  of  anogenital  HPV  type  VLPs  to  mice  has  been  shown  to  induce 
systemic and mucosal virus-neutralising antibody responses (Rose et al. 1999; Gerber et 
al. 2001; Rose 2002). Whether such vaccines would be innocuous in the WBB would of 
course  need  to  be  investigated,  and  the  development  of  a  bait  targeting  the  
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insectivorous/  omnivorous  WBB  specifically  could  prove  challenging  given  the 
vulnerable marsupial and native mice species, and numerous bird and reptilian species 
present on the island, to whom a WBB-specific bait may also appeal (Short et al. 1997; 
Menkhorst and Knight 2001; IUCN 2002; Richards 2003).  
6.3.4 Genetic characterisation of putative marsupial 
papillomaviruses 
The  detection  and  characterisation  of  a  prototype  “hybrid-like”  virus  BPCV1  has 
eloquently  demonstrated  the  quite  significant  pitfalls  of  relying  purely  on  virus 
morphology, structural antigens and/ or sequencing of a DNA fragment from the L1 
region for the proposal of new papillomavirus (PV) types. If investigations carried out 
in the study had ceased following the amplification of DNA demonstrating homology to 
PV  L1  from  tissues  with  pathological  and  immunohistochemical  evidence  of  PV 
infection,  we  likely  would  have  assumed  the  causative  agent  of  this  syndrome  was 
simply a new PV type. 
 
Previous studies proposing the existence of putative PV types in Australian marsupials 
have  done  so  on  the  basis  of  DNA  fragments  sequenced  from  the  L1  region  only 
(Perrott et al. 2000; Antonsson and McMillan 2006). Given that BPCV1 was isolated 
from  a  marsupial  species,  it  is  highly  probable  that  the  putative  possum,  koala  and 
kangaroo PV types may in fact exhibit the genomic organisation of and ORFs encoded 
by  the  presently  unclassified  BPCV1.  Future  work  should  be  dedicated  towards  the 
complete genomic characterisation of these putative marsupial PVs, and in addition, the 
PVs isolated from other species that have not yet been completely characterised. 
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6.3.5 Increasing knowledge of the BPCV1 lifecycle in differentiating 
epithelia and mechanisms of oncogenesis  
Future  work  should  also  focus  on  the  elucidation  of  the  BPCV1  lifecycle  in  WBB 
differentiating  epithelia.  Suggested  methodologies  include  examining  viral  protein 
transcription and nucleic acids in formalin-fixed paraffin embedded tissues (Peh et al. 
2002; Peh and Doorbar 2005), quantifying viral gene expressing in infected tissue using 
real time PCR (Shi et al. 1999; Cubie et al. 2001; Seth et al. 2005) and establishment of 
cell culture systems supportive of BPCV1 infection using either lesional or non-lesional 
biopsies  taken  from  WBB  epithelia  (Meyers  et  al.  1997;  McLaughlin-Drubin  and 
Meyers 2005; Stanley 2005). Methodologies allowing the exploration of the oncogenic 
mechanisms  of  BPCV1  T  antigens  would  also  be  of  significant  interest,  such  as 
transfection of established cell lines (e.g. rodent) with plasmids containing the BPCV1 
early region (wild type and mutant) (Zhu et al. 1992). 
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6.5 Final comment 
This thesis describes the pathologic features of the papillomatosis and carcinomatosis 
syndrome and the detection and characterisation of the novel viral aetiological agent, 
BPCV1, with which it is associated. The frequency and geographical distribution of this 
disease in both wild and captive WBB populations is analysed, and a multifactorial 
pathogenesis is explored.  
 
Infectious diseases have the potential to drive  population declines  and contribute to 
species extinction (Daszak and Cunningham 1999; Daszak et al. 2000). The importance 
of disease investigation and control in recovery plans for endangered species of wildlife 
is becoming more evident as the impact of disease syndromes on conservation efforts 
becomes alarmingly more recognisable. Early diagnosis and control of disease in wild, 
captive and reintroduced populations of endangered animals is critical in ensuring the 
overall survival of the population (Viggers et al. 1993; Cunningham 1996; Young and 
Deane  2003).  The  papillomatosis  and  carcinomatosis  syndrome  in  the  WBB  is  a 
pertinent  example  of  a  disease  compounding  efforts  to  prevent  the  extinction  of  an 
endangered species.   
 
The  IUCN  defines  endangered  as  “Taxa  (species  and  sub-species)  in  danger  of 
extinction and whose survival is unlikely if the causal factors continue operating…taxa 
whose numbers have been reduced to a critical level or whose habitats have been so 
drastically  reduced  that  they  are  deemed  to  be  in  immediate  danger  of  extinction” 
(World Conservation Monitoring Centre 1992). The WBB population was decimated on 
mainland Australia in the years that followed European settlement, unable to withstand 
the changes that accompanied habitat destruction and introduction of predator species 
such  as  the  European  fox  (Vulpes  vulpes)  and  the  domestic  cat  (Felis  catus).  Wild  
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populations of the WBB are now restricted to two small islands off the coast of Western 
Australia. The levels of genetic diversity in the WBB are estimated to be amongst the 
lowest  ever  recorded  for  a  population  of  marsupials,  which  likely  increases  the 
susceptibility of this species to novel diseases, environmental stresses and, ultimately 
extinction (World Conservation Monitoring Centre 1992; Frankham 1997; Smith and 
Hughes 2007a). The BPCV1-associated papillomatosis and carcinomatosis syndrome 
may  in  fact  be  an  expression  of  an  underlying  and  more  consequential  (genetically 
determined or otherwise) immunological defect in this species. Whilst the impact of the 
papillomatosis and carcinomatosis syndrome in the wild WBB population is not readily 
observable, it is quite obviously an animal welfare issue in captive breeding facilities 
and  affected  animals  are  highly  unsuitable  for  reintroduction  programmes.  For  this 
reason, the syndrome remains one of many hurdles in the recovery of this precious 
marsupial.  
 
Valuable information on the papillomatosis and carcinomatosis syndrome is presented 
in this thesis, alongside proposals for its future management. Equally as importantly, 
multiple avenues of future research are also identified. These findings and suggested 
paths aim to not only benefit the plight of the endangered WBB, but provide further 
insight into the mechanisms of the small DNA tumour viruses for the benefit of the 
wider research community. 
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Appendices 
Appendices  1  and  2  detail  work  performed  by  Dr  Annabel  Rector  (Laboratory  of 
Clinical and Epidemiological Virology, Department of Microbiology and Immunology, 
Rega  Institute  for  Medical  Research,  University  of  Leuven,  Belgium),  which  is 
complementary  to  the  work  presented  in  Chapter  4  and  referred  to  within  the  text. 
Appendix 3 details the identities of WBBs examined during field monitoring activities 
carried out during this study. 
Appendix 1: Long template PCR 
Materials and methods 
Long template PCR. Long range PCR primers, designed from BPCV1 sequence data 
obtained from cloning and sequencing of RCA products, were applied directly to the 
lesional DNA extract from WBB 1 to sequence parts of the putative BPCV1 genome 
independently of RCA. Primers were chosen to produce amplicons encompassing the 
regions linking the PV-like and PyV-like ORFs of the BPCV1 genome, in order to 
confirm  the  occurrence  of  both  PV-  and  PyV-like  ORFs  in  a  single  viral  genome. 
Primer  pairs  used  were  LTPCR-LTF1  in  large  T  (5’-
GCCTCTAGAAAGCACATTATTACCTCCAGGGTTTGG-3’)  and  LTPCR-L1R1  in 
L1 (5’-ATGTAAAGTCCCTCTCAAGCCAGAAGTCCTAGC-3’) for amplification of 
a fragment of 2130 nt, linking the large T and L1 ORFs of BPCV1, and LTPCR-L2F2 
in  L2  (5’-CACCACCTCTACCTGTTCCTATACCTAATCCACC-3’)  and  LTPCR-
STR2 in small t (5’-CATCACCTTCACTCTCGTAGCAGAACAGATCTTCC-3’) for a 
second fragment of 1259 nt, encompassing the region that connects the L2 ORF with 
the small t ORF. Long template PCR was performed with the Expand Long Template 
PCR  System  (Roche  Diagnostics)  according  to  the  manufacturer’s  instructions.  The  
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amplification  profile  consisted  of  2  minutes  denaturation  at  94  °C,  followed  by  10 
cycles  of  10  seconds  denaturation  at  94  °C,  30  seconds  annealing  at  63  °C  and  4 
minutes elongation at 68 °C. This was followed by 25 cycles of 10 seconds denaturation 
at 94 °C, 30 seconds annealing at 63 °C and 4 minutes elongation at 68 °C with an 
increase in elongation time by 20 additional seconds each cycle. After a final elongation 
step of 7 minutes at 68 °C the samples were then cooled to 4 °C. The PCR products 
were  gel-purified  by  using  the  QIAquick  Gel  Extraction  Kit  (Qiagen),  followed  by 
direct sequencing of the purified amplicons with nested sequencing primers. Primers 
LTF1  (5’-TCACCAAAGCTCATAAAGCAG-3’)  and  L1R1  (5’-
GAGAAAGTTCTTGTATCAGAGC-3’)  were  used  to  determine  a  1531  nucleotide 
stretch  of  the  first  amplicon,  and  with  primers  L2F2  (5’-
CTGTTCCTATACCTAATCCACC-3’)  and  STR2  (5’-
GCCATCACAAGTATCACAACC-3’) 1051 nucleotides of the second amplicon were 
sequenced. 
Results 
Long range template PCR was applied to lesional DNA extracts independently of RCA. 
Amplicons  were  generated  that  were  identical  to  BPCV1  sequences  obtained  by 
sequencing of cloned RCA products and encompassed sequences from both the early 
and late ORFs, revealing that early and late region ORFs were continuous with one 
another on template DNA (BPCV1 genome) and the sequences were identical to those 
retrieved from the cloned RCA products. 
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Appendix 2: Phylogenetic analysis 
Materials and methods 
To determine the evolutionary relationship of the BPCV1 sequence to other PV types, 
phylogenetic analysis was performed on the nucleotide sequences of the L1 and L2 
ORFs of BPCV1, the 46 PV types that are classified as type species of the different PV 
genera and species, and 7 recently identified and currently unclassified PV types. The 
L1 and L2 protein coding regions of these sequences were aligned at the amino acid 
level with ClustalW (Thompson et al. 1994) using the BLOSUM protein weight matrix 
in the DAMBE software package version 4.2.13 (Xia and Xie 2001). This amino acid 
alignment  was  then  used  as  a  template  for  aligning  the  corresponding  nucleotide 
sequences in DAMBE.  The nt alignments were corrected manually in  the GeneDoc 
Multiple  Sequence  Alignment  Editor  and  Shading  Utility  software  package  version 
2.6.002 (Nicholas et al. 1997), retaining only the unambiguously aligned parts. Based 
on these alignments, phylogenetic trees were constructed for L1 and L2 separately, as 
well as for a concatenated alignment of both ORFs, by using the neighbour-joining 
method and with calculation of bootstrap support values for 10,000 replicates by the 
neighbour-joining method in MEGA version 3.1 (Kumar et al. 2004).  
 
For the BPCV1 large T antigen (LT Ag), the evolutionary relationship to PyVs was 
investigated. For this analysis, 13 PyV species for which a complete genomic sequence 
was  available  in  GenBank  were  included.  Because  the  intron  sequence  within  the 
BPCV1 LT Ag gene could not be confidently identified, the analysis was performed on 
the complete LT Ag genomic sequences, so including intron sequences. The LT Ag 
nucleotide sequences were aligned with the ClustalW algorithm (Thompson et al. 1994) 
implemented  in  the  DAMBE  software  package  version  4.2.13  (Xia  and  Xie  2001).  
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Divergent  regions  and  positions  in  which  the  sequences  were  not  unambiguously 
aligned were removed from the alignment by using the Gblocks computer programme 
version 0.91b (Castresana 2000). Based on this corrected alignment, a neighbour joining 
phylogenetic tree was constructed in the same way as described above. 
Results 
Since BPCV1 shows similarity to polyomaviral genomes in its early region but has a 
late region encoding papillomaviral proteins, the evolutionary history of BPCV1 was 
reconstructed  separately  for  both  regions,  based  on  comparison  to  the  polyomaviral 
large  T  antigen  and  the  papillomaviral  L1  and  L2  capsid  genes,  respectively.  A 
neighbour-joining phylogenetic tree was constructed based on an alignment of the large 
T antigen sequences of BPCV1 and 13 members of the Polyomaviridae (Figure A2.1). 
This  tree  showed  two  major  branches,  containing  the  PyVs  infecting  Eutherian 
mammals in one cluster, and those infecting birds in the other. BPCV1 did not belong to 
either  cluster  but  branched  off  directly  from  the  root  between  the  mammalian 
(Eutherian)  and  avian  PyVs,  which  is  in  agreement  with  the  WBB  host  species 
belonging to the marsupials (Metatheria infraclass of mammals), in which no PyV has 
been isolated thus far. This corroborates a scenario in which the BPCV1 early region 
would have branched off of the PyV evolutionary tree very early in evolution.  
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Figure A2.1 Large T antigen phylogenetic tree of BPCV1 and 13 established polyomavirus 
species [Lymphotropic polyomavirus of African Green Monkey (LPyV) NC_004763, Simian 
virus  40  (SV40)  NC_001669,  Simian  agent  12  (Sa12)  NC_007611,  Hamster  polyomavirus 
(HaPyV)  NC_001663,  Mouse  polyomavirus  (MPyV)  NC_001515,  Kilham  strain  of  mouse 
polyomavirus (MptV) NC_001505, Bovine polyomavirus (BPyV) NC_001442, JC virus (JCV) 
NC_001699,  BK  virus  (BKV)  NC_001538,  Budgerigar  fledgling  disease  polyomavirus 
(BFPyV)  NC_004764,  Goose  hemorrhagic  polyomavirus  (GHPyV)  NC_004800,  Crow 
polyomavirus  (CPyV)  NC_007922,  Finch  polyomavirus  (FPyV)  NC_007923]  showing  the 
evolutionary  relationship  of  the  PbPV-1  sequence  to  members  of  the  Polyomaviridae. 
Phylogenetic  reconstruction  was  performed  with  the  neighbour-  joining  method.  Bootstrap 
percentages (based on 10,000 iterations) of ≥ 80% are shown at internal nodes (arrowheads), 
and the genetic distance in nucleotide substitution per site is indicated by the scale bar. The 
clusters  of  polyomaviruses  that  infect  avian  and  eutherian  host  species  respectively  are 
indicated. 
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An L1 neighbour-joining phylogenetic tree was constructed based on alignment of the 
L1 ORF of BPCV1 and 53 members of the Papillomaviridae (Figure A2.2). This L1 
tree clustered the PVs in the previously defined genera, and the nodes joining different 
PVs that belong to the same genus were supported by high bootstrap values. This tree 
indicated that the WBB virus was most closely related to the members of the  -PV 
genus, but it branched off very close to the root of the common branch of this genus and 
this clustering was only supported by a low bootstrap value (66%). In a neighbour-
joining  phylogenetic  tree  based  on  an  L2  sequence  alignment  of  the  same 
papillomaviruses, BPCV1 did not share a common branch with the members of the  -
PV genus. Instead, it originated near the root of the evolutionary tree in a common 
branch  with  the   -PV  and  the  rodent  PVs  HaOPV,  McPV2  and  MmPV  (data  not 
shown). Again, this clustering showed only low bootstrap support.  
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Figure  A2.2  Evolutionary  relationship  of  the  BPCV1  sequence  to  members  of  the 
Papillomaviridae. Neighbour-joining phylogenetic tree of the L1 sequences of BPCV1 and 53 
papillomaviruses  [ -PV  genus  HPV32(NC_001586),  HPV10  (NC_001576),  HPV61 
(NC_001694),  HPV2  (NC_001352),    HPV26  (NC_001583),  HPV53  (NC_001593),  HPV18 
(NC_001357),  HPV7  (NC_001595),  HPV16  (NC_001526),  HPV6  (NC_001355),  HPV34 
(NC_001587),  RhPV1  (NC_001678),  HPV54  (NC_001676),  HPV90  (NC_004104),  HPV71 
(AY330621);  -PV genus HPV5 (NC_001531), HPV9 (NC_001596), HPV49 (NC_001591), 
HPV92  (NC_004500),  HPV96  (NC_005134);   -PV  genus  HPV4,  (NC_001457),  HPV48 
(NC_001690), HPV50 (NC_001691), HPV60 (NC_001693);  -PV genus EEPV (NC_001524), 
DPV  (NC_001523),  OvPV1  (NC_001789),  BPV1  (NC_001522);   -PV  genus  BPV5 
(NC_004195);  -PV genus EcPV1 (NC_003748);  -PV genus FcPV (NC_004068);  -PV genus 
PePV  (NC_003973);   -PV  genus  MnPV  (NC_001605);   -PV  genus  CRPV  (NC_001541), 
ROPV  (NC_002232);   -PV  genus  COPV  (NC_001619),  FdPV1  (NC_004765),  PlPV1  
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(NC_007150);  -PV genus HPV1 (NC_001356), HPV63 (NC_001458);  -PV genus HPV41 
(NC_001354);  -PV genus BPV3 (NC_004197);  -PV genus PsPV1 (NC_003348);  -PV genus 
HaOPV (E15111);  -PV genus TmPV1 (NC_006563);  -PV genus EdPV1 (NC_006951); and 
unclassified  types  RaPV1  (NC_008298),  BPV7  (NC_007612),  CPV2  (NC_006564),  CPV3 
(NC_008297),  ChPV1  (NC_008032),  McPV2  (DQ664501)  and  MmPV  (NC_008582)].  The 
established  PV  genera  are  indicated  with  their  Greek  symbols.  The  scale  bar  indicates  the 
genetic distance (nucleotide substitutions per site), and numbers at internal nodes represent the 
bootstrap probabilities in percent as determined for 10,000 iterations with the neighbour-joining 
method. Only bootstrap values of 80% or more are shown. 
Discussion 
Alignment  of  papillomavirus  L1  sequences  inclusive  of  BPCV1  and  the  subsequent 
phylogenetic analysis demonstrates BPCV1 is most closely related to the members of 
the   -PV  genus  (containing  the  Epidermodysplasia  verruciformis  associated  human 
PVs) however it branches off very close to the root of the common branch of this genus 
(Figure  A2.2).  This  seems  to  be  an  argument  for  the  virus  being  the  result  of 
recombination between existing or ancient papilloma- and polyomaviruses rather than 
being a descendent of the ancient common ancestor of both virus families. In the large T 
antigen tree (Figure A2.1), BPCV1 appears as a close-to-root sequence, branching off 
from the root between the mammalian and avian polyomaviruses. In contrast to the L1 
analysis, this would be in agreement with the virus being a descendent of a common 
papilloma- and polyomavirus ancestor, or at least having arisen as long ago as the two 
major phylogenetic clades of polyomaviruses, so in the earliest evolutionary history of 
the Polyomaviridae.  
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Appendix 3: WBBs examined during field monitoring activities  
Table A3.1 Identities of WBBs examined on Dorre Island 2005-2007. 
 
Location  Study ID  Microchip no.  DEC ID  Sex  Age at exam  Date/s examined 
White Beach  B05Do1  6667F4C  WB99  M  Adult  2005 July 
B05Do2  666D701  WB42  F  Adult  2005 July 
B05Do3  607875F  WB43  M  Adult  2005 July, 2003 March (DEC), 2000 September (DEC) 
B05Do4  6642165  WB77  M  Adult  2005 July 
B05Do5  6642D5A/ 982009104967464  WB01  M  Adult  2007 April, 2005 July 
B05Do6  666A24C  WB50  F  Adult  2005 July 
B05Do7  6381608  WB79  F  Adult  2006 August, 2005 July, 2003 March (DEC) 
B05Do8  6668D05  WB71  F  Adult  2005 July 
B05Do9  666A0F7  WB2  M  Adult  2005 July 
B05Do10  6668A38  WB72  F  Juv  2005 July 
B05Do11  6671091  WB74  F  Adult  2005 July 
B05Do12  6667E71  WB04  M  Adult  2005 July 
B05Do13  6669AAC  WB80  F  Juv  2005 July 
B06Do1  n/a  WB113  M  Adult  2006 August 
B06Do2  n/a  WB114  M  Adult  2006 August 
B06Do3  982009104969045  WB115  F  Adult  2007 April, 2006 August 
B06Do4  n/a  WB117  M  Adult  2006 August 
B06Do5  n/a  WB119  M  Adult  2006 August 
B06Do6  n/a  WB121  M  Juvenile  2006 August 
B06Do7  n/a  WB123  M  Adult  2006 August 
B06Do8  n/a  WB113  F  Adult  2006 August 
B06Do9  n/a  WB27  F  Adult  2006 August 
B06Do10  n/a  WB115  M  Juvenile  2006 August 
B07Do01  982009104877254  n/a  M  Adult  2007 April 
B07Do02  982009104809332  n/a  F  Juvenile  2007 April 
B07Do03  982009104816967  n/a  M  Adult  2007 April  
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Table A3.1 cont’d 
Location  Study ID  Microchip no.  DEC ID  Sex  Age at exam  Date/s examined 
Disaster Cove  B07Do04  982009104565564  n/a  M  Adult  2007 April 
B07Do05  982009104820664  n/a  M  Adult  2007 April 
B07Do06  982009104894681  n/a  F  Adult  2007 April 
B07Do07  982009104848836  n/a  F  Adult  2007 April 
B07Do08  982009104821896  n/a  F  Adult  2007 April 
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Table A3.2 Identities of WBBs examined on Bernier Island 2005-2007. 
 
Location  Study ID  Microchip no.  DEC ID  Sex  Age at exam  Date trapped  Notes 
Red Cliff  B06B01  98009104836732  WB01  M  Adult  2007 April, 2006 August   
B06B02 
 
n/a  WB02  M  Adult  2006 August  Clinical evidence of papillomatosis, small lesions on left lateral radius, right lateral  
carpus and thickening of upper and lower palpebrae bilaterally. Lesions positive for 
BPCV1. Figure 5.15. 
B06B03  n/a  WB03  F  Adult  2006 August   
B06B04  n/a  WB04  M  Juvenile  2006 August   
B06B05  n/a  WB05  F  Adult  2006 August   
B06B06  n/a  WB06  F  Adult  2006 August   
B06B07  982009104861130  WB07  M  Adult  2007 April, 2006 September   
B06B08  n/a  WB08  M  Adult  2006 September  R palpebrae slightly thickened, BPCV1 positive. 
B06B09  n/a  WB09  F  Juvenile  2006 September   
B06B10  n/a  WB10  F  Adult  2006 September   
B06B11  n/a  WB11  F  Juvenile  2006 September   
B07B01  982009104967453  n/a  M  Adult  2007 April  Left eye muco-purulent conjunctivitis. 
B07B02  982009104855921  n/a  F  Adult  2007 April  Left eye muco-purulent conjunctivitis. 
B07B03  982009104792869  n/a  F  Juvenile  2007 April  Right eye muco-purulent conjunctivitis and mildly thickened of eyelids, BPCV1 negative. 
B07B04  982009104799921  n/a  F  Juvenile  2007 April  Right eye muco-purulent conjunctivitis and ruptured globe. 
B07B05  982009104837375  n/a  F  Adult  2007 April  Right eyelid mildly thickened, BPCV1 negative. 
B07B06  982009104864827  n/a  F  Adult  2007 April   
B07B07  982009104806389  n/a  F  Adult  2007 April   
Hospital 
Bay 
B07B08  982009104835989  n/a  M  Adult  2007 April   
B07B09  982009104969223  n/a  M  Adult  2007 April   
B07B10  982009104859665  n/a  M  Adult  2007 April  Left eye, ruptured globe and muco-purulent conjunctivitis. 
B07B11  982009104813865  n/a  M  Adult  2007 April   
B07B12  982009104945351  n/a  F  Juvenile  2007 April   
B07B13  982009104868152  n/a  F  Adult  2007 April    
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Table A3.3 Identities of WBBs examined at Heirisson Prong 2005-2006. 
 
Study ID  Microchip no.  Sex  Age at exam  Date trapped 
B05H01  6335683  F  Adult  2005 October 
B05H02  66730F9  M  Adult  2005 October 
B05H03  638B483  F  Adult  2005 October 
B05H04  6391C3C  M  Adult  2005 October 
B05H05  639523C  M  Adult  2005 October 
B05H06  6394A80  M  Adult  2005 October 
B05H07  638ABD4  M  Adult  2005 October 
B05H08  5FD10C3  F  Adult  2005 October 
B05H09  666E363  M  Adult  2005 October 
B05H10  66E2513  F  Adult  2005 October 
B05H11  615864C  F  Adult  2005 October 
B05H12  638AABA  M  Adult  2005 October 
B05H13  6673F19  M  Adult  2005 October 
B05H14  63928AD  M  Adult  2005 October 
B05H15  6188525  F  Adult  2005 October 
B05H16  6157998  F  Adult  2005 October 
B05H17  66DD531  M  Juvenile  2005 October 
B05H18  5FE8435/ 5FD0913  M  Adult  2005 October 
B06H01  66E0DC5  F  Adult  2006 May 
B06H02  6392C43  M  Adult  2006 May 
B06H03  66DEE37  M  Juvenile  2006 May 
B06H04  66DE6D  M  Adult  2006 May 
B06H05  61737CD  M  Adult  2006 May 
B06H06  671136A  M  Adult  2006 May 
B06H07  68AFDFD  M  Juvenile  2006 May 
B06H08  68B28B9  M  Adult  2006 May 
B06H09  66721AC  F  Adult  2006 May 
B06H10  68B5B52  M  Adult  2006 May 
B06H11  68BA1C8  F  Adult  2006 May 
B06H12  68AE591  F  Juvenile  2006 May 
B06H13  668B7CC  M  Adult  2006 May 
B06H14  6672734  M  Adult  2006 May 
B06H15  6395779  M  Adult  2006 May 
B06H16  6393FC6  M  Adult  2006 May 
B06H17  68ABBE0  M  Adult  2006 May 
B06H18  6397312  M  Adult  2006 May 
B06H19  68AB49E  M  Juvenile  2006 May 
B06H20  68AC4CD  M  Juvenile  2006 May 
B06H21  68AF8E5  M  Adult  2006 May 
B06H22  68B0400  M  Adult  2006 May 
B06H23  68B7A5A  M  Juvenile  2006 May 
B06H24  66DE461  F  Juvenile  2006 May 
B06H25  63921FC  M  Adult  2006 May 
B06H26  68B9FD1  M  Juvenile  2006 May 
B06H27  6393998  F  Adult  2006 May 
B06H28  68AFC76  M  Juvenile  2006 May 
B06H29  68B9EBD  M  Juvenile  2006 May 
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Table A3.4 Identities of WBBs translocated to Faure Island in October 2005. 
 
Study ID  Microchip no.  Sex 
B05H10  66E2513  F 
B05H11  615864C  F 
B05H13  6673F19  M 
n/a  6393F20  F 
n/a  6642990  M 
n/a  66DD0A7  F 
n/a  6710EDD  M 
n/a  615909D  F 
n/a  66DEE0A  M 
n/a  639ACC5  M 
n/a  6134E00/ 638A98C  M 
n/a  6390BC0  M 
n/a  6674636  F 
n/a  6131803  F 
n/a  6393C59  M 
n/a  6189A3A  F 
n/a  66DFF95  M 
n/a  6395549  M 
n/a  639A791  M 
n/a  66748A6  F 
n/a  613206B  M  
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Table A3.5 Identities of WBBs examined at Dryandra 2005-2006. 
 
Study ID  Microchip no.  DEC ID  Sex  Year of birth  Dates examined at Dryandra  Notes 
B05DrS01  5FFB77F  D038  F  2001  2005 April  Deceased, found dead in enclosure August 2005 
B05DrS02  63969B6  D078  M  2002 or before  2005 April, December  Papillomatosis, translocated to Kanyana December 2005 BPCV1 positive 
B05DrS03  63DF0E7  D073  F  2003  2005 April  Deceased, found dead in enclosure August 2005 
B05DrS04  637FD74  D063  F  2002  2005 April, August, December   
B05DrS05  5FE48A3  D027  M  2000 or before  2005 July  Papillomatosis, severe disease euthanased July 2005 
B05DrS06  1EF438E  D56  F  2002 or before  2005 April, December; 2006 April, December   
B05DrS07  6738B9F  D096  F  2003 or before  2005 April, December; 2006 April, December   
B05DrS08  6641A5E  D091  F  2004  2005 April, December   
B05DrS09  66E977B  D110  M  2003 or before  2005 December; 2006 April  Papillomatosis and BPCV1 positive, translocated to Kanyana August 2006. 
B05DrS10  66E8I36  D099  M  2004  2005 April  Papillomatosis and BPCV1 positive, translocated to Kanyana April 2005.  
B05DrS11  6737E00  D097  M  2004  2005 October  Papillomatosis and BPCV1 positive, translocated to Kanyana August 2005 BPCV1. 
B05DrS12  6377468  D005  M  2005 or before  2006 April  Found dead in enclosure, suspected predation. 
B05DrS13  673729E  D098  F  2003 or before  2005 December   
B05DrS14  66DD947  Unknown  F  2005  2005 December   
B05DrS15  66E1304  Unknown  F  2005  2005 December; 2006 April, December   
B06DrS01  66DFD7A  D108  F  2005 or before  2006 December   
B06DrS02  66E1514  D113  F  2006  2006 December  Areas of alopecia, BPCV1 positive. Remains at Dryandra. 
B05DrN01  6695712  D101  M  2004 or before  2005 July   
B05DrN02  658F219  D088  M  2004  2005 July; 2006 March, July   
B05DrN03  63DD4C1  D082  F  2002 or before  2005 July  Papillomatosis and BPCV1 positive, translocated to Kanyana on August 2005. 
B05DrN04  63DFD4A  D80  F  2003  2005 July; 2006 March, July, November    
B05DrN05  6641C66  D89  M  2004  2006 March, July, November  Papillomatosis and BPCV1 positive, translocated to Kanyana November 2006. 
B06DrN01  66DEA72  Unknown  F  2005 or before  2006 March   
B06DrN02  6714400  Unknown  M  2005 or before  2006 March   
B06DrN03  63DAE2A  D083  F  2003  2006 March, July, November   
B06DrN04  66E07A1  Unknown  M  2006, mid  2006 November   
B06DrN05  66DCCE4  Unknown  M  2006, mid  2006 November   
B06DrN06  677118 E 3  Unknown  F  2006, mid  2006 November   
B06DrN07  66E23A4  Unknown  M  2006, mid  2006 November   
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